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Parkinson’s disease (PD) is a progressive and severely debilitating neurodegenerative 
disorder that is characterised by a range of motor symptoms and the selective loss of 
dopaminergic neurons in the substantia nigra.  While the aetiology of PD remains poorly 
understood, it is hypothesised to involve a combination of various environmental, genetic and 
cellular factors that independently or collectively contribute to neurodegeneration and 
ultimately disease.  To date, a number of genes including Parkin, PINK1, LRRK2, SNCA, DJ-
1, ATP13A2 and VPS35 that have been directly associated with disease and investigations of 
their functions have provided significant insights into the pathobiology of PD.  However, 
these genes do not play a significant role in the South African PD cohort and for this reason, 
novel genes and pathogenic mutations must be investigated and identified.  This will aid in 
early diagnosis of patients and also ultimately for the design of more effective therapeutic 
strategies to treat this debilitating and poorly understood chronic systemic disorder. 
 
The present study aimed to identify novel PD-causing mutations in the South African  
Afrikaner population using a genealogical and whole exome sequencing (WES) approach..  
The Afrikaner are unique to South Africa and are known to have undergone a bottleneck in 
the 1800s which has led to genetic founder effects for a number of different disorders in this 
particular group.  Additionally, we further aimed to determine whether the identified putative 
disease-causing mutation(s) could be attributed to the development of PD in other South 
African ethnic groups.  A total of 458 patients were recruited, of which 148 were self-
identified as Afrikaner.  From these, a total of 48 Afrikaner probands were subjected to 
extensive genealogical analyses and 40 of them could be traced back to a single common 
couple.  For this reason, it was hypothesised that the disorder in these patients may be due to 
a genetic founder effect.  
 
The use of a whole genome SNP array confirmed the relatedness of the individuals to varying 
degrees (8 to 12 generations back) and subsequently three of the probands and one affected 
sibling were selected for WES.  The selected individuals were sequenced using the Illumina 
Genome Hiseq 2000
TM
 and approximately 78 000 variants were identified for each 
individual.  Numerous bioinformatics tools were used to scrutinize the variants but none were 
able to produce a candidate list of plausible disease-causing variants.  All variants identified 
were either present at high frequency, did not co-segregate with the disorder or were 
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artefacts.  In order to facilitate and expedite the variant prioritisation process, a novel method 
for the filtration of WES data was designed in-house.  This strategy named TAPER™ (Tool 
for Automated selection and Prioritisation for Efficient Retrieval of sequence variants) 
implements a set of logical steps by which to prioritise candidate variants that could be 
pathogenic.  It is primarily aimed at the support of resource-constrained scientific 
environments with limited bioinformatics capacity.  As a proof of concept various 
independent WES datasets for PD, severe intellectual disability and microcephaly as well as 
ataxia and myoclonic epilepsy were used, and TAPER™ was able to successfully prioritise 
and identify the causal variants in each case. 
 
Through the use of TAPER™, two putative candidate variants in SYNJ1 and USP17 were 
identified.  The homozygous V1405I variant in SYNJ1 was found only in the affected sibling 
pair and in none of the 458 patients and 690 control individuals that had been screened.  This 
variant is predicted to be deleterious across multiple platforms and has a CADD score of 
29.40 and may alter synaptic vesicle recycling.  The homozygous C357S variant in USP17 
was found in 18/458 probands (12 Afrikaner, two white and four mixed ancestry) but was 
identified in 0.14% of the controls (1/184 Afrikaner, 0/160 white, 0/180 mixed ancestry and 
0/160 black).  This variant is also anticipated to be deleterious across multiple platforms and 
has a CADD score of 34.89.  In summary, the results of the present study reveal that PD in 
the 40 South African Afrikaner patients studied is not due to a founder effect, but highlights 
two variants of interest for future studies.  Further work is necessary to analyse both of these 
variants and to assess their possible effect on protein structure and function. 
 
The discovery of novel PD-causing genes is important as this allows for the generation of 
disease-linked protein networks, thereby facilitating identification of additional disease genes 
and subsequently providing insights into the underlying pathobiology.  Moreover, this 
knowledge is critical for the development of improved treatment strategies and drug 
interventions that will ultimately prevent or halt neuronal cell loss in susceptible individuals.  
Although the present study did not conclusively identify a novel PD-causing gene, it does 
provide a solid foundation for future work in our laboratory in the challenging and rapidly 
evolving research area of WES and bioinformatics, and its application to studies on PD. 
  




Parkinson se siekte (PS) is ŉ erg aftakelende neuro-degeneratiewe siekte wat gekenmerk 
word deur 'n verskeidenheid van simptome en uiteindelik die inkorting van beweging 
veroorsaak. Hierdie toestand is die gevolg van selektiewe degenerasie van die 
dopaminergiese neurone substantia nigra pars compacta in die midbrein.  Dit lei tot 
patologiese simptome naamlik bradikinese, rus tremore, posturale onstabiliteit en rigiditeit.  
Aanvanklik was die hipotese dat persone wat PS ontwikkel blootgestel was aan 
omgewingsverwante snellers wat die aanvang van die siekte veroorsaak. Maar onlangse 
bewyse dui daarop beide omgewing- en genetiese faktore speel ŉ rol in die patogenese van 
die siekte.  Tans is daar sewe gene (Parkin, PINK1, LRRK2, SNCA, DJ-1, ATP13A2 en 
VPS35) wat direk betrokke is by PD.   
Die doel van die huidige studie is om ŉ 'n PS oorsaak-mutasies in die Suid-Afrikaanse 
Afrikaner bevolking te identifiseer met behulp van 'n genealogiese en die heel eksoom 
volgorde-benadering (WES). Die Afrikaner is uniek aan Sui Afrika en het in die 1800s ń 
genetiese knelpunt ondervind wat tot genetiese stigterseffek gelei het. Daarbenewens het ons 
verder ten doel om te bepaal of die geïdentifiseerde vermeende siekte-veroorsakende 
mutasie(s) toegeskryf kan word aan die ontwikkeling van PS in ander Suid-Afrikaanse 
etniese groepe. ŉ Totaal van 458 pasiënte is vir die studie gewerf, waarvan 148 self-
geïdentifiseerde Afrikaners is. ŉ Totaal van 48 Afrikaner probandi was onderworpe aan 
genealogiese analise en 40 van hulle kon teruggevoer word na 'n enkele gemeenskaplike 
voorouer. Dit word dus veronderstel dat die individue aan mekaar verwant is en dat PS weens 
ń stigterseffek is. 
Die gebruik van 'n hele genoom SNP verskeidenheid bevestig die verwantskap van die 
individue in verskillende grade (tussen 8 en 12 generasies) en daarvolgens is drie van die 
probandi en een geaffekteerde bloedverwant gekies vir WES. Die gekose eksooms is georden 
volgens die Illumina Genome Hiseq 2000
TM 
en ongeveer 78 000 variante is geïdentifiseer vir 
elke individu. Verskeie bio-informatika instrumente is gebruik om die variante wat deur WES 
verkry is te bestudeer maar geen een was in staat om ŉ beweerde lys van geloofwaardige 
siekte-veroorsakende variante te identifiseer nie. Ten einde die variante identifikasie proses te 
ondersteun, is ŉ nuwe metode vir filtrasie van WES-data ontwikkel, naamlik TAPER™ (Tool 
for Automated selection and Prioritization for Efficient Retrieval of sequence variants). 
TAPER™ implementeer ŉ stel logiese stappe waardeur kandidaat variante gekies word wat 
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met die siekte geassosieer word; dit het ten doel om ondersteuning te bied aan wetenskaplike 
omgewings met beperkte bioinformatika kapasiteit. Verder is die sukses van TAPER™ 
geëvalueer op reeds bestaande data-stelsels wat die konsep bewys. 
 
Met behulp van TAPER™ is twee waarskynlike kandidaat variante in SYNJ1 en USP17 
geïdentifiseer. Die V1405I variant in SYNJ1 is slegs in ŉ geaffekteerde bloedverwant paar  
gevind en in geen van die 458 pasiënte of 690 gekeurde kontrole groep individue.  Dit word 
voorspel dat hierdie variant skadelik is en het  ń CADD telling van 29.40. Die C357S variant 
is homosigoties in USP17 in 18/458 probandi (12 Afrikaner, twee wit en vier gemengde 
afkoms) gevind is. Maar dit is ook geïdentifiseer in 0.14% van die kontrole individu (1/184 
Afrikaner, 0/160 wit, 0/180 gemengde afkoms en 0/160 swart) wat verkry is van die 
Westelike Provinsie Bloedoortappingsdienste. Dit word voorspel dat hierdie variant skadelik 
is en het  ń CADD telling van 34.89.  Die resultate van die huidige studie toon dat PD in die 
Suid-Afrikaanse Afrikaner nie die oorsprong het by 'n stigterslid nie, maar beklemtoon twee 
variante van belang. Verdere werk is nodig om elkeen van die variante te analiseer en hul 
moontlike patogenese te ondersoek. 
Die ontdekking van nuwe PS veroorsakende gene is belangrik omdat dit help met die 
ontwikkeling van siekte-verwante proteïen netwerke, en om sodoende addisionele gene te 
identifiseer in sleutel siekte prosesse en gevolglik kern biologiese insig in onderliggende 
prosesse te verskaf.  Alhoewel die huidige studie nie ń nuwe PS-veroorsakende geen 
geïdentifiseer het nie, dit bied wel ń ferm platform vir toekomstige navorsing in die 
uitdagende en versnellende veranderende velde van WES en bioinformatika en die toepassing 
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OUTLINE OF THE DISSERTATION 
This dissertation involves a next generation sequencing, more specifically whole exome 
sequencing (WES) investigation of Parkinson’s disease (PD) in the South African cohort, 
identifies numerous Afrikaner PD patients that are related to one another through 
genealogical tracking and a whole genome SNP array and makes use of WES as a means for 
the discovery of putative disease-causing candidates.  Moreover, this dissertation also 
provides a detailed description of a novel bioinformatics filtration pipeline. 
This dissertation is divided into four chapters: 
Chapter One provides a comprehensive background and overview of what is currently 
known about PD, with specific focus on the genetics and pathobiology of the disease.  In 
addition to this, previous findings of studies conducted on the South African PD patients as 
well as the overall aims and objectives of the present study  will be outlined. 
Chapter Two provides a detailed overview of the methodological approaches used 
throughout the course of this study.  Moreover, it describes in detail the design and 
implementation of a novel bioinformatics pipeline, TAPER™ (Tool for Automated selection 
and Prioritisation for Efficient Retrieval of sequence variants) that was utilised during the 
course of the study so as to identify novel, putative disease-causing variants in the South 
African PD cohort. 
Chapter Three is a detailed description of the results obtained throughout the course of the 
present study.  This includes results from the whole genome SNP array showing the 
relatedness of the 40 Afrikaner PD probands as well as results obtained using conventional 
WES filtration processes and those obtained through the use of TAPER™. 
Chapter Four provides a detailed discussion of the important findings of the dissertation, 
highlight the possible relevance of the findings and the relevance that they may have to the 
understanding of PD.  In addition to this, it advises on possible future work that may expand  
the current knowledge of PD in South African patients. 
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CHAPTER 1:  Introduction 
“Involuntary tremulous motion, with lessened muscular power, in parts not in action and 
even when supported; with a propensity to bend the trunk forwards, and to pass from a 
walking to a running pace: the senses and intellects being uninjured.” Dr James Parkinson – 
1817 
Although first medically described in detail as a neurological syndrome by Dr James 
Parkinson in an essay entitled “An essay on the shaking palsy”¸ Parkinson’s disease (PD) is a 
condition that had been identified long before its first official medical documentations 
(Parkinson 1817); (Raudino 2011).  It was first described in the ancient Indian medical 
system and was (and in some places still is) known as “Kampa Vata”.  In Western medicine 
and medical literature, PD was described in 175AD as the ‘shaking palsy’ by a medical 
physician known as Galen (Pearce 1989).  However, it was only 1642 years later that it was 
established as a recognised medical condition.  Much has been learned about the disease but 
concomitantly, much of it remains a mystery.  
PD (OMIM # 168600) is a severely debilitating neurodegenerative disorder that is 
characterized by a range of motor symptoms, all of which significantly compromise the 
movement abilities of an individual (Goetz 2011; Caviness 2014).  This disorder is currently 
without a cure and the root cause for the disease has been pinpointed to the substantia nigra 
pars compacta (SNpc) in the midbrain (Figure 1.1) (Caviness 2014).  Here, the pathological 
degeneration of the dopaminergic neurons results in an overall decrease in the production of 
the neurotransmitter dopamine, specifically at the nerve terminals, thus leading to motor 
circuit dysregulation (Cookson and Bandmann 2010). 
The pathology of PD is well understood, but the aetiology remains unclear.  For this reason, 
there are numerous hypotheses that have been constructed in various attempts to solve the 
conundrum that is PD.  Initially, it was suggested that PD is an environmental disease and 
subsequently caused by environmental factors (Dawson and Dawson 2003), but more recent 
developments have suggested that it is more likely to be a combination of genetic 
susceptibility as well as environmental contributors that will result in disease development 
(Goetz 2011; Caviness 2014).  




Figure 1.1 Regions of the brain affected by Parkinson’s disease (PD).  The regions affected by PD are 
specifically identified in the diagram.  Voluntary movements are established in the motor cortex and the output 
is regulated to the brain stem.  The output signal is managed by the subcortical targets that include the thalamus 
and putamen (taken from http://ayurvedayogashram.com/parkinson-disease.asp). 
 
1.1 Symptoms and diagnosis of PD 
The clinical diagnosis of PD is predominantly based on the motor symptoms that include 
bradykinesia (the inability of a patient to start and continue movements, as well as the 
inability to adjust the body’s position), resting tremor, postural instability and rigidity.  In 
order for the patient to be diagnosed with PD, at least three of the above-mentioned four 
symptoms must be present.  However, bradykinesia is a hallmark characteristic of PD and for 
this reason, is always required as one of the symptoms for diagnosis (Gibb and Lees 1988).  
Due to the complexity of the disease, the United Kingdom (UK) Parkinson’s disease Brain 
Bank has established a standardized method of diagnosis.  These criteria are divided into 
three major steps, each with specific subsections so as to ensure a diagnosis that it is as 
accurate as possible.  These steps for proper disease diagnosis are highlighted in Appendix I. 
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It should be noted that motor symptoms will only arise in PD patients when approximately 
80% of the striatal dopamine and 50% of the nigral neurons have been lost (Bezard and 
Fernagut 2014).  In addition to these prominent motor symptoms, a range of non-motor 
symptoms that occur prior to the first motor signs characterize PD.  Throughout this so-called 
“premotor period” patients may present with an array of non-motor symptoms with the most 
common being olfactory disturbances/dysfunction which is characterized by hyposmia 
(lessened sensitivity to odours) or anosmia (loss of smell – may be total or partial) (Savica, 
Rocca, and Ahlskog 2010; Bezard and Fernagut 2014).  Moreover, patients may also suffer 
from depression and anxiety, anaemia, rapid eye movement, sleep disturbances as well as 
gastrointestinal disturbances (Savica, Rocca, and Ahlskog  2010; Bezard and Fernagut 2014). 
Regardless of the advances in imaging, clinical diagnostic approaches and tools that are 
available, pathological confirmation through the use of autopsy is still considered to be the 
gold standard for PD diagnosis (Poulopoulos, Levy, and Alcalay 2012).  Anatomically, the 
loss of dopaminergic neurons in the SNpc (Figure 1.2) is considered to be the main 
pathological feature, whereas the accompaniment of intraneuronal accumulation of Lewy 
bodies (LBs) and Lewy neurites (LNs) both of which are responsible for the dopamine 
deficiency supports a PD diagnosis (Figure 1.3). 
 
 
Figure 1.2 Substantia nigra pars compacta (SNpc) and Parkinson’s disease.  The SNpc is almost intangible 
in an individual that is affected with PD (taken from http://health.kernan.org/imagepages/19515.htm). 
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LBs are intra-cytoplasmic inclusions that have a tremendously dense eosiniophilic core and 
are highly proteinaceous (Gasser 2001; Poulopoulos, Levy, and Alcalay 2012).  Interestingly, 
the major fibrillar component of LBs is α-synuclein, a protein predominantly expressed in the 
thalamus, SNpc, neocortex and cerebellum.  It is hypothesised that amino acid changes or 
whole gene duplications and triplications of α-synuclein may lead to an increase in aberrant 
proteins, ultimately leading to neuronal dysfunction and death (Gasser 2001; Dawson and 
Dawson 2003; Poulopoulos, Levy, and Alcalay 2012). 
 
Figure 1.3 Immunohistochemical stain showing Lewy bodies (LBs) in a Parkinson’s disease (PD) patient.  
Lewy bodies are intra-cytoplasmic inclusions that can be identified in patients following autopsy (taken from 
http://www.medicinenet.com/image-collection/lewy_body_dementia_picture/picture.htm). 
 
1.2 Prevalence and incidence of PD 
There is currently no diagnostic test or marker that can be used to identify PD in patients 
without performing an autopsy post mortem.  Although sophisticated equipment such as 
single photon emission computerized tomography (SPECT) scans and positron emission 
tomography (PET) scans have been developed, these have yet to be applied to large, 
population based epidemiological studies.  For this reason, clinical criteria established is the 
most effective means for the diagnosis of PD (de Lau and Breteler 2006; Jankovic 2012).   
PD is a global disease that affects numerous individuals across various ethnic groups, 
however the individual and prevalence estimates may vary based on methodological 
applications as well as geographic locations – both of these factors significantly complicate 
comparisons of individual studies (de Lau and Breteler 2006).   
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The prevalence of PD in developed countries is estimated at approximately 0.3% of the entire 
population and in individuals that are over the age of 60 years of age, this figure increases to 
around 1% (de Lau and Breteler 2006).  It is estimated that the prevalence rate of PD in 
European countries lies between 108 and 257 per 100 000 individuals but it should be noted 
that this figure differs from country to country.  Interestingly the prevalence of PD in Asian 
countries is significantly lower, with figures varying from 51.3 to 176.9 per 100 000 
individuals across all age groups (Muangpaisan, Hori, and Brayne 2009).   Globally, 
investigations have shown that the prevalence of PD among populations is rising with age; in 
individuals between 40 – 49 years of age, the prevalence is estimated at 41 per 100 000, 
between 50 – 59 years of age, prevalence lies at 107 per 100 000.  This estimated figure 
increases four fold between 60 – 69 years of age as the prevalence lies at 428 per 100 000 and 
nearly triples at 1087 per 100 000 in the 70 - 79 years age categories.  This figure increases to 
1903 per 100 000 in individuals that age beyond 80 years (Pringsheim et al. 2014). 
Interestingly, this figure is significantly lower in developing countries and in Africa this 
figure is strikingly lower, with reported prevalence rates falling between 7 and 43 per 
100 000 (Melcon et al. 1997; Okubadejo et al. 2006; de Lau and Breteler 2006).   
There are currently standardized incidence rates for PD.  The reported incidence rates of PD 
in developed countries lie between 8 – 18 per 100 000 person years, with a 1.5% lifetime risk 
of developing the disease (de Lau and Breteler 2006).  Moreover, the incidence rates for PD 
across all age groups has been reported to range between 1.5 – 22 per 100 000 person years 
but studies that focus exclusively on older populations (where individuals are older than 60 
years of age) report PD incidence rates of 529 per 100 000 per year, with an estimated 59 000 
new cases per year being reported in the United States alone (Kaplin et al. 2007).  The 
incidence rates of PD in developing countries such as those in Africa is estimated to be 
around the 4.5 per 100 000 person years mark (Okubadejo et al. 2006; de Lau and Breteler 
2006).   
The use of stricter diagnostic criteria yields significantly lower estimates of incidence and 
prevalence and concurrently, these estimates are also directly influenced by so-called case-
finding strategies (de Lau and Breteler 2006; Jankovic 2012).  Additionally, the estimates 
surrounding incidence and prevalence rates in developing countries such as sub-Saharan 
Africa (SSA) are likely to be a gross underestimation due to the methodological problems 
experienced with some of the studies (hospital-based studies are thought to underestimate PD 
as most patients are in the community and are not in a hospital or clinical environment) and 
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the fact that many patients are either misdiagnosed or undiagnosed (Dotchin and Walker 
2012).   
1.3 Genetic aetiology of PD 
PD was long considered to be the direct result of environmental factors.  Until 1997, the 
concept that PD carries a genetic component and subsequently the notion of heritability in PD 
was contentious – it was considered by many as a “nongenic disorder” (Farrer 2006).  
Interestingly, the factors supporting PD as a result of environmental influences occurred after 
the epidemic of postencephalitic Parkinsonism (PEP) after World War I (Casals, Elizan, and 
Yahr 1998).  PEP is thought to be a viral disease which initiates the degeneration of the 
neurons in the SNpc, thus leading to Parkinsonism, defined as the clinical manifestation of 
PD symptoms but the predominant phenotype is atypical (Klein, Schneider, and Lang 2009).  
Two additional factors that suggested PD is an environmental disease was firstly the 
discovery that MPTP, a by-product of synthetic heroin production, could induce features of 
PD (Dauer and Przedborski 2003), and secondly a lack of disease concordance in 
monozygotic twin studies (Tanner et al. 1999).   
Over the past 17 years or so, the advances in molecular biology have provided the necessary 
platform and supporting evidence that PD has a strong genetic component.  To date, at least 
eleven genes have been implicated in PD pathogenesis, each of them contributing 
independently to the development of the disease or interacting with one another in various 
molecular processes (Figure 1.4).    
Mutations within LRRK2, SNCA, VPS35, EIF4G1, Parkin, ATP13A2, DJ-1, CHCHD2 and 
PINK1 have all been identified in cases of autosomal dominant and autosomal recessive PD 
(Table 1.1) (Trinh and Farrer 2013).  Genes such as GBA (glucocerebrosidase), MAPT and 
DNAJC6 and DNAJC13 have also been identified as key role players in PD.  Homozygous or 
compound heterozygous mutations in GBA have been linked to Gaucher disease – and 
patients with Gaucher disease type III have often reported Parkinsonism and Lewy body 
disease post mortem (Sidransky and Lopez 2012).  Glucocerebrosidase activity can modulate 
ceramide metabolism and α-synuclein processing and therefore theoretically α-
synucleinopathy, and for this reason has become a potential therapeutic target (Spencer et al. 
2011).  MAPT (Microtubule associated protein Tau) produces a protein product commonly 
known as tau, which is found to be highly expressed in neurons and is essential in the 
maintenance of cell structures through microtubule modulation (McMillan et al. 2014).  
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Genetic association studies have provided significant evidence that there is a relationship 
between MAPT defects and idiopathic PD (Vandrovcova et al. 2010).  Aggregation of the tau 
protein results in so-called “tauopathies” which have been observed in numerous 
neurodegenerative disorders such as cortico-basal degeneration, frontotemporal dementia 
with Parkinsonian features, Pick disease and progressive supranuclear palsy (Vandrovcova et 
al. 2010).  The gene most recently identified to be associated with PD is DNAJC6 and a point 
mutation within the DNAJC6 gene was identified in a Dutch-German-Russian Mennonite 
kindred with late onset PD and the presence of LBs in the autopsies of these individuals 
(Edvardson et al. 2012).  It has been suggested that further research is warranted on the 
DNAJC genes to ensure that this was not a mutation unique to this family (Trinh and Farrer 
2013).  In addition to this, there are numerous disorders of multiple system degeneration, 
more commonly known as Parkinson-plus syndromes.  These are a group of 
neurodegenerative diseases that feature the classical symptoms of PD (tremor, rigidity, 
postural instability and bradykinesia) but with additional features (Trinh and Farrer 2013; 
Verstraeten, Theuns, and Van Broeckhoven 2015).  The most common Parkinson-plus 
syndromes are progressive supranuclear palsy, multiple system atrophy, cortical-basal 
ganglionic degeneration and dementia with Lewy bodies.  However, there are recessively 
inherited Parkinson-plus conditions for which genes and variants have been identified.  These 
include a loss of PLA2G6, thereby resulting in neuroaxonal dystrophy and a loss of FBXO7 
which results in juvenile onset pallido-pyramidal Parkinsonism (Trinh and Farrer 2013; 
Verstraeten, Theuns, and Van Broeckhoven 2015)..   
 
 




Figure 1.4 Key molecular processes implicated in Parkinsonism as identified through genetic findings and 
exploratory models of disease.  An axon of a presynaptic glutamatergic cortical neuron (in blue), a dendritic 
spine of a medium spiny neuron (in yellow) and a dopaminergic SNpc neuron (in green) are shown.  In 
presynaptic terminals, α-synuclein (1) promotes exocytosis and aids endocytosis.  LRRK2 (2) regulates 
phosphorylation of endophilin A, neuronal polarity and arborisation (all postsynaptically).  Moreover LRRK2 
also plays a role in chaperone-mediated autophagy, microtubule stabilization and MAPT phosphorylation.  
VPS35 (3) is a vital part of the retromer complex that facilitates cargo recognition early endosomes and 
membrane recruitment in order to form a clathrin-independent carrier.  Cargoes may be destined for lysosomal 
degradation or exosome secretion.  VPS35 facilitates recycling from endosomes to the Golgi apparatus or 
plasma membrane and vesicle transport between perioxisomes and mitochondria.  GBA (4) and additional 
lysosomal acid hydrolases also require the retromer complex for receptor cycling.  Loss-of-function mutations in 
PINK1 (6), DJ-1 (7) and Parkin (5) affect mitochondrial biogenesis and the induction of autophagy.  Parkin is 
directly involved in proteasomal function and ubiquitination and Parkin and PINK1 are involved in 
mitochondrial maintenance.  ATP13A2 (8) has a role in lysosome mediated autophagy while MAPT (9) regulates 
cargo trafficking and delivery (primarily in the axons) (taken from Trinh and Farrer 2013).  Abbreviations: 
GBA, glucocerebrosidase; LRRK2, leucine-rich repeat kinase 2; VPS35, vacuolar protein sorting 35. 
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Table 1.1 List of genes involved in Parkinson’s disease and how they were first identified. 
Genes Mutations Clinical Features How was the gene discovered 
Juvenile and Early Onset PD 
Parkin Various point mutations;  
exonic rearrangements 
LD responsive PD; slowly progressive Linkage analysis 
PINK1 Various point mutations; 
rare, large deletions 
LD responsive PD; akinetic with postural instability 
and gait disturbance; slow progression 
Linkage analysis 
DJ-1 Point mutations; large 
deletions 
LD responsive PD; psychological and behavioural 
disturbances, amyotrophy and cognitive impairment 
Linkage analysis 
ATP13A2 Point mutations LD responsive atypical PD associated with 
supranuclear gaze palsy, spasticity and dementia 
Linkage analysis 
Late Onset PD 
VPS35 Point mutations Inconclusive – possibly Lewy body disease Whole exome sequencing and 
linkage analysis 
LRRK2 Point mutations Brainstem Lewy body disease, neurofibrillary tangle of 
TDP43 pathology as well as nigral neuronal loss 
Linkage analysis 
SNCA Four point mutations; gene 
duplications and triplications 
Diffuse Lewy body disease with protuberant nigral and 
hippocampal neuronal loss 
Linkage analysis 
EIF4G1 Point mutations Loss of dopaminergic neurons in the substantia nigra 
and diffuse Lewy body disease 
Whole exome sequencing and 
linkage analysis 
CHCHD2 Point mutations - Whole exome sequencing and 
linkage analysis 
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Genes Mutations Clinical Features How was the gene discovered 
Genes associated with PD 
GBA Point mutations Glucosidase is a lysosomal hydrolysing 
glucosylceramide, the penultimate intermediate in 
degradation of complex glycolipids 
Linkage analysis 
MAPT Two distinct haplotypes can 
be associated with PD (H1 
and H2) 
Promotion of microtubule assembly and stability Linkage analysis 
DNAJC6 Point mutations Regulates the transport of target proteins from the 
endoplasmic reticulum to the cell surface 
 
Whole exome sequencing 
DNAJC13 Point mutations Regulates the transport of target proteins from the 
endoplasmic reticulum to the cell surface 
 
Whole exome sequencing 
FBOX7 Point mutations Substrate recognition component of a SKP1-CUL1 F-
box protein E3 ubiquitin ligase complex which 
mediates the ubiquitination and proteasomal 
degradation of target proteins 
Linkage analysis 
UCHL1 Point mutations A thiol protease that hydrolyses a peptide bond at the 
C-terminal glycine of ubiquitin 
Linkage analysis 
PLA2G6 Point mutations Catalyses the release of fatty acids from phospholipids. Homozygosity mapping 
 
Adapted from Trinh and Farrer 2013;  Abbreviations:  AR - Autosomal Recessive;  AD - Autosomal Dominant;  GBA - glucocerebrosidase; LRRK2 - leucine-rich repeat 
kinase 2; VPS35 -  vacuolar protein sorting 35;  EIF4G1 - eukaryotic translation initiation factor 4G1;  PINK1 - PTEN-induced kinase 1;  SNCA -  α synuclein;  UCHL1 - 
ubiquitin carboxyterminal hydrolase 1;  MAPT - microtubule-associated protein tau;  FBOX7 - F-box only protein 7;  DNAJC -  DNAJ- Homolog Subfamily C;  CHCHD2 – 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2. 
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1.3.1 Genes directly implicated in PD 
Parkin, PINK1 and DJ-1 
Parkin, PINK1 and DJ-1 have been referred to as the “Three Musketeers of Neuroprotection” 
(Trempe and Fon 2013).  These genes encode very specific proteins, each with distinct 
enzyme activities whose separate functions and combined interactions appear to confer a role 
in neuroprotection (Trempe and Fon 2013).  For this reason, mutations found in these three 
genes contribute to neurodegenerative disorders such as PD.  PINK1 and Parkin are active 
role players in mitophagy (the selective degradation of mitochondria through autophagy), 
while DJ-1 acts as a redox sensor against oxidative stress. 
Parkin was the first gene to be associated with autosomal recessive PD (Kitada et al. 1998; 
Luecking et al. 2000).  It encodes a 465 amino acid protein that belongs to the E3 ubiquitin 
ligase family (Beasley, Hristova, and Shaw 2007).  Parkin has five specific domains that 
enable it to carry out its function.  These domains are the N-terminal ubiquitin-like domain 
(UBL), a cysteine-rich unique parkin domain and two C-terminal RING domains that are 
separated by an in-between-RING domain (IBR).  It should be noted that E3 ligases are of 
particular importance within the cell as an integral part of the Ubiquitin Proteasome System 
(UPS), which is responsible for removal and recycling of dysfunctional and damaged 
proteins. E3 ligases catalyse the transfer of ubiquitin from an E2 ubiquitin conjugating 
enzyme to a protein substrate, tagging the protein for degradation via the 26S proteasome 
(Trempe and Fon 2013).  Parkin therefore plays an essential role as an E3 ligase in protein 
degradation via the UPS by tagging proteins with ubiquitin (Beasley, Hristova, and Shaw 
2007). 
PTEN–induced putative kinase 1 (PINK1) was the first gene that effectively linked PD to the 
mitochondria (Valente et al. 2004) and was then further identified in autosomal recessive PD.  
PINK1 encodes a 581 amino acid protein which is cytoplasmic, but associates with the 
mitochondria and is composed of an N–terminal mitochondrial targeting sequence, a 
serine/threonine kinase domain, a C-terminal domain (function is unknown) and a 
transmembrane helix (Valente et al. 2004; Trinh and Farrer 2013).  Studies support the 
concept that PINK1 has significant neuroprotective roles within the cell and protects the cell 
from oxidative stress, mitochondrial dysfunction and cell apoptosis (Matsuda, Kitagishi, and 
Kobayashi 2013).  Mutations in this protein have differential effects on its ability to 
phosphorylate protein substrates and more specifically, PINK1 is thought to prevent 
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apoptosis as well as mitochondrial dysfunction that is a direct consequence of protein 
inhibition (Rohe et al. 2004; Trempe and Fon 2013; Trinh and Farrer 2013). 
The DJ-1 gene was initially identified as an oncogene but mutations in this gene have now 
been linked to autosomal recessive early onset PD (Nagakubo et al. 1997; Bonifati et al. 
2003).  The protein product of this gene is 189 amino acids in length and is  located in the 
cytoplasm (van Duijn et al. 2001; Bonifati et al. 2003).  This protein belongs to the DJ-
1/Thi/PfpI protein superfamily.  All proteins belonging to this family are oligomers that are 
responsible for the maintenance of cellular biochemical activity and stability (Wilson et al. 
2004).  DJ-1 has neuroprotective activity and directly affects cell sensitivity to oxidative 
stress (Canet-Avilés et al. 2004; Martinat et al. 2004).  However, it remains unclear as to how 
DJ-1 carries out these functions – it is hypothesised that the neuroprotective effects as well as 
oxidative stress sensitivity is mediated through the localization of the mitochondria where 
oxidative stress reduction is induced through the inhibition of components (one such 
component is rotenone, a pesticide that inhibits mitochondrial complex I) within the 
respiratory chain (Canet-Avilés et al. 2004; Blackinton et al. 2009; Trempe and Fon 2013).  
Although the complete mechanism by which DJ-1 functions within the cell is not yet 
understood, it has been documented that DJ-1 deficiency leads to altered mitochondrial 
morphology, and increases in reactive oxygen species (ROS) due to the changes in 
mitochondrial dynamics (Irrcher et al. 2010). 
To summarize, PINK 1 and Parkin play an essential role in mitophagy while DJ-1 is a redox 
sensor of oxidative stress; PINK1 (a mitochondrial-associated protein kinase that is located at 
outer mitochondrial membrane) acts upstream of Parkin (an E3 ubiquitin ligase that 
facilitates the degeneration of damaged mitochondria) and together, the trio plays an essential 
role in the maintenance of healthy mitochondria (Narendra et al. 2008; Kahle, Waak, and 
Gasser 2009).  Early onset PD (age at onset younger than 50) as well as juvenile 
Parkinsonism (age at onset younger than 20 years) accounts for less than 4% the total PD 
cases.  However, a loss of function in Parkin contributes to an approximated total of 15% of 
the sporadic, early onset and juvenile cases (Bonifati 2014).  At autopsy, patients that have 
been identified with Parkin–associated PD do not have LB pathology, but significant nigral 
neuronal loss is present; on the other hand patients with compound heterozygous mutations 
(these patients therefore have two different disease associated alleles at a specific locus) have 
been documented to carry LB or tau pathologies (van de Warrenburg et al. 2001; Bonifati 
2014). As yet, there has been only one documentation of PINK1–related PD with LB disease 
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whereas the pathology for DJ-1-related PD has yet to be determined (Trinh and Farrer 2013).  
Mutations (either compound heterozygous or homozygous) which result in autosomal 
recessive forms of the disorder can be identified most commonly in Parkin (Kitada et al. 
1998; Abbas et al. 1999), intermittently in PINK1 (Rohe et al. 2004; Trempe and Fon 2013) 
and seldom in DJ-1 (Bonifati et al. 2003; Annesi et al. 2005). 
 
ATP13A2 
The gene ATP13A2 is an infrequent cause of PD and was first reported in 2006 when 
mutations were identified in Chilean and Jordanian families that had been reported to have 
Kufor Rakeb Syndrome (KRS) (Ramirez et al. 2006).  KRS is significant as it is a form of 
autosomal recessive PD, which has a significantly lower age at onset and more extensive 
neurodegenerative features, which include dementia (Ramirez et al. 2006; Vilariño‐ Güell et 
al. 2008; Bras et al. 2012).  The protein encoded by this gene is relatively large and is 
comprised of 1 180 amino acids spanning ten transmembrane domains that are located in the 
lysosomal membranes (Ramirez et al. 2006; Vilariño‐ Güell et al. 2008).  ATP13A2 belongs 
to the P-type superfamily of ATPases that are directly involved in the conveyance of 
substrates (some of which include inorganic cations) across the cell membrane (Fan et al. 
2013).  The protein is universally expressed and is also found in the brain – with the highest 
levels identified in the SNpc.  Remarkably, the protein has also been reported to be up-
regulated in late-onset sporadic PD patients (Vilariño‐ Güell et al. 2008; Fan et al. 2013). 
 
SNCA 
SNCA was the first gene to be directly linked to PD, thus paving the way for further 
investigation into the genetic aetiology of PD (Polymeropoulos et al. 1996).  SNCA encodes a 
small, 140 amino acid protein called α-synuclein that is composed of three major regions:  a 
C-terminal region, an amphipathic N terminal region and a non-amyloid B component 
domain (Fortin et al. 2004; Bisaglia et al. 2009).  α-Synuclein is a member of the synuclein 
family and is one of three proteins that are structurally related to one another.  The additional 
proteins that can be found in this family include β- Synuclein (implicated as an antagonist to 
α- Synuclein) and γ- Synuclein (implicated in neurodegeneration as well as cancer) 
(Surguchov and Jeon 2008; Devine et al. 2011).  All proteins belonging to the synuclein 
family are small and soluble and are expressed in neural tissues.  Structurally, these 
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molecules have two noteworthy characteristics - the presence of a degenerative, repetitive 
KTKEGV motif throughout the first 87 residues as well as acidic stretches throughout the C-
terminal region (Surguchov and Jeon 2008).  α-synuclein is a notable protein as it is the 
major component of LBs.  Linkage analyses - the classic study of genetic markers and 
recombination events in pedigrees with multiple effects – have associated point mutations as 
well as genomic multiplications (duplications and triplications) with familial, late onset PD 
(Chartier-Harlin et al. 2004; Devine et al. 2011).  It should be noted, however that patients 
harbouring SNCA whole gene duplications or triplications lead to prominent LB formation, 
earlier onset and dementia (Devine et al. 2011). 
 
LRRK2 
PD associated mutations in LRRK2 result in the development of autosomal dominant forms of 
the disease.  This gene encodes a large, multi-domain protein that is 2 527 amino acids in 
length (Zimprich et al. 2004).  LRRK2 is composed of six domains namely the mitogen-
activated protein kinase kinase kinase (MAPKKK), Ras of complex proteins (ROC), 
armadillo domain (ARM) carboxy terminal of ROC (COR), ankyrin repeat domain (ANK) 
and a leucine-rich repeat domain (LRR).  The LRRK2 protein has been studied in depth and 
has very well defined GTPase and kinase functions within the cell (Anand and Braithwaite 
2009).  Moreover, LRRK2 possesses multiple roles in autophagy, immunity, 
neurotransmission and endocytosis (Cookson 2012).  To date, there are seven PD-associated 
mutations in LRRK2; these mutations include N1437H, R1441C/G/H, Y1699C, G2019S and 
I2020T and patients with LRRK2 mutations have a clinical presentation of idiopathic PD 
(Cookson 2012).  What is most interesting about patients that carry LRRK2 mutations, is the 
fact that in many of the cases, patients have some form of LB disease or at the very least, 
neurofibrillary tangle pathology coupled to gliosis and nigral neuronal loss (Trinh and Farrer 
2013).  This is of particular interest to researchers as LBs and Lewy Neurites (LN) are by 
definition the pathological trademarks of PD, but these abnormal aggregations are largely 
comprised of α-synuclein.  This then challenges the doctrine that pathogenesis should be 








EIF4G1 is one of the most recent genes that has been implicated in autosomal dominant PD 
with LB disease.  EIF4G1 produces a protein product of 1 396 amino acids in length which is 
an active component of the multi-subunit protein complex EIF4G1 that expedites the 
recruitment of mRNA to the ribosome (Siitonen et al. 2013).   A dominantly inherited point 
mutation R1205H, has been linked to late onset PD (Chartier-Harlin et al. 2011).  It should be 
noted, however, that several unaffected carriers of this mutation have been identified – it is 
hypothesised that this may be due to reduced or incomplete penetrance (Chartier-Harlin et al. 
2011; Trinh and Farrer 2013).  For this reason, the role of EIF4G1 in PD remains unclear and 
further studies to support or disprove the hypothesis of its role are therefore necessary.  
Numerous studies have subsequently been conducted in various global PD cohorts in an 
attempt to provide supportive evidence that EIF4G1 mutations are involved in PD (Lesage et 
al. 2012; Tucci et al. 2012; Siitonen et al. 2013; Blanckenberg et al. 2014; Nishioka et al. 
2014).  Each of these studies failed to find an association between variations in EIF4G1 and 
PD.  In a large-scale meta-analysis of genome-wide association studies (GWAS) using a 
custom designed genotyping array NeuroX, three of the known sequence variants in EIF4G1, 
namely R1205H, R1197W and A502V were assessed (Nalls et al. 2014; Nichols et al. 2015).  
Here, a total of 6 249 PD patients and 6 032 control individuals were screened using the 
array.  The data revealed an excess of the heterozygous R1205H variant as it was present in 
five control individuals compared to one PD patient, thereby suggesting that this variant is a 
benign polymorphism as opposed to a mutation.  Moreover, the A502V variant was identified 
in a heterozygous state in one control and five PD cases and the R1197W variant was not 
identified in any cases but was found in a heterozygous state in a single control individual 
(Nichols et al. 2015).  For these reasons, it has been concluded that variations in EIF4G1 are 
not a cause of PD. 
 
VPS35 
VPS35 encodes a 796 amino acid residue known as vacuolar sorting protein 35 (VPS35).  
VPS35 plays an essential role in the retromer system that mediates intracellular retrograde 
transport of endosomes to the trans-Golgi network.  The discovery of the D620N mutation in 
VPS35 is noteworthy as it was the first gene implicated in PD using next generation 
sequencing (NGS), more specifically whole exome sequencing (WES). The mutation was 
first identified in a Swiss kindred with autosomal dominant late-onset PD (Vilariño-Güell et 
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al. 2011).  WES performed on an affected pair of first degree cousins identified the mutations 
(Vilariño-Güell et al. 2011) and subsequently GWAS performed on 4,326 PD patients and 
3,309 unaffected controls; only four additional patients were identified as carriers of the 
novel variant in VPS35. None of the controls were found to carry the VPS35 variant thus 
identifying it as a novel disease-causing mutation in PD (Vilariño-Güell et al. 2011).  Not 
only did the discovery of VPS35 provide significant insights into PD aetiology, it also 




The CHCHD2 gene encodes a small protein of 150 amino acid residues known as the coiled-
coil-helix-coiled-coil-helix domain-containing protein 2 (Funayama et al. 2015).  It is a small 
protein that is localised to the mitochondria thereby providing evidence that CHCHD2 may 
fit into the disease-related network that is associated with PINK1, Parkin and DJ-1.  A novel 
missense mutation was identified in the CHCHD2 gene in a Japanese family with autosomal 
dominant PD.  Through the use of WES, whole genome sequencing and linkage, a 
heterozygous T61I mutation was identified in the CHCHD2 gene as the possible cause for 
disease.  Moreover, Funayama and colleagues then screened a total of 341 patients with 
familial PD and 517 with sporadic PD as well as 559 control individuals.  Three additional 
families were identified as carriers of CHCHD2 mutations; one family carried the same T61I 
mutation, a family with R145Q mutation and a family with a splice site mutation 
(300+5G>A).  The two families that carry the same mutation were found to be unrelated and 
this mutation arose independently in each family. 
 
1.4 Pathways implicated in PD 
Neurodegeneration requires an alteration in neuronal structure as well as a change in 
function.  Disease modification and neuroprotection to decrease and possibly even stop PD 
progression and hence provide a cure, requires a detailed understanding of PD pathogenesis 
as well as the molecular aetiology of the disease (Trinh and Farrer 2013).  In PD, as is the 
case with most brain disorders, genetic analysis of blood samples provides a non-invasive 
and unbiased means by which to identify genes and pathways that can be targeted in the 
disease. 
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1.4.1. Mitochondrial dysfunction and oxidative stress 
As previously discussed in section 1.3, the initial identification of MPTP and its effects led 
some researchers to develop an opinion that PD is a result of environmental stimuli due to 
Parkinsonian features presented by some heroin addicts (Langston 1983).  However, the 
discovery of MPTP simultaneously highlighted the role of mitochondria in PD. The active 
metabolite of MPTP is 1-methyl-4-phenyl-pyridinium ion (MPP
+
) and it is selectively 
transported into the dopaminergic neurons, thereby causing irreparable damage to these 
neurons.  Interestingly, MPP
+
 is an active inhibitor of mitochondrial complex I (Nicklas 
1987) and the inhibition of this specific mitochondrial complex is directly related to an 
increase in free radical generation such as reactive oxygen species (ROS).  Free radical 
generation results in an increase in oxidative stress through changes in the electron transport 
chain (Schapira et al. 1997; Schapira 2010).  This discovery is of relevance to PD as some 
studies have shown that PD patients have significantly lower activity of complex I but that 
this lack of activity is not due to levodopa treatment administered to the patients (Mann et al. 
1994; Haas et al. 1995; Cooper et al. 1995). 
 
Oxidative stress results in significant damage to numerous cellular structures, both intra and 
extra-cellular as well as major damage to nucleic acids and proteins – because of the excess 
ROS that is produced (Storz and Imlayt 1999).  Increases in ROS within the cells are 
beneficial to the immune system and may play a role in cell signalling (Zhou, Ma, and Sun 
2008).  However, it is important that ROS levels are carefully maintained within the cell or 
damage may occur – if ROS levels increase to beyond a certain point, the cells can no longer 
neutralize and eliminate them from the targeted cells, thereby causing structural damage to 
the cells as well as causing damage to DNA, lipids and proteins (Zhou, Ma, and Sun 2008). 
Research conducted on transgenic mice suggests that an overexpression of α-synuclein 
significantly impairs mitochondrial function and may heighten the toxicity of MPTP as the 
levels of oxidative stress within the cell increase (Song et al. 2004).  The protein products of 
PINK1, Parkin and DJ-1 all interact with one another during oxidative stress – Parkin 
associates with the outer mitochondrial membrane, where it prevents the activation of 
caspases and the release of cytochrome c (Darios et al. 2003).  DJ-1 translocates to the 
mitochondrial intermembrane space and matrix where the PTEN-tumour suppressor protein 
is down-regulated thereby protecting the cells against oxidative stress induced apoptosis 
(Kim et al. 2005).  Finally, PINK1 is capable of localising to the mitochondrial matrix and is 
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hypothesised to protect against apoptosis (Petit et al. 2005).  The knowledge gained through 
the identification and analysis of each of these genes strengthens the importance of 
mitochondrial dysfunction and oxidative stress as a vital mechanism in PD pathogenesis. 
 
1.4.2 The Ubiquitin-Proteasome System 
The UPS is a pathway that is conserved from yeast to mammals and is necessary for the 
degradation of most short-lived proteins (cytosolic, secretory and membrane) in the 
eukaryotic cell (Hershko and Ciechanover 1998).  Some of the targets of the UPS include cell 
regulatory proteins, whose judicious destruction is essential for controlled cell division as 
well as proteins that are unable to fold properly within the endoplasmic reticulum.  Other 
networks on which the UPS functions include cell cycle regulation, cellular differentiation 
and cell development, morphogenesis of neuronal networks, intra-cellular stress responses 
and extra-cellular effectors and most importantly, DNA repair (Glickman and Ciechanover 
2002; Dawson and Dawson 2003).  In short, the purpose of the pathway is to tag proteins 
with ubiquitin so that they can be recognised by the 26S proteasome for degradation.   
 
Parkin plays a pivotal role in the UPS.  Parkin belongs to the E3 ubiquitin ligase family due 
to the fact that it has an in-between-ring domain.  This domain is important as it is the region 
that interacts with the ubiquitin–conjugating enzymes (E2) and catalyses the attachment of 
ubiquitin molecules to specific protein targets (Moore et al. 2005).  This process allows for 
'ubiquitin tagging' to take place in order to specify the destruction of specific proteins by the 
proteasome (Shimura et al. 2000).  Ubiquitination results from the consecutive actions of the 
ubiquitin activating E1, E2 and E3 enzymes.  Subsequent cycles of ubiquitination result in 
the formation of a poly–ubiquitin chain that can then be recognised by the 26S proteasome 
(Moore et al. 2005).  E3 ubiquitin ligases provide substrate specificity to the ubiquitination 
process as each ligase binds to specific subsets of proteins (Figure 1.5).  Defects in Parkin 
may therefore interfere with the proteolytic pathway that could lead to the deleterious 
accumulation of particular proteins, in turn contributing to the death of nigral neurons 
(Matsumine et al. 1997; Kitada et al. 1998).  The tagging of proteins with ubiquitin may also 
occur for processes that are proteosome-independent: some of these roles include signal 
transduction and protein trafficking (Kahle and Haass 2004).  Moreover, it has been 
established that Parkin is associated with mitochondrial DNA in a neuroblastoma cell line as 
well as in cells that are undergoing proliferation (Rothfuss et al. 2009).  The conclusions 
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reached through various studies are that Parkin protects the mitochondrial DNA from 
oxidative damage and may act to stimulate mitochondrial repair (Rothfuss et al. 2009; da 
Costa et al. 2009). Parkin acts together with PINK1 in a pathway which promotes the 
maintenance of mitochondrial functioning and integrity (Rothfuss et al. 2009). 
 
Figure 1.5 The Ubiquitin Proteaseome System.  The ubiquitylation and degradation of substrate proteins 
occurs by a series of reactions that are controlled by the enzymes of the ubiquitin–proteasome system (UPS).  
During the activation reaction, ubiquitin is transferred to an E1 enzyme in process that is ATP dependant (step 
1).  The activated ubiquitin is subsequently transferred to an E2 enzyme in the conjugating reaction (step 2). The 
E2 enzyme then carries the ubiquitin to the E3 enzyme – this is known as an ubiquitin ligase (step 3). The E3 is 
important not only because it covalently ligates ubiquitin to Lys residues on the substrate protein, but also 
because it mediates substrate specificity. This process of ubiquitin ligation may be repeated with a Lys of the 
ubiquitin protein itself serving as the substrate, which leads to the formation of a polyubiquitin chain on the 
target protein. Deubiquitylating enzymes may reverse substrate protein ubiquitylation (step 4). Ligation of 
polyubiquitin has diverse biological consequences for the recipient protein. For example, Lys11- and Lys48-
linked polyubiquitin chains serve as tags to target substrate proteins for proteasomal degradation (step 5). 
Conversely, linear, Lys63- and Lys11-linked chains promote the assembly of signalling complexes (step 6). X, 
Y and Z indicate ubiquitin-binding proteins. Pi, inorganic phosphate; PPi, inorganic diphosphate; Ub, ubiquitin 
(taken from Vucic, Dixit, and Wertz 2011). 
 
 
1.4.3 The Autophagy-Lysosomal Pathway 
The autophagy-lysosomal pathway (ALP) is another system by which unwanted proteins are 
removed from the cell.  The ALP can be divided into three different pathways, each of which 
is based on the substrates that will reach the lysosomal lumen: macroautophagy, 
microautophagy and chaperone-mediated autophagy (CMA) (Figure 1.6) (Cuervo et al. 2005; 
Levine, Mizushima, and Virgin 2011).  The induction of autophagy can occur within 
relatively short periods of nutrient deprivation, CMA is the result of prolonged nutrient 
deprivation while the induction of microautophagy is not dependent on any form nutritional 
deprivation or stress (Pan et al. 2008).  
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In contrast to the UPS, macroautophagy (the most inducible pathway) is hypothesised to be 
the primary mechanism by which entire organelles such as mitochondria are recycled.  Large 
membrane proteins and complexes that are unable to pass through the tapered proteasome 
barrel can thus be degraded (Cuervo et al. 2005; Levine, Mizushima, and Virgin 2011).  ALP 
dysfunction may result from the failure of autophagosome formation or autophagosome 
fusion with lysosomes, dysfunction of molecular chaperones or lysosomal membrane 
receptors or deficiency of enzymes in the lysosomes (Pan et al. 2008).  Moreover, it has been 
shown that the ALP clears α-synuclein from cells (Cuervo et al. 2005; Levine 2005) and 
abnormal functioning of the ALP could therefore lead to the toxic accumulation of this 
protein and subsequently neurodegeneration.  The role of the ALP in diseases such as PD has 
been strengthened by the fact that mutations in the ATP13A2 gene lead to insufficient protein 
degradation (Ramirez et al. 2006; Pan et al. 2008).  ATP13A2 is a lysosomal protein and it is 
thought to be responsible for cation transport and the regulation of manganese levels.  Loss of 
ATP13A2 levels result in lysosomal dysfunction with an accumulation of lysosomes and 
autophagosomes as well as a decrease in proteolytic activity (Manzoni and Lewis 2013) 
 
 
Figure 1.6 The Autophagy Lysosomal Pathway.  The macroautophagy pathway is the most common pathway 
by which cytosolic proteins and cellular components are degraded.  Inhibition of the autophagosome formation 
by 3-methyladenine (3MA) without affecting ATP levels or protein synthesis, or the inhibition of the fusion of 
the autophagosome with the lysosome by bafiloycin A1 (BafA1) may lead to dysfunction of macroautophagy.  
In microautophagy, the lysosomal membrane will deform so as to engulf the cytosolic substrates.  Specific 
cytosolic proteins that can be identified by cytosolic chaperone, the heat-shock cognate protein of 70kDA 
(hsc70) which targets them specifically to the surface of lysosomes, are degraded through the CMA pathway 
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1.5 Next generation sequencing and whole exome sequencing  
Since this PhD thesis focuses on the use of WES as a means for novel gene discovery for PD, 
the next section with provide an introduction to this methodology.  The discovery of dideoxy 
nucleotides for the use in the “chain terminator sequencing method” by Sanger marked a 
massive breakthrough in the history of DNA sequencing (Cawley 2005).  This concept 
revolutionized DNA sequencing and drove the development of automated Sanger sequencing 
– the choice method for DNA sequencing over the course of about 20 years.  Throughout this 
time, the technological advancements have allowed for longer fragments of DNA to be 
sequenced as well as a greater degree of parallelism – interestingly, the technology that 
currently exists supports the concurrent sequencing of 1000 base pairs per DNA fragment in 
96 capillaries (Cawley 2005; Metzenberg 2008).  Although Sanger sequencing provided a 
means by which to analyse DNA, this approach has not allowed for the analysis of DNA in a 
high throughput manner (http://genome.tugraz.at/Theses/AbstractFischerM2010.pdf).   
 
Automated Sanger sequencing was the fundamental principle on which the Human Genome 
Project (HGP) was based.  This project was initiated in 1990 and aimed at determining the 
full genomic sequence (all three billion base pairs) of the human genome.  The project took a 
total of 13 years to complete.  Initial draft results were produced within the first ten years 
(Lander et al. 2001; Venter et al. 2001)  and was completed in its entirety in the following 
three years (Jasny and Roberts 2003).  The HGP was not the only outcome of 13 years of 
work; numerous spin-off projects have since been developed, but two of the most notable 
ones are the International HapMap Project and the 1000 Genomes Project.  The 1000 
Genomes Project focussed on the sequencing of the genomes of at least 1000 individuals of 
various ethnicities so as to provide a comprehensive resource/reference on genetic variation 
in humans (http://www.1000genomes.org/about).  The International HapMap Project, on the 
other hand, intended to develop a haplotype map of the human genome, that describes 
common patterns in the human genome as well as those regions particularly prone to 
sequence variations (Gibbs et al. 2003).  
 
The HGP, 1000 Genomes Project and the International HapMap Project required a large 
amount of time and resources and one of the major outcomes of these projects was the 
conclusion that faster, cheaper and high throughput platforms were necessary (Schloss 2008).  
This was one of the major contributing factors that led to the development of the National 
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Human Genome Research Institute (NHGRI) funding scheme, with the goal of reducing the 
cost of human genome sequencing to US$1000 within ten years (Schloss 2008; van Dijk et 
al. 2014).  This drove the development of Next Generation Sequencing (NGS) technologies, 
each of which share the following significant improvements:  NGS libraries are prepared in a 
so-called free cell system and therefore bacterial cloning of DNA fragments is no longer 
required; secondly sequencing output is directly detected and electrophoresis is no longer 
necessary as the base pair interrogation is performed cyclically and in parallel.  Lastly, 
hundreds of thousands of sequencing reactions can be produced in parallel.  The effectiveness 
of large scale, high throughput sequencing generated large amounts of sequencing data but 
with a notable drawback.  NGS technologies produce short sequencing reads, thereby making 
assembly challenging and in turn, driving the development of novel alignment algorithms 
(van Dijk et al. 2014).  The advent of NGS has enabled researchers to study biological 
systems at a level that has never before been possible.  Moreover, NGS technologies are an 
effective strategy for the discovery of genetic causes underlying various disorders; more 
specifically, those disorders for which a genetic basis was intractable using conventional 
approaches such as positional cloning and linkage analysis (Bras, Guerreiro, and Hardy 2012; 
Grada and Weinbrecht 2013; van Dijk et al. 2014)   NGS is fast becoming an important 
technology in basic science and is becoming an reputable tool in translational research (Grada 
and Weinbrecht 2013).  The continual reduction in cost of sequencing as well as the 
development of standardized methodologies for both alignment and data analysis is making 
NGS an appealing tool for routine applications, even in small scale laboratories (van Dijk et 
al. 2014). 
 
Two arms of NGS are whole genome sequencing (WGS) and the aforementioned WES 
(Hedges et al. 2009).  WGS examines the entire genome of an individual – large volumes of 
data are obtained per single sample analysed, making this form of NGS very complex and 
costly (Ng et al. 2009; Robinson, Krawitz, and Mundlos 2011).  Due to the complexity and 
volumes of data obtained, bioinformatics infrastructure and proficiency is necessary for data 
processing; the result being that WGS is beyond the scope of most laboratories (Bras and 
Singleton 2011). 
 
WES on the other hand, is a so-called targeted sequencing approach, where only 
approximately 1.2% of the human genome is examined for genetic variation in order to 
identify potential disease-causing variants.  WES involves the sequencing of only the protein 
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coding regions of the genome (exons), more commonly referred to as the exome.  WES is 
considered to be an effective strategy for novel variant discovery because: 
 It has long been hypothesised that most functional variants are in the coding regions 
of the genome i.e. the variants in these regions are most likely to have a direct effect 
on the protein (Botstein and Risch 2003; Ng et al. 2009), 
 There are approximately 180 000 exons in the human genome and therefore only 30 
mega bases (Mb) of the genome need to be sequenced (Ng et al. 2009), 
 It has been documented that the most common causes for Mendelian disorders are 
single nucleotide variants (SNVs) found in coding regions – these are a source for the 
mapping of complex genetic traits (Horner et al. 2009). 
 
WES has already been used in numerous applications some of which include the elucidation 
of disorders that are genetically heterogeneous, the identification of molecular defects within 
single gene disorders and improving diagnostics (Ng et al. 2009; Hedges et al. 2009; 
Robinson, Krawitz, and Mundlos 2011).  Given the region that is examined using WES, it is 
not surprising that the volume of both the raw and processed data is significantly smaller than 
with WGS (Pabinger et al. 2013).  However, it is important to bear in mind that each 
sequencing run will identify a large number of SNVs, including single nucleotide 
polymorphisms (SNPs) as well as insertions and deletions (indels).  The number of variants 
that are identified may lie anywhere between 50 000 and 100 000, of which approximately 
90% are hypothesised to already have been recorded in the public online databases (Ng et al. 
2009; Bamshad et al. 2011; Ng et al. 2010).  In contrast, WGS generates approximately 5 
million SNVs per individual and for this reason, it is understandable that WES has become 
the more favourable approach in the exploration of Mendelian disorders, thereby contributing 
to the functional annotation of the human genome and providing insights into disease 
development and mechanisms (Pabinger et al. 2013). 
 
1.6 Whole exome sequencing platforms and bioinformatics 
Currently, a formidable challenge is faced when analysing WES data is the difficulty of 
identifying a single pathogenic mutation amongst the background of polymorphisms and 
possible sequencing errors that are generated for each sequenced individual.  For this reason, 
it becomes imperative that a detailed understanding of the WES platform as well as the data 
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obtained from each sequencing reaction is understood so as to aid in post-sequencing variant 
processing as well as variant prioritization. 
 
1.6.1 Commonly used whole exome sequencing platforms  
(i) Illumina Hi-Seq  
Illumina, like most NGS platforms, relies on the chain termination method and both 
the Hi-Seq 2000 and 2500 integrate improvements in engineering that currently 
produce the highest output available on the market.  Before sequencing is conducted, 
the DNA is sheared into fragments to generate a library and is run on a gel in order to 
separate each of the fragments based on size.  A fragment with an average length 
between 200 and 300bp is then selected for further replication through PCR.  This so-
called automated cluster generation is used to distribute the fragment library to the 
surface of a flow cell amongst a sea of adaptors.  Each fragment will then bind to a 
complementary adaptor and a process known as bridge amplification will then occur – 
thereby allowing for the generation of copies of a specific molecule to be made on the 
surface of the flow cell.  As each individual base is added, a camera records the 
location of each cluster through the capture of the fluorescent signal emitted by the 
cluster.  The combination of these images creates the sequence.  It should be noted 
that although the addition and sequencing of a single base at a time seems slow, each 
flow cell is capable of analysing approximately 150 million of these clusters, thereby 
making this an extremely efficient system 
(http://systems.illumina.com/systems/sequencing.ilmn).    
Although the Hi-Seq 2000/2500™ is still the most favoured Illumina sequencing 
platform to use for WES, January 2015 brought exciting news that Illumina had 
developed two new machines, the Hi-Seq 3000/4000™.  These systems are both 
developed off the success of the Hi-Seq 2000 / 2500™ and include a leveraging 
pattern flow technology, providing unparalleled sequencing speeds and multiple 
applications for high throughout sequencing.  The development of these improved 
systems means that the Hi-Seq 4000™ is capable of sequencing up to 12 whole 
genomes, 100 whole transcriptome samples or a total of 180 full human exomes in 3.5 
days or less – thereby currently making Illumina the biggest driver in the field of NGS 
(http://www.illumina.com/company/news-center/press-releases/press-release-
details.html?newsid=2006979).   
(ii)   Roche 454 Genome Sequencer FLX™ 
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Roche’s 454 Genome Sequencer FLX became commercially available in 2005 and is 
a modification of the Sanger sequencing method – more specifically, Roche managed 
to significantly simplify the preparation process.  The principle behind this platform is 
the use of custom design fibre chips that house adaptor-flanked fragments in order to 
hold the primers and polymerase enzymes and start the synthesis of complementary 
strands.  Moreover, the 454 sequencer also employs emulsion PCR amplification that 
replicates the strands attaching to beads – this is of particular significance as it 
ensures that the reaction can be detected at a specific light intensity.  The sample is 
then loaded onto a picotiterplate, where the beads enter individual wells.  Packing 
beads are then also added to the plate in order to assist with the spectrophotometric 
reading of the sample.  The result of this method is that the 454 is capable of 
analysing numerous samples in parallel – a significant improvement on the Sanger 
sequencing method.  The 454 system does, however have a significant drawback as it 
is incapable of managing homopolymers, thereby producing a significant error rate 
(http://www.454.com/).  
(iii)  Applied Biosystems SOLiD System
™
 
The Applied Biosystems SOLiD System is considered to be an extremely flexible 
system in that it allows for genome sequencing in numerous applications.  There are 
five major primary steps namely (1) enzyme and sample preparation; (2) PCR and 
substrate preparation; (3) ligation; (4) imaging and (5) data analysis.  Interestingly, 
enzyme and sample preparation are the only samples that need to change based on the 
desired application.  SOLiD uses emulsion PCR, that is similar to Roche, but the 
fragment library is distributed onto microbeads that can vary in size and richness of 
slides that they are on.  Slides containing one, four or eight sections can be used, 
based on the required application.  Fluorescence is then emitted when each fragment 
is ligated onto a single strand sequence.  Data analysis occurs through Exact Call 
Chemistry, which relies on an eight base pair interrogation system with four different 
coloured primers so as to map out possible combinations within the sequence.  This 
system is effective in the detection of SNVs 
(http://www.appliedbiosystems.com/absite/us/en/home/applications-
technologies/solid-next-generation-sequencing.html).    
(iv)  IonTorrent™ by Life Technologies 
The Ion Torrent is a long read, high-density semiconductor sequencing platform that 
was developed by Roche 454 Life Sciences in partnership with DNA Electronics and 
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is largely considered to be the “new kid on the block” when it comes to NGS.  It is 
based on the detection of hydrogen ions that are released during the polymerization of 
DNA.  As the deoxyribonucleotide triphosphate (dNTP) is incorporated into the DNA 
strand that is complementary to the template strand, the release of a hydrogen ion 
triggers an in-sensitive field-effect transistor (ISFET) ion sensor that will record the 
reaction.  The Ion Torrent differs from other NGS sequencing technologies as no 
modified nucleotides or optics are made use of; rather a single species of dNTP is 
used per unit time as opposed to all four dNTPs that are used on other platforms.  
Should there be no complementarity between the dNTP and the template nucleotide, 
there will be no reaction.  It has been estimated that the Ion Torrent has a per base 
accuracy of 99.6% based on 50 base reads with 100Mb per run, with read lengths 
averaging 100 bases.  One of the disadvantages of the Ion Torrent is that the 
enumeration of long repeats is a difficult exercise as multiple ions will be released as 
multiple nucleotides are incorporated, therefore making signal differentiation different 
(http://www.lifetechnologies.com/za/en/home/brands/ion-torrent.html).    
 
1.6.2 Data analysis strategies 
The current achievements in molecular biology specifically pertaining to WES have 
contributed greatly to the understanding of various diseases, but there have been significant 
bioinformatics challenges that may limit the efficiency and application of WES as a whole 
(D’Antonio et al. 2013).  One such example is the fact that the interpretation and 
manipulation of sequencing data that is obtained through WES presents notable 
computational challenges (D’Antonio et al. 2013; Pabinger et al. 2013).  As already 
mentioned, the first major obstacle to overcome when analysing WES data is the 
management of the actual volume of data that is obtained through various sequencing 
platforms.  It is estimated that a researcher may be confronted with a vast number of variants 
that may range anywhere from between 50 000 and 100 000 per sample sequenced, 
dependant on the sequencing platform that is used.  Of these, approximately 10 000 will be 
predicted as insertions, deletions, splice-site alterations or non-synonymous amino acid 
substitutions (Clark et al. 2011).  Analysis of the raw data can be cumbersome due to the 
volume of data as well as the read lengths that are obtained.  Moreover, erudite informatics 
tools are necessary and the management and storage of the data files is very often 
impractical.  To date, there is no “gold standard” that can be applied to WES data due to the 
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array of file formats, software and analytical tools that are available– more importantly, it has 
become common knowledge that scientists are required to have the necessary skills in 
computational biology to analyse, mine and interpret the data (Bras, Guerreiro, and Hardy 
2012; D’Antonio et al. 2013; Pabinger et al. 2013).  For this reason there has been much 
focus on the development of a streamlined and highly automated pipeline for WES analysis.  
An example of one such pipeline is illustrated in Figure 1.7. 
 
 
Figure 1.7 Sample pipeline for whole exome sequencing result filtration (taken from http://d-
scholarship.pitt.edu/18107/1/WesterfieldL_Thesis_2013etd.pdf).  
 
It should be noted that variants that are consistently found to be common in the general 
population are unlikely to be attributed to a specific disease.  Variants that occur at high 
frequencies (very often greater than 5%) are found in databases such as dbSNP, the 1000 
Genomes Project, and various exome databases.  One of the major drawbacks for making use 
of these databases is the fact that there may be a change or error in information pertaining to 
specific genes and variants; there are approximately 17 million SNPs that have been recorded 
in the human genome but the false positive rates for these SNPs is estimated to lie between 
15 and 17% (Ku, Naidoo, and Pawitan 2011).  Computational algorithms have been 
incorporated into WES data analysis so as to identify genes that have been consistently 
shown to have high false positive or negative results and can be applied to the data analysis 
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so as to narrow the list of candidate genes to a more manageable size (Robinson, Krawitz, 
and Mundlos 2011).  WES variant prioritisation is further supported by numerous additional 
computational algorithms, most of which will predict the pathogenicity of a particular 
variant.  The two most commonly used tools for pathogenicity predictions are SIFT (Sorting 
Intolerant From Tolerant) (http://sift.bii.a-star.edu.sg/) and PolyPhen2 
(genetics.bwh.harvard.edu/pph2/dokuwiki/start).  The removal of SNPs that are predicted to 
be functionally benign or tolerated allows for further trimming of the list of variants that 
require further analysis.  Once a list of variants of interest has been identified, validation of 
the selected variants becomes imperative – variants of the greatest interest are confirmed 
through the use of Sanger sequencing and should the variant be identified as a plausible 
candidate, functional studies should be conducted on the variant so as to determine the 
possible physiological effects of said mutation. 
 
1.6.3 Proof of concept: use of WES to identify PD-causing genes 
Diseases such as PD are amenable to WES approaches with both rare Mendelian as well as 
common sporadic forms of the disorder being suitable for this type of analysis (Bras and 
Singleton 2011).  For recessive forms of PD, as few as three individuals may provide 
significant insight into the disease when using WES; for clearly dominant disorders, as few as 
four or five individuals may be sufficient to identify novel mutations (Wang et al. 2010; 
Glazov et al. 2011).   
The success of this approach in identifying novel mutations in diseases such as PD has been 
shown by the identification of a novel gene VPS35 (vacuolar sorting protein associated 
protein 35) in a Swiss kindred with autosomal dominant late-onset PD (Vilariño-Güell et al. 
2011).  WES was performed on an affected pair of first degree cousins (Vilariño-Güell et al. 
2011).  The NimbleGen Sequence Arrays were used for exonic capture and sequencing 
performed on the Illumina Genome Analyser and the number of variants identified in each 
patient was 34,754 and 29,952 respectively.  Filtering was carried out using HapMap to filter 
the results further by eliminating additional polymorphisms.  Structural alterations such as 
CNVs were eliminated using the Database of Genomic Variants (version 6) and a total of 
4,265 candidate variants remained.  Upon further filtering, where variants found on the X and 
Y chromosomes as well as synonymous and non-coding variants that were already present in 
dbSNP (version 130) were excluded, a preliminary candidate list of 69 disease-causing 
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variants was identified (Vilariño-Güell et al. 2011).  Notably, of these, 36 were found to be 
artefacts using Sanger sequencing, leaving 33 validated variants.  Only two variants were 
identified as novel - namely A1012V found in Integrin alpha X (ITGAX) and D620N, found 
in VPS35.  Upon further screening of 4,326 PD patients and 3,309 controls, four additional 
patients were identified as carriers of the novel variant in VPS35 and none of the patients 
carried the ITGAX variant, but it was identified in one of the controls.  None of the controls 
were found to carry the VPS35 variant thus validating it as a novel disease-causing mutation 
in PD (Vilariño-Güell et al. 2011).  The use of first-degree cousins and the specific filtering 
strategy employed was a proof of principle that WES could be used to successfully identify 
novel PD-causing genes. 
Notably, this same gene and mutation was identified by an independent group (Zimprich et 
al. 2011).  They studied an Austrian family and in this case, two second degree cousins were 
selected for WES under the assumption that any shared rare variants identified in these 
patients would be plausible disease-causing mutations (Zimprich et al. 2011).  Once the 
sequencing results were obtained and the sequences aligned, the SNVs were identified using 
dbSNP (version 131).  Further filtering made use of SAMtools (version 0.1.7), which 
eliminated SNVs recorded in dbSNP as well as known indels (Zimprich et al. 2011).  This 
approach resulted in only ten non-synonymous coding variants to be short-listed as 
candidates, possibly as more distantly-related individuals had been used (second degree 
cousins) as opposed to the first degree cousins which had been used for the first study 
(Vilariño-Güell et al. 2011).  The D620N change in the VPS35 gene was observed in all eight 
patients available for genetic study but was not found in any of the 2,783 controls screened 
(Zimprich et al. 2011).  These two studies provided further evidence that WES is an effective 
tool that can be used in the identification of novel disease genes even if the filtration 
processes to identify the mutations differs from study to study. 
 
1.7 Parkinson’s disease research in South Africa 
Numerous investigations into both the clinical and genetic characteristics of PD have been 
conducted in the Japanese, European and North American populations but such investigations 
into the clinical and genetic characteristics of PD in the Sub-Saharan African (SSA) 
populations are very limited (Okubadejo 2008; Blanckenberg et al. 2013).  
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There is an increasing urgency in the need to identify novel genes that play a direct role in the 
development of PD or may contribute directly to the development or protection against the 
progress of the disease (Farrer 2006; Gasser 2010; Trinh and Farrer 2013).  Africa is 
experiencing a demographic transition; some of these changes include an increase in fertility 
rates - the population on the African continent is expected to peak at 1.6 billion in 2030, 
thereby representing 19% of the global population; urbanization.  It is hypothesised that there 
will be considerable migration from rural areas into urban areas which poses formidable 
challenges pertaining to land access, infrastructure and service delivery; finally, decreases in 
mortality rates -thus increasing the average life expectancy and increasing the incidence of 
neurodegenerative disorders such as PD (Africa’s Demographic Trends, http://www.afdb.org)  
There is currently a very limited knowledge about clinical presentations of SSA patients or 
the genetic aetiology of PD in these individuals; it remains important that mutations in the 
known PD genes or mutations in novel genes be investigated as the root cause for the disease 
in this population. 
 
To our knowledge, the PD genetics research group at the Division of Molecular Biology and 
Human Genetics at Stellenbosch University in Cape Town, South Africa is currently the only 
group studying the genetic aetiology of PD in South African patients.  It has been determined 
that the known PD genes do not appear to play a significant role in these affected patients 
(Bardien et al. 2009; Keyser et al. 2010; Haylett et al. 2012).   
 
A total of 458 South African PD patients from diverse ethnic groups have been recruited for 
genetic analysis (Table 1.2).  For the purposes of the study, the PD cohort was split into 
various ethnic groups.  This is due to the fact that there are a number of diseases that may be 
specifically related to a particular ethnic group.  Moreover, these diseases may share 
overlapping clinical features but the genetic cause for the disease is different (Klein, 
Schneider, and Lang 2009).  In addition, the English-speaking Whites and the White 
Afrikaans-speaking patients were analysed independently from each other due to the unique 
ancestry of the Afrikaner. 
The various ethnic groups can be defined as follows: 
 The English-speaking White population is composed of individuals of European 
descent. 
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 The Afrikaner population is unique to South African and is composed only White 
Afrikaans speaking individuals.  These individuals are mainly of Dutch and German 
decent but also have French ancestral lines (Greeff 2007).  
 The Mixed Ancestry population is defined as an admixture or a combination of 
various ethnic groups.  These various combinations include immigrants from 
Western Europe, India, Malaysia and Madagascar as well as combination of ethnic 
groups which are indigenous to South Africa, such as San and Khoi–Khoi (de Wit et 
al. 2010). 
 The Black African population is composed of individuals whose ancestry can be 
directly traced to the African continent.  This ethnic group is comprised of 
individuals who speak traditional African languages such as Zulu, Xhosa, Ndebele, 
Tsonga, Venda, Swazi, Northern Sotho, Tswana and Sesotho.   
 The Indian population is composed of individuals who migrated from colonial India 
to the African continent in the latter part of the 19
th
 century. 
Table 1.2 Ethnic breakdowns of 458 South African Parkinson’s disease patients recruited for 
genetic studies. 
Ethnicity n (% of 458) Positive family history of PD 
n (%) 
White (non-Afrikaner) 175 (38.2) 46 (26.3) 
White Afrikaner 148 (32.3) 36 (24.5) 
Mixed Ancestry 104 (22.7) 16 (15.4) 
Black 26 (5.7) 5 (19.2) 
Indian 5 (1.1) 2 (33.3) 
 
The numbers of PD patients from each of the ethnic groups and their disease inheritance 
patterns are illustrated in Figure 1.8.  From this, it is clear that for the majority of South 
African PD patients, the familial inheritance pattern is not known but dominant inheritance 
patterns appear more common than recessive inheritance patterns.  Moreover, 70.5% 
(323/458) of the cohort are white and of these, 45.8% are Afrikaner. 




Figure 1.8 Graphic representation of the South African PD patient group according to ethnicity and 
disease inheritance pattern. 
 
In the following section, a more detailed account of the Afrikaner will be provided, as this 
particular ethnic group is the focus of the present study. 
 
1.7.1 The South African Afrikaner population 
The South African Afrikaners are a unique group of individuals that are mainly descended 
from Western Europeans who came to settle on the southern tip of Africa from the middle of 
the 17
th
 century (Greeff 2007; http://www.sahistory.org.za/people-south-africa/afrikaans). 
The Dutch East India Company (DEIC) established a refreshment station in Table Bay, 
which is today known as Cape Town.  In 1657 executives from the DEIC were allowed to 
retire from the Company’s service and become “Free Burghers” (independent farmers) – 
these retirees were mainly of Dutch and German descent – and subsequent settlers in the 
Cape (Heese, 1971).  Moreover, in 1688 a group of French Protestants, who were intent on 
obtaining religious freedom, fled from France and also settled in the Cape.  For this reason, 
the French, German and Dutch are considered to be the forefathers of the Afrikaner nation.  It 
is estimated that between 1652 and 1806, approximately 4000 emigrants had arrived at the 








Autosomal Dominant 54 38 19 4 1
Autosomal Recessive 9 9 6 1 1
Unknown 112 101 79 21 3
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were composed of a mixture of Dutch (34.8%), Germans (33.7%), French (13.2%), People of 
Colour (7%), British (5.2%), Unknown origin (3.5%) and Other Europeans (2.6%) (Heese, 
1971).  
 
The colonization of the Cape by the British resulted in numerous consequences, one of which 
was the drive for the Afrikaners to become an independent entity.  It is understood that this is 
what led to the Great Trek, a north eastward and eastward migration away from British 
control into the interior of South Africa – over a period of 18 years (1836–1854).  For this 
reason, groups of Afrikaner settlers became geographically isolated; more importantly 
consanguinity was common especially in the early generations (Hall et al. 2002).  Due to the 
suggested inbreeding and genetic isolation, the Afrikaners have become a widely used 
example of founder effects (Botha and Beighton 1983a; Botha and Beighton 1983b).  A 
founder effect results when there is reduced genetic diversity due to the fact that a population 
is descended from a small number of colonising ancestors.  Although in recent years some 
admixture has occurred in this population, for approximately the first 15 generations, 
population growth was almost entirely attributed to reproduction as immigration prior to the 
founding was minimal (Hall et al. 2002).   
 
The demographic account of this population is reflected in the unusually high frequency of 
specific rare Mendelian disorders which has been recorded to be between 5-10 times higher 
than in other population groups (Brink and Torrington 1977; Hayden et al. 1980; Botha and 
Beighton 1983a; Tipping et al. 2001; Hall et al. 2002).  In addition to this, this population 
carries an unusually low allelic diversity at associated loci. At any susceptibility locus, all 
affected individuals in the specific population may carry a limited set of alleles that are 
identical by descent from a few common ancestors.  Moreover, due to the fact that the origins 
of the Afrikaner are relatively recent, the chromosomal regions that surround the disease 
allele are distinctly larger than outbred populations therefore sparse genetic maps are 
informative (Roos, Pretorius, and Karayiorgou 2009).  As a result of this, founder populations 
are more amenable to linkage disequilibrium (LD) approaches, which is considered to be 
more informative than traditional linkage for the analysis of complex traits (Karayiorgou et 
al. 2004)  In summary, due to the high LD in the Afrikaner population, they are considered to 
be important for the identification of genes that are associated with disease.   
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There are numerous disorders that occur in the Afrikaners at high frequencies because of 
founder effects.  These include long QT syndrome (Brink et al. 2005), Fanconi anaemia 
(Tipping et al. 2001), pseudoxanthoma elasticum (PXE) (Saux et al. 2002), schizophrenia 
(Karayiorgou et al. 2004), Huntington’s Disease (HD) (Hayden 1980), progressive familial 
heart block 1 (Brink and Torrington 1977), familial colonic polyposis, porphyria variegate, 
osteogenesis imperfecta  (Knoll, de Vries and de Wet 1988) and familial hypercholestrolemia 
(FH) (Brink et al. 1987).  Studies on FH revealed that it is found at a prevalence of 1 in 100, 
which is approximately five times more common in a South African Afrikaner population 
than in populations from Europe and North America.  In addition to this, studies on FH 
identified three founder mutations that could be associated with 95% FH cases in the 
Afrikaner population (Roos, Pretorius, and Karayiorgou 2009).  These mutations were 
subsequently identified in FH cases from the Netherlands (Defesche et al. 1993) and one of 
the mutations was specifically shown to have originated in the Netherlands and introduced to 
South Africa by a single individual (Defesche et al. 1996).   
 
The present day Afrikaners are an identifiable group with a relatively small gene pool and 
more importantly extremely well kept family records over a period of more than 350 years 
thereby allowing for accurate historical tracing and examination (Prof. Geldenhuys, personal 
communication).  The family records that are available for inspection include annals of 
christenings, marriages, deaths and membership records of the Reform Church (Prof. 
Geldenhuys, personal communication; http://www.gisa.org.za).   
 
1.8 The present study 
As it was observed that approximately one third (32.3%; 148/458) of our study participants 
are Afrikaner, and due to the high incidence of founder effects for other disorders in the 
Afrikaners, it was postulated that a founder effect for PD may exist in this ethnic group.  For 
this reason, extensive genealogical analysis was conducted on all recruited Afrikaner PD 
families with a positive family history of the disorder. A genealogist specialising in the 
Afrikaner (Prof Gerhard Geldenhuys, Department of Applied Mathematics, Stellenbosch 
University) constructed comprehensive genealogical charts, and it was determined that the 
genealogical information for most of the families partaking in the study could be traced back 
at least eight generations.  Theoretically, a single ancestral chart could contain 511 
individuals, equivalent to the eight generations that are ancestral to the proband.   
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The complete genealogical trees for six PD affected individuals were constructed and it was 
determined that there was a single ancestral couple that was common to each of these six 
families – a so-called founder couple (Figure 1.9).  The couple identified was married in 
South Africa in the year 1668 – the husband was originally from the Netherlands and arrived 
on South African shores in 1661, while the wife was a German, having arrived in South 





Figure 1.9 Pedigree of the six Afrikaner PD probands shown to be distantly related through genealogical 
studies.  The probands used in this study are coloured in black and the three probands and affected sibling 
selected for exome sequencing are numbered ZA92_proband, ZA_92_sibling, ZA106 and ZA111 and these are 
indicated by a red arrow.  Males are denoted as squares and females are denoted as circles in the pedigree.  
Numerical values indicate date of birth and the double lines indicate consanguinity. 
 
1.8.1 Hypothesis 
These findings led to the hypothesis for the present study, that these six PD probands share a 
common pathogenic mutation as the cause of their disease due to a founder effect.  
Furthermore, it was hypothesised that the gene involved would be a novel gene for PD, as all 
known PD-causing genes had previously been excluded as the cause in these six individuals.   
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1.8.2 Aims and objectives  
The aim of the present study was therefore to identify a PD-causing gene in the South 
African Afrikaner population using the WES approach and further to identify whether or not 
this putative disease-causing mutation could be attributed to the development of PD in other 
South African ethnic groups. 
 
The objectives of the study are as follows: 
1. To identify any additional Afrikaner probands that may be related to the common 
founder couple as identified. 
2. To determine the degree of relatedness of Afrikaner probands may have been linked 
to a common founder couple using a whole genome SNP array. 
3. To identify a novel PD-causing gene in the South African Afrikaner population 
through the use of WES and bioinformatics approaches. 
4. To develop a bioinformatics pipeline for the analysis of data that potentially can be 
universally applied to any WES project. 
5. To determine the frequency of the novel mutation(s) in the PD patients recruited to 
date from the Afrikaner population as well as the other ethnic groups (English-
speaking Whites, Black and Mixed Ancestry). 
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CHAPTER 2:  MATERIALS AND METHODS 
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CHAPTER 2:  Materials and Methods 
2.1 Study participants 
Ethics approval was obtained from the Committee for Human Research at Stellenbosch 
University, Cape Town (Protocol number:  2002/C059).  A total of 458 PD patients had been 
recruited from the Movement Disorders Clinic at Tygerberg Hospital in Cape Town, as well 
as from the Parkinson’s Association of South Africa. The patients were diagnosed according 
to the UK Brain Bank Diagnostic criterion which requires that patients present with 
bradykinesia as well as at least one of the following symptoms: resting tremor, rigidity and 
postural instability (Gibb and Lees 1988).  All study participants met the criteria.  The cohort 
included 277 (60.5%) male and 181 (39.5%) female patients.  The average age at onset 
(AAO) of the patients was 56.8 years of age.  The standard deviation (SD) is 12.7 years and 
the range of the AAO falls between 13 and 82.  A total of 35% of these patients reported a 
positive family history while 65% could either not provide any information regarding 
possible family history, or had no known reported history of PD.   
Written, informed consent was obtained from each of the patients and a blood sample was 
taken in order to obtain a DNA sample for the genetic analysis.  A total of 690 controls were 
recruited from the Western Province Blood Transfusion Services, the Geriatric Clinic as well 
as from other sources.  These individuals were not examined for PD, but were used as a 
means to assess the frequency of specific sequence variants in each ethnic group.  The 
controls were ethnically matched and were made up of 184 white Afrikaners, 160 white 
individuals, 180 mixed ancestry individuals and 166 black individuals. 
 
2.2 Genealogical analysis 
Extensive genealogical analysis was conducted by a genealogist, Prof. Gerhard Geldenhuys, 
on all recruited Afrikaner PD families with a positive family history of the disorder and an 
early age at onset (mostly ≤ 60 years of age).  Upon the initiation of the genealogical study in 
2009, a total of 193 PD probands had been recruited and of these, around one third (62/193) 
were self-identified as Afrikaner.  Subsequently, Afrikaner probands that met the criteria of 
early onset PD and a positive family history of the disease (at least one first, second or third 
degree relative that presented with the disease), were subjected to genealogical analysis and 
six of these individuals were traced back to a common founder couple (B. Glanzmann, MSc 
Thesis, March 2013, Prof. Geldenhuys, personal communication).  In February 2013 a total 
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of 48 Afrikaner families had been investigated and for each of these, a proband was chosen 
for whom an ancestral chart could be constructed.  Methods for the accurate genealogical 
tracing of individuals included interviews with the probands as well as their relatives and in 
depth searches into various sources such as state archives, marriage and baptismal records, 
death notices and certificates, published genealogies, tombstone inscriptions, voter’s rolls and 
telephone directories, as well as the internet.  Moreover, it is well known that the three 
mainstream Afrikaner churches, the Nederduitse Gereformeerde Kerk (Nether-Dutch 
Reformed Church), Gereformeered Kerk (Reformed Church) and the Nederduitsch 
Hervormde Kerk van Afrika (Nether-Dutch Reformed Church of Africa) keep concise and 
complete records of both marriages and baptisms.  Many of these are available in either film 
or microfiche form at the Genealogical Institute of South Africa in Stellenbosch (Prof. 
Geldenhuys, personal communication). 
 
2.3 Multiplex ligation-dependent probe amplification (MLPA) 
Exonic rearrangements, whole gene duplications and triplications are common in PD patients 
(Hedrich et al. 2002) but are not detected by techniques such as High Resolution Melt (HRM) 
analysis or Sanger sequencing.  All patients should thus be subjected to MLPA analysis to 
exclude copy number variations or rearrangements within the known PD genes.  Moreover, 
WES does not identify copy number variations (CNVs) such as duplications, triplications and 
deletions.  CNVs are thought to influence gene expression and can be directly associated with 
a range of phenotypes and diseases.  Also as new genes are discovered, CNVs analysis of 
these genes should be included in the mutation screening strategies.  Two commercially 
available probe kits namely SALSA P051-B1 and P052-B1 Parkinson MLPA kits (MRC 
Holland, Netherlands) were used to detect possible copy number variations in the 40 South 
African Afrikaner probands.  Each of the probe kits contains oligonucleotides for the ligation 
to the exons that are known to cause PD - more specifically to SNCA, GCH1, UCHL1, 
ATP13A2, LRRK2, DJ-1, PINK1 and Parkin as well as specific reference probes.    
 
Patient and control DNA was diluted to a final concentration of 30ng/µl for each MLPA 
reaction.  Control samples that were included in the MLPA were known samples with no 
CNVs in the PD genes.  Samples were denatured at 95°C for 5 min in the GeneAmp
®
 PCR 
system 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA), and were 
subsequently cooled for 5 min at a temperature of 25°C.  A hybridisation master mix 
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consisting of 0.75µl of MLPA buffer and 0.75µl probe mix was prepared for each sample 
(both patients and controls) and mixed gently.  Each tube was then placed into the 
thermocycler for incubation at 95°C for 1 min and then for 16 hours at 60°C.  Thereafter the 
thermocycler was paused at 54°C.  The following day, a Ligase-65 master mix was prepared 
using 1.5µl Ligase buffer A and B respectively, 0.5µl Ligase-65 enzyme and 12.5µl dH2O for 
each sample and a total of 16µl of the master mix was added to each sample while in the 
thermocycler at 54°C.  Ligation of the probes to the DNA sample was initiated by running 
the thermocycler at 54°C for 15 min, followed by heat inactivation of the ligase enzyme at 
98°C for 5 min and cooling at 20°C for 5 min. 
 
Finally, the polymerase master mix consisting of 0.25µl SALSA polymerase, 1µl SALSA 
PCR primer mix and 3.75µl dH2O was prepared.  Sample tubes were removed from the 
thermocycler after ligation and 5µl of the polymerase master mix was added to each tube.  
Tubes were returned to the thermocycler for PCR amplification using the following 
conditions:  30s at 95°C, 30s at 60°C and 60s at 72°C for 35 cycles, followed by 20 min at 
72°C and cooling at 15°C for 5 min.  Fragment separation by capillary electrophoresis was 
then performed on the PCR products at the Central Analytical Facility of the Department of 
Genetics, Stellenbosch University on the ABI 3130xl
®
 Genetic analyser (Applied 
Biosystems, Foster City, CA, USA).  The raw data was then analysed using the 
Coffalyser.Net software, version .131211 
(http://coffalyser.software.informer.com/download/). 
 
Verification of the MLPA results was performed using quantitative PCR (qPCR) on the 
Lightcycler 96 (Roche Diagnostics, Mannheim, Germany).  Primers were available for each 
gene of interest, as well as HBB (haemoglobin beta), the housekeeping gene that was used in 
all the aforementioned experiments.  Primers were diluted to a final working concentration of 
20µM and 30ng/µl DNA was used.  A master mix consisting of 0.5µl forward primer, 0.5µl 
reverse primer, 10µl Lightcycler 480 SYBR Green I Master Mix and 7µl dH2O was prepared.  
A total of 18µl of master mix was added to each using the epMotion™ 5070 (Brinkmann 
Instruments, Canada) which allows for automated pipetting and preparation of PCR reactions.  
Thereafter, 2µl of sample DNA was added to each well.  All samples and controls were 
prepared in triplicate.  PCR was performed under the following conditions:  pre-incubation at 
95°C for 10 min, followed by 45 cycles of a three step amplification that included 95°C for 
10s, 60°C for 10s and followed by a touchdown to 55°C after the second cycle and 72°C for 
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10s and finally a melting period of 95°C for 10s, 65°C for 60s and 97°C for 1s – the final step 
of the reaction was a cooling period of 37°C for 30s.  Results were then analysed on the 
Lightcycler 96 software version 1.1 (www.roche.com), which performs the ΔΔCt method 
automatically. 
 
2.4 Whole genome SNP array 
In order to determine whether or not the Afrikaner probands that traced back to the common 
founder couple were genetically related, thereby supporting the genealogical data, a whole 





 Human Core-24 BeadChip (Illumina, San Diego, California, USA) through the 
collaborative efforts of Professor André Franke at the Institut für Klinische 
Molekularbiologie (IKMB; Institute for Clinical Molecular Biology) in Kiel, Germany.  This 
is a customizable BeadChip that contains more than 240 000 highly informative genome-
wide SNPs and over 20 000 high value markers, including indels.  A total of 306 670 markers 
were screened for in each of the related Afrikaner probands.  The whole genome SNP array 




 System and the results visualized using the 
GenomeStudio
™
 Genotyping Module v1.0 (Illumina, San Diego, California, USA).  The final 
output of results to be analysed were in .ped and .map formats for easy manipulation. 
 
 2.4.1. Identification of regions of identity by descent (IBD) 
The information obtained from the whole genome SNP array was used to identify regions of 
identity by descent (IBD) in the related Afrikaner probands thereby ascertaining a measure of 
relatedness in these individuals.  The IBD was performed using the open source software 
package PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/contact.shtml#cite).  Quality 
control was performed on the .ped files according to the following criteria: 
1. Calculate the genotyping call rate.  The per sample rate is calculated.  This is done 
through the use of the following calculation: 
 (Total number of non-missing genotypes) / (Total number of markers 
genotyped) 
 It should be noted that a low genotyping call rate is an indication of a sample 
issue such as low DNA concentration. 
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 Thresholds may vary between 3 – 7%. 
2. Calculate the heterozygosity call rate.  The per sample rate is calculated.  The 
following calculation is used: 
 Number of (Total non-missing genotypes (N) – homozygous genotypes (O)) / 
(Total number of non-missing genotypes (N)) 
 Excess heterozygosity could be an indication that there is possible sample 
contamination while less than expected heterozygosity is an indication that 
there is possible inbreeding among individuals.   
 Thresholds for the inclusions are approximately the mean ±3 from the 
standard deviation across all samples. 
Genotyping call rate and heterozygosity rate are plotted against each other so as to determine 
appropriate cut-off values for the minor allele frequencies (MAF), genotyping call rate and 
overall percentage of data genotyped rather than using arbitrary values.  For the purposes of 
the current study, the following criteria were established: 
 Remove all individuals who have less than 95% of data genotyped; 
 Remove all individuals who have SNPs that have less than 1% MAF; 
 Remove all SNPs that have less than 95% genotype call rate  (or greater than 
5% genotype error) 
Initial investigation into IBD looked only at the original six probands that had initially been 
related back to the common founder couple.   Subsequently, the same quality control was 
performed on the additional Afrikaner probands.  Through the calculation of IBD, PI(hat) 
scores were generated in order to identify the degree of relatedness between these 
individuals.  In addition to the calculation of PI(hat) scores as well as IBD, segmental sharing 
was also calculated.  High levels of segmental sharing are indicative of relatedness.  The 
identification of segments also allows for specific regions of chromosomal overlap between 
the related individuals to be identified.  In order to identify regions of segmental sharing, 
PLINK was used and results verified using GERMLINE 
(http://www1.cs.columbia.edu/~gusev/germline/).   The following steps were utilized to 
identify shared segments: 
1. Prune the set of SNPs by performing linkage disequilibrium based SNP pruning.  This 
function recursively removes SNPs within a sliding window.  SNPs are therefore 
pruned on the variance inflation factor (VIF).  VIF is a measure of how much 
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variance of the estimated regression coefficients are inflated when compared to 
predictor variables that are not linearly related.   
2. Identify regions of IBD and segmental sharing.  IBD is calculated in order to 
determine the degree of relatedness across individuals.  Subsequently, the degree of 
segmental sharing is calculated in order to identify which segments of specific 
chromosomes are identical to one another and therefore further infer IBD as these 
segments will be identical as a result of inheritance as opposed to sequence similarity.  
Siblings are expected to share anything between 0-100% of IBD regions – at certain 
loci the sibling may not share anything, whereas there may be 100% sharing at other 
loci.  
 
2.5 Whole exome sequencing 
Genomic DNA of three Afrikaner patients and one affected sibling belonging to both the 
original pedigree, which identified the six Afrikaner probands as related to a common 
founder as well as to the large pedigree of affected individuals, were selected and subjected 
to WES.  The individuals that were selected for WES are shown in Table 2.1 (Pedigree pg 
36). 
 
Table 2.1 Afrikaner Parkinson’s disease patients selected for whole exome sequencing. 
Family 
ID 




selection for WES 
Part of the 
original six 
pedigree 
ZA92 ZA92 (proband) 
ZA92 (affected sibling) 
ZA92 (unaffected sibling) 
Yes Proband had both 
an affected and 
unaffected sibling 
Yes 
ZA106 ZA106 (proband) Yes Proband had early 
AAO and positive 
family history 
Yes 
ZA111 ZA111 (proband) Yes Proband had early 
AAO and positive 
family history 
Yes 
AAO = age at onset 
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In addition to the three families that form part of the larger pedigree, an unaffected, unrelated 
control (Control_1) was included for WES as a means to discern which of the variants are 
present in a control individual that is unrelated to the affected patients and which of the 
variants may be shared across the sibling pair as a result of inheritance.  Three of the 
probands (ZA92, ZA106 and ZA111) had already been sequenced in the laboratory of our 
collaborator, Prof. Owen Ross at the Department of Neuroscience at the Mayo Clinic College 
of Medicine in Florida, USA.   
For the purposes of the current study, one of the probands (ZA92) that had already been 
subjected to WES, was resequenced along with the affected sibling and unaffected sibling for 
both quality control methods and as a means to exclude common variants across siblings.  
WES was performed at Otogenetics Corporation in Norcross, United States.  Exome capture 
was performed using the Agilent SureSelect Human All Exon Kit, a liquid-phase 
hybridization method that covers 1.22% of the human genome.  This coverage includes all 
known genes, over 700 human miRNAs and over 300 non-coding RNAs, which include 
small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs (scaRNAs).  WES 
was performed using an Illumina Genome Hiseq 2000™, by paired end reads.  The input 
DNA was diluted and the DNA sheared (Agilent Technologies, Santa Clara, California, 
USA).  Samples were purified using the QIAquick PCR Purification Kit (Agilent 
Technologies) and the quality of the DNA subsequently checked through the use of the 
Agilent 2100 Bioanalyser™ - DNA quality could be observed in the form of an 
electropherogram and samples with a distribution peak at a height of 150 ± 10% nucleotides 
were selected for further analysis.  Further purification of the sheared DNA then took place 
and 'A' bases were then added to the 3' end of the fragments.  The samples were then purified 
through the use of Qiagen MinElute PCR Purification Column (Qiagen, Hilden, Germany).  
The paired end adaptors were then ligated to the fragments and the samples further purified 
through the use of the AMPure DNA Purification Kit (Agilent Technologies).  An adaptor 
ligated library was then generated, purified and the quality assessed and at this stage, a 
minimum of 500ng of library was needed for the hybridization amplification.  The 
sequencing was then carried out following cluster amplification of the library 
(http://www.chem.agilent.com/Library/datasheets/Public/5990-6319en_lo.pdf). 
This design covers approximately 50Mb of the genome with a minimum of thirty-fold 
redundancy that provides coverage of more than 99% and a concordance of 99.9%.  Raw data 
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was obtained from Otogenetics Corporation in order to perform in-house bioinformatics 
analysis.   
 
2.6 Bioinformatics analysis 
The raw, unaligned sequences were obtained in FASTQ format.  Quality control was 
performed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and 
aligned to the NCBI Human Reference Genome hg19 using NovoAlign 
(http://www.novocraft.com/main/page.php?s=novoalign).  Due to the fact that the sequence 
alignment is a computationally expensive endeavour, the alignment for each proband that was 
sequenced was performed at the South African National Bioinformatics Institute (SANBI) as 
well as in the laboratory of our collaborators at UBC to ensure concordance – we obtained 
100% concordance.  Following sequence alignment, the output file is in Sequence 
Alignment/Map (SAM) format, a text format for the storage of sequencing data in a series of 
tab delimited ASCII columns.  SAM files were subsequently converted to Binary 
Alignment/Map (BAM) files, which carries the same data as a SAM file, but is compressed, 
indexed and in binary form.  Thereafter, local rearrangements around the indels were 
performed, duplicates removed using the Genome Analysis Toolkit (GATK), quality scores 
recalibrated and a Variant Call Format (VCF) file was generated, containing so-called 
analysis ready reads.  The workflow is illustrated in Figure 2.1.  
 
Figure 2.1 Basic workflow for the generation of a Variant Call File (VCF) for further analysis 
Illumina Raw 






Convert SAM files 
to BAM files 
Local realignment 
around indels and 
duplicates removed 
using GATK 
Base quality score 
recalibrated  
Analysis ready 
files (VCF files) 
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The VCF files are important as the files themselves store gene sequence variations in such a 
way that each sequence variant can be analysed in multiple ways.  In the case of the current 
project, the aim was to determine which of the novel variants overlap across all four affected 
patients namely ZA92, ZA92 affected sibling, ZA106 and ZA111.  The VCF files that were 
generated were subjected to two modes of analyses namely hypothesis based analyses and 
alternatively, non-hypothesis based analysis (Figure 2.2).   
The first method of variant analysis made use of a combination of an in-house or custom 
method, whereby variants across all four affected individuals were compared and analysed 
using open source software and basic scripting methods coupled to variants called by 
commercially available software programs such as Ingenuity Variant Analysis (IVA).  The 
second made use of a custom-designed program called TAPER™ (Tool for Automated 
selection and Prioritisation for Efficient Retrieval of sequence variants). 





Figure 2.2 Flow diagram of the two approaches used for variant prioritisation 
VCF file 
Analysis using a Hypothesis 
Based Approach 
What variants were 
highlighted as plausible 
candidates? 
What variants overlap 
between the probands? 
Shortlist of the "best fit" 
variants 
Which of the variants overlap 
in a commercially available 
software program? 
Analysis using a Hypothesis-
Free Approach:  the design of 
TAPER™ 
Look at significant variants 
that overlap across both 
affected siblings 
What variants are significant 
and are in both siblings and at 
least one other WES patient? 
Candidate list of variants 
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2.6.1 Variant prioritisation using the hypothesis based approach 
For the custom-designed bioinformatics analysis pipeline, VCF files were submitted to the 
web interface of ANNOVAR, namely wANNOVAR (http://wannovar2.usc/).  ANNOVAR is 
a fast and efficient tool that can be used for the annotation of functional consequences of 
SNPs as well as insertions and deletions that are identified through high-throughput 
sequencing data.  ANNOVAR can therefore be used to generate a shortlist of variants for 
further analysis by examining the functional consequence of SNPs and indels by examining 
their functional consequence on genes, reporting functional significance scores, the 
identification of variants in conserved regions, inferring cytogenetic bands and identifying 
variants that are already listed in databases such as the 1000 Genomes Project (1KGP), 
Exome Sequencing Project (ESP6500) and dbSNP.  The output of the wANNOVAR analysis 
is a tab delimited file that was spilt into a number of smaller files according to the following 
criteria: 
 Novel insertions, deletions, frameshifts, substitutions, gain of function and loss of 
function (in both heterozygous and homozygous forms) – these sequence variations 
are considered to be novel as there is no record of them in any of the available online 
databases;   
 Known insertions, deletions, frameshifts, substitutions, gain of function and loss of 
function (in both heterozygous and homozygous forms). 
Note that for any of the variations to be considered for further analysis, the following 
conditions were imposed:  no record of the variant in dbSNP, 1KGP or HapMap (therefore 
novel); if the variant is present, the minor allele frequency (MAF) must be lower than 3%, the 
read depth must be greater than or equal to 50, call quality must be greater than or equal to 30 
and the variant must have predicted functional significance across multiple variant prediction 
tools. 
 
Following the file split, SNPs of interest were identified.  This was done by identifying SNPs 
of interest that met all of the above mentioned criteria in all of the patients.  Finally, in order 
to identify a shortlist of prioritised variants for further scrutiny, each of the outputs from the 
individual patients was compared in order to determine which of the variants did, in fact, 
overlap across all four individuals.  A shortlist of prioritised variants was generated for 
further analysis and comparison with a commercially available prioritization tool, Ingenuity 
Variant Analysis (IVA) (www.ingenuity.com). 
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2.6.1.1 Variant prioritisation using Ingenuity Variant Analysis  
Variant identification and prioritization is in itself is extremely variable and versatile because 
of the various ways in which the data can be analysed.  For this reason it was decided that a 
commercially available variant analysis software package be used as a means for comparison 
so as to determine which of the variants overlap between the two filtration methods.  The 
package used was IVA.  VCF files were uploaded onto the server and the following filtering 
cascade was used for variant prioritization: 
1. Confidence – this filter allows for the filtering and subsequent disregard of variants 
that are of low quality.  This is based on variant call quality and read depth.  Variants 
that pass this filter must satisfy all selected criteria. Confidence settings were as 
follows: 
 Call quality is at  greater than or equal to 30 in all probands; 
 Read depth is at greater than or equal to 50 in all probands. 
2. Common variants – this filter allows for the inclusion or exclusion of variants that 
may be commonly observed in a particular population.  It is considered extremely 
valuable for the identification of novel, potentially disease-causing variants as one 
would not expect such a variant to be present at high frequencies in the general 
population.  Common variants were filtered according to the following criteria: 
 Variants with a MAF of  greater than or equal to 3% in 1KGP, Complete 
Genomics genomes as well as those present in the ESP6500 were excluded – 
however variants that were present in these databases as well as in dbSNP 
were included if the MAF was less than or equal to 3%. 
3. Predicted deleterious – this filter allows for the identification of variants that have 
either predicted or observed evidence that may suggest that gene expression and 
function may be disrupted.  The benchmarks for this filter were as follows: 
 Variants that were associated with loss and gain of function and have been 
experimentally observed to be associated with a specific phenotype were kept 
for further scrutiny. 
4. Genetic analyses – this filter allows for filtration that is based on genotypes as well as 
inheritance models.  Here, the filter can be used to filter and test variants for particular 
inheritance patterns; the comparison and filtration of variants in one sample set from 
another (examples include affected vs. unaffected, responders vs. non-responders etc.) 
and finally for the comparison of frequency of specific variants either to other 
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samples or to control samples.  The criteria for this filtration step was set up as 
follows: 
 Variants that were associated with a loss or gain of function were examined as 
well as heterozygous, homozygous, compound heterozygous, hemizygous, 
haploinsufficient or het-ambiguous variants.   
5. Biological significance – this filter allows for the selection of biological or clinical 
concepts and phenotypes that may be of interest to the particular disorder that is 
examined – genes of interest or known genes can be selected and scrutinized.  
 
2.6.1.2 Prioritisation of filtered WES results 
Cumulatively, the shortlist of variants identified through IVA’s filtration cascade was 
compared to that obtained through the custom method.  The reason for this was two-fold: in 
order to determine whether or not the custom filtration cascade could be deemed as a true 
reflection of results i.e. were the same prioritised variants obtained from both methods, the 
variant list was compared to that obtained from the commercially available IVA; moreover, 
the cross platform comparison was used to further whittle down the lists into a workable 
number of variants as opposed to the investigation of each variant identified independently.  
Initial analysis of WES results focussed only on the variants that were found to be common in 
both of the siblings across both filtering methods.  Extensive bioinformatics was employed in 
order to determine the frequency of each variant in the online databases such as dbSNP, 
1KGP, HapMap and the ESP6500.  Additionally, a total of 20 genes that have been flagged 
as false positives by numerous WES studies were excluded (Fajardo et al. 2012).  This 
generated a list of variants that are considered to be common in the databases (greater than 
5%), which could then be excluded from further analysis and uncommon variants (less than 
5%) thus selected for further analysis.  Following the prioritization of uncommon variants in 
the affected siblings, a comparison of variants in all four affected individuals was then done – 
uncommon variants across all four individuals were identified.  Furthermore, theoretical 
functional prediction tools were used to determine whether or not the selected variants may 
be predicted to cause disease.  The tools that were made use of are summarized as follows: 
1. SIFT (Sorting Intolerant From Tolerant) – SIFT predicts whether or not an amino 
acid substitution will affect protein function.  This is based on sequence homology 
and the actual physical properties of the amino acids.  SIFT can be applied to 
spontaneously occurring non-synonymous polymorphisms as well as laboratory 
induced missense mutations (http://sift.bii.a-star.edu.sg/); 
Stellenbosch University  https://scholar.sun.ac.za
52 
 
2. PolyPhen (Polymorphism Phenotyping) – PolyPhen is a software tool that predicts 
the possible impact of amino acid substitutions on both the structure and function of 
human proteins but making use of straightforward physical as well as evolutionary 
comparative considerations (genetics.bwh.harvard.edu/pph2/dokuwiki/start); 
3. MutationTaster – this is another web server that predicts the possible effects that a 
SNP in a particular position may have on protein structure and function 
(http://www.mutationtaster.org/info/documentation.html).  MutationTaster, is 
however different as pathogenicity scores are calculated within a range of 0 and 1.  
The closer a variant is to 1, the more likely it is to be pathogenic; the converse is also 
true:  the closer the score is to 0, the more likely the SNP is to be benign and/or 
tolerated; 
4. Project Hope – this is an interactive web server that is capable of analysing the 
structural effects of a mutation of interest.  The server allows the user to submit a 
protein sequence as well as the mutation.  All available information is then accessed 
and analysed in order to determine the whether or not there is a significant functional 
effect on the protein (http://www.cmbi.ru.nl/hope/home).  
The use of theoretical functional prediction tools allows for the prioritization of variants 
based on the likelihood that they will affect protein function or folding, thereby moving the 
specific variant up or down the list for further examination.  
 
2.6.2 Analysis of WES data using a hypothesis-free approach and the 
construction of TAPER™ 
Continual identification of sequencing artefacts and high frequencies of variants in control 
populations as well as no formal, established means by which to filter the data, led to a re-
analysis of WES data.  A so-called “hypothesis-free” approach was developed in which the 
approach to variant analysis was aimed at identifying significant variants that were in the 
affected sibling pair and in at least one of the other two samples that had been subjected to 
WES.  Moreover, for the intention of excluding variants that are non-pathogenic, but that 
may be familial or possibly commonly occurring in healthy individuals, the two WES 
controls were considered to be pertinent to the data analysis. VCF files were generated in the 
same manner as described in Chapter 2, Section 2.6, page 46. 
 
As described previously, VCF files were submitted to the web interface of ANNOVAR, 
namely wANNOVAR (http://wannovar.usc.edu/).  However, following the release of the 
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updated version of the human reference genome, wANNOVAR was also updated 
(http://wannovar.usc.edu/).  VCF files were submitted to wANNOVAR produced tab 
delimited files that were very similar to those from the original version, but with additional 
features such as MAFs for the 1KGP, ESP6500, Exome Aggregation Consortium (ExAC) 
database as opposed to the conventional dbSNP frequencies.  Moreover, the tab delimited file 
also contained information specifically pertaining to functional and clinical relevance and 
significance of the variants.  Given the volume of the information contained in the 
wANNOVAR output, it was decided that files would not be split into known or novel 
outputs, but .csv files would be generated for each patient and control in order to do an 
overlap comparison at the end of variant analysis. 
 
The generation of the wANNOVAR files produced output files with significant information 
and an approach that did not possibly exclude the candidate variants had to be developed.  
The first step in the targeted approach involved the removal of all variants that were 
synonymous and those that did not result in frameshift mutations.  This was then followed by 
an intricate eight step approach for the prioritization of variants as possibly disease-causing 
candidates (Figure 2.3).  It should be noted that this was not done manually, but a custom 
design bioinformatics pipeline program, TAPER™ (Tool for Automated selection and 
Prioritisation for Efficient Retrieval of sequence variants).  TAPER™ is composed of a 
number of steps to filter and prioritise candidate variants across individual patients that have 
been subjected to WES.  It was constructed using Microsoft Visual Studio Professional 2013 
(Microsoft Corporation, Microsoft Redmond Campus, Redmond, Washington, United States) 
and additional packages downloaded in order to support the development of TAPER™ 
included Visual C#, CSV Helper (http://joshclose.github.io/CsvHelper/) and HTML Agility 
Pack (https://htmlagilitypack.codeplex.com/).  It should be noted that TAPER™ has been 
designed in such a way as to filter all prioritised variants according to a default setting, by 
which all of the predetermined filtration criteria are implemented or filtered according to a 
so-called custom method, whereby the user is able to filter the data independently and 
optionally according to specific parameters.  TAPER™ therefore creates a user-friendly 
environment for a wet bench scientist to analyse and identify variants of interest 
independently. 





Figure 2.3 A diagrammatical representation of the approach used for the hypothesis-free approach to novel 
variant discovery and the backbone for TAPER™. 
 
1. The submission of the processed .vcf files to an online variant caller such as 
wANNOVAR (http://wannovar.usc.edu/), allows for the annotation of functional 
consequences of genetic variants from high-throughput sequencing data. 
2. Removal of all synonymous variants as well as variants that do not cause frameshifts 
– synonymous variations are defined as codon substitutions that do not change the 
amino acid and are unlikely to be the underlying cause for rare diseases – for this 
reason, these variants, along with those that do not cause frameshifts, are removed 
from the list of prioritised variants.     
3. Removal of variants in the 1KGP that are found at a frequency of  greater than 1% - 
any variant that is found in the 1KGP database at a frequency of 1% or less is 
considered to be rare.  It is hypothesised that rare variants are likely to cause disease 
and for this reason, variants with very low or no available frequency data are 
prioritised.   
4. Removal of variants in the Exome Sequencing Project (ESP) 6500 
(http://evs.gs.washington.edu/EVS/) with a frequency of greater than 1% - this step is 
based on that of the 1KGP data.  Rare, possible disease-causing variants are likely to 
be at an extremely low frequency in this database and any variant with a frequency 
that is higher than 1% is removed from the list of interest. 
5. Removal all variants with positive FATHMM scores - functional analysis through 
hidden Markov Models (FATHMM) scores are used to determine the species-specific 
VCF File wANNOVAR 
All synonymous and 
non-frameshifts 
removed 
Remove variants in 
1KGP with frequency 
>1% 
Remove all variants 
in ESP6500 with 
frequency >1% 
Remove all variants 
with positive 
FATHMM scores 




variants on X and Y 
chromosomes (if not 
sex linked disease) 
[Optional] Variants 
linked to specific 
disease 
Candidate list of 
variants per single 
individual 
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weightings for the predictions of the functional effects of protein missense variants.  
The use of FATHMM scores have been shown to outperform the conventional 
prediction methods such as SIFT, PolyPhen2 and MutationTaster (Rackham et al. 
2014).  Positive FATHMM scores predict a tolerance to the variation while negative 
FATHMM scores predict an intolerance to the variation, and is subsequently 
considered to be pathogenic. 
6. Removal of variants with negative GERP+++ scores – Genomic Evolutionary Rate 
Profiling (GERP) +++ scores are the conservation scores from dbNSFP (database for 
nonsynonymous SNPs functional predictions); higher scores are indicative of greater 
conservation; scores of > 0 are considered to be conserved.   
7. Remove all variants on X and Y chromosomes – this step is incorporated as an 
additional, independent step.  This is to allow the researcher the freedom to determine 
whether or not a particular disease has been sex-linked.  Should the disease not have 
previously been identified as a sex-linked disease, the variants may be removed so as 
to decrease the overall number of candidate variants. 
8. Variants linked to a specific disease – the final step of TAPER™ determines whether 
the genes of interest have been linked to any other disorders using OMIM (Online 
Mendelian Inheritance in Man) (http://www.omim.org/) database as well as the 
DISEASES (http://diseases.jensenlab.org) database.  If any of these disorders are 
similar to the disorder under study then that gene and variant(s) becomes top 
candidates for further study. 
 
The implementation of the new filtering criteria generated a shortlist of potential candidate 
variants that warranted further examination.  Following the prioritization of variants per 
individual, the following comparative approach was employed:  the affected sibling pair was 
analysed and any variants that overlapped across these two individuals were identified.  
Following the identification of overlapping variants between the siblings, an additional 
comparison was performed so as to exclude any variants that were present in either of the 
control samples (both related and unrelated unaffected controls).  Subsequently, the sib pair 
shortlist of variants was compared to ZA106 and ZA111 independently and three candidate 
lists of variants were obtained.  Candidate variants were therefore present in at least three of 
the four probands from the original six pedigree that was constructed.  Additionally, any 
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variants that were identified in either of the two control individuals were excluded from 
further analysis. 
 
2.7 Sanger validation of prioritised variants 
NGS technologies such as WES have emerged as extremely effective and powerful tools for 
the investigation of the genetic aetiology of diseases and the use of such technologies has 
proven invaluable in both clinical treatment of disease as well as bench research (Patel et al. 
2014).  Typically WES generates between 50 and 70 million bases of sequence and it is 
hypothesised that 99.99% of the bases will effectively realign accurately to the reference 
genome.  However, the remaining 0.01% of bases that differ from the reference will be 
identified as variants (Patel et al. 2014).  However it should be noted that the majority of 
these 0.01% of bases that are called as variants are actually sequencing artefacts as opposed 
to actual sequence variants.  For this reason, each of the prioritised variants were Sanger 
sequenced in all four of the probands that had originally been subjected to WES as a means to 
determine whether or not the variants were real or rather a sequencing artefact.   
 
2.8 TaqMan® SNP genotyping 
Genotyping was performed in patient and control samples in order to determine the frequency 
of candidate variants in both patients and controls.  A total of 458 patients (all PD probands 
available at the time of the study) and 690 controls were included for genotyping.  The 
controls were ethnically matched and made up of 184 white Afrikaners, 160 white 
individuals, 180 mixed ancestry individuals and 166 black individuals.  The DNA samples 
were subjected to TaqMan® allelic discrimination technology using the ABI TaqMan® 
Custom SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA).  The 
genotyping was outsourced to a commercial company, IKMB in Kiel, Germany.  Each ABI 
TaqMan® Custom SNP Genotyping Assay consists of two primers in order to amplify the 
sequence of interest, as well as two TaqMan® MGB (minor groove binding) probes for allele 
detection.  Each probe contains a reporter dye at the 5’ end of each allele specific probe (the 
first allele contains the VIC reporter dye and the second allele probe contains the FAM 
reporter dye).  It should be noted that each probe also contains the MGB as well as a non-
fluorescent quencher (NQF) at the 3’ end of the probe.  The MGB will increase the probe’s 
melting temperature (Tm) without increasing the length of the probe, thereby generating 
greater differences in Tm values between matched and mismatched probes, thereby improving 
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allelic discrimination (Beaucage et al. 2001).  Figure 2.4 provides a diagrammatic 
explanation of how detection is achieved with proven 5’ proven nuclease chemistry by means 
of exonuclease cleavage of a 5’ allele specific dye label, thereby producing a stable assay 
signal by removing the effect of the 3’ non-fluorescent quencher.   
 
Figure 2.4 Overview of TaqMan® allelic discrimination technology.  Selective annealing of the TaqMan® 
probes as well as the exonuclease cleavage of a 5’ allele specific dye label generates the assay signal, thereby 
enabling allelic discrimination (taken from www.dnavision.com). 
 
 
 2.8.1 Real time PCR amplification conditions 
A total of 1148 PD patients and controls were selected and subjected to SNP genotyping at 
IKMB.  A total of three thermostable 384-well plates were prepared, with each well 
containing 5ng of DNA as per the service provider’s instruction.   SNP amplification was 
done by polymerase chain reaction (PCR) in a single reaction tube on an ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). An EpMotion® 
liquid handling robot was used to dispense the PCR reagents into the 384-well plates 
(Eppendorf, Hamburg, Germany).  Each PCR reaction consisted of 2.5µl ABI TaqMan® 
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Universal PCR Master Mix, the stipulated 5ng of genomic DNA, 0.25µl ABI TaqMan® 
primer and probe dye mix and 1.25µl Dnase-free sterile water so as to generate a total 
reaction volume of 5µl.  Each of the thermostable 384-well plates consisted of a total of 383 
samples (either patients or controls) and one non-template control.  Each reaction was 
subsequently subjected to the following PCR conditions:  2 min at 50°C, 10 min at 95°C 
followed by 40 cycles of 15s at 92°C and 90s at 55°C each. 
2.8.2 Allelic discrimination 
 Allelic discrimination was performed on the ABI Prism 7900HT using the end-point analysis 
which was carried out using the Sequence Detection System (SDS) 2.4 software that has a 
95% confidence level.  This software allows for the fluorescence of the samples to be 
detected and calibrated and subsequently performs automatic allele calling through the 
generation of allelic discrimination plots. 
 
2.9 SNP genotyping using High Resolution Melt 
High Resolution Melt (HRM) is an analytical method in which DNA fragments are 
distinguished from each other through their melting behaviour.  It is an expansion of existing 
DNA dissociation methods that allow for the characterization of DNA fragments according to 
the way in which they dissociate ('melt').  Double stranded DNA (dsDNA) (pre-melt phase) is 
converted to single stranded (ss) DNA (post-melt phase) as it is subjected to increases in 
temperatures (Figure 2.5).  This is analysed or monitored by adding a fluorescent dye (e.g. 
EvaGreen, Syto 9 and Sybr Green) to the PCR reaction mixture that is allowed to intercalate 
within the dsDNA of the PCR products.  As the strands separate, the dye is released, causing 
a decrease in fluorescence as the temperature increases.  HRM instrumentation collects and 
analyses fluorescent signals in real time, thereby characterising the different DNA fragments. 




Figure 2.5 Illustration of the principle underlying high resolution melt. With an increase in temperature 
double stranded (ds) DNA melts and becomes single stranded (ss) DNA.  As the melt progresses, an 
intercalating dye is released - the fluorescence produced is used to create a thermal denaturation profile that is 
unique for each DNA sequence.  As the temperature increases, more of the dsDNA is converted to ssDNA.  





A thermal denaturation profile can be constructed in which fluorescence is plotted against the 
temperature; this profile is specific for the PCR product as well as the length of the sequence, 
base and GC content (Ye et al. 2010).   Alterations in the nucleotide sequence will affect the 
way in which the fragment melts.  This will allow fragments with nucleotide sequence 
alterations to be identified when they are compared to the wild type sample; these can then be 
sequenced in order to characterize the sequence variant (Ye et al. 2010).  HRM data can be 
analysed as either normalised graphs (Figure 2.6) or as difference graphs (Figure 2.7). 




Figure 2.6 Example of a HRM normalised graph.  Temperature range in a specific region is selected to allow 
for identification of variation between different wild type and mutant samples respectively.  Blue and red lines 
are homozygous wild type and homozygous mutant respectively; green line is a heterozygous mutant sample 




Figure 2.7 Example of a HRM difference graph.  This graph is used when a particular genotype is identified 
and used as a reference/baseline for the other DNA samples. The position of each sample relative to the 
reference is plotted against the temperature thereby showing differences between various samples.  The 
homozygous wild type is used as a reference (red) and the other samples are compared to it.  Blue is the 
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HRM is a relatively simple and cost effective means to screen patients for known mutations.   
It is also a means of identifying novel as well as rare variants and is sufficiently sensitive to 
identify single base pair changes.  An additional advantage is that it is a closed-assay system, 
and no post PCR processing is therefore necessary. 
 
2.9.1 HRM real time amplification conditions 
The real-time PCR and HRM analysis was set up and carried out on a RotorGene 6000 
instrument (Corbett Life Science, Australia) with the following cycling conditions:  an initial 
step at 95⁰ C for 5 min; 40 cycles with conditions of denaturation at 95°C for 15 s, varying 
annealing temperatures for each SNP for 15 s and extension at 72°C for 20 s. Thereafter, two 
additional holding steps were included: 95°C for 1 min to allow for complete denaturation of 
the double stranded DNA and then at 50°C for 1 min to allow for renaturation of the DNA.  
HRM analysis was performed with melt temperatures ranging from 65°C to 99°C with the 
temperature increasing by 0.1°C increments at each step.  A wild-type (WT) reference sample 
was included in every run and samples with altered HRM profiles were selected and Sanger 
sequenced in order to identify the sequence variant. 
 
2.10 In silico prediction of prioritised variants 
In order to determine the effect of the selected variants on the structural integrity of the 
selected proteins, in silico modelling was performed on selected candidate variants.  For each 
gene and variant that was analysed, information about the sequences, protein product of the 
gene, isoforms of a particular protein and the domains for each of the proteins was obtained 
through UniProt (www.uniprot.org; Consortium 2015).  UniProt is an important collection of 
protein sequences as well as their annotations.  Moreover, additional domain information was 
obtained using the NCBI Conserved Domains Database 
(www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml).  For those genes for which sufficient 
information could be obtained, modelling was performed using SWISS-MODEL 
(www.swissmodel.expasy.org; Benkert, Biasini, and Schwede 2011).  SWISS-MODEL 
consists of six major steps used to build the protein model and these are summarized below: 
1. Template search – performed with Basic Local Alignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and HHBlits 
(http://toolkit.genzentrum.lmu.de/hhblits/) against the SWISS-MODEL template 
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library (SMTL).  The target sequence was searched with BLAST against the primary 
amino acid sequences that were contained in the STML; 
2. Template selection – multiple templates were identified and the quality of each of the 
templates was predicted from the features of the target template alignment.  Only the 
templates with the highest quality were selected; 
3. Model building –target templates are used to build specific models and Promod-II was 
used for the modelling.  Coordinates that were observed between the target and the 
template were subsequently copied to the model.  Insertions and deletions were 
remodelled using a fragment library and side chains were rebuilt; 
4. Model quality estimation – the global and per-residue model quality was assessed 
using the QMEAN scoring function (Benkert, Biasini, and Schwede 2011); 
5. Ligand modelling – ligands that were present in the template structure were 
transferred by homology to the model when an established using the following 
criteria: 
a. The ligands were annotated as biologically relevant in the template library; 
b. The ligand was in contact with the model; 
c. The ligand did not clash with the protein; 
d. The residues that were in contact with the ligand that were conserved between 
the template and the target.   
6. Oligomeric state conservation – homo-oligomeric structure of the target protein was 
predicted and this was based on the analysis of pairwise interfaces of the identified 
template structures.  
Subsequent to the modelling of the protein, the protein structures were visualized using two 
separate visualization programs namely Swiss PDP Viewer and PyMol 
(www.schrodinger.com).  The last part of the in silico analysis was to identify motifs in the 
sequences.  This was performed using the Eukaryotic Linear Motif (www.elm.eu.org).  
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CHAPTER 3:  Results 
3.1 Genealogical analysis to identify additional families 
As previously illustrated, the South African PD cohort is composed of individuals spanning 
numerous ethnic groups (Table 1.2 page 34).  Notably, the South African Afrikaner makes up 
32.3% (148/458) of the total PD cohort which prompted us to investigate evidence for a 
founder effect in these patients.  Initial genealogical analysis identified the aforementioned 
six families that were related to one another through a common founder couple (Geldenhuys 
et al. 2014;  B Glanzmann, MSc thesis 2013).  While the complete family trees were 
constructed for the six families, the genealogical analyses for the other PD patients 
concentrated on finding at least one line of descent from the founder couple to the affected 
proband.  A total of 42 additional probands met the criteria established (positive family 
history of PD, age at onset younger than 60 years) in order to be scrutinized further.   
Intensive genealogical research revealed that for 40 (including the six original probands) of 
the PD probands, at least one line of descent was found that connected them.  Selected lines 
of descent from the founder couple to each of the 40 probands are highlighted in Figure 3.1.  
Interestingly, it was determined that on average, a total of four ancestral lines could be 
identified for each of the probands (note that this may vary between one and fourteen lines 
per individual).  This finding is significant from a genealogical standpoint as this gives strong 
indication for a founder effect for PD, with the founder couple plausibly identified.  For the 
remaining eight families, the family history that had been provided was insufficient to 
determine their possible relationship to the founder couple (Geldenhuys et al. 2014).  It has 
been documented that the founder couple had twelve children, but only the five children that 
have direct ancestral links to the PD probands have been shown.  A summary of the available 
demographic and clinical information for these 40 families is provided in Supplementary 
Table 1, Appendix II.  In these families both AD and AR patterns of inheritance are evident, 
based on currently available information. However, it is plausible that reduced penetrance 
and marriage to spouses with a family history of PD could influence the pattern of inheritance 








Figure 3.1 Pedigree of the 40 individuals affected with Parkinson’s disease shown to be linked to a common founder couple.  The pedigree illustrates the ancestral lines 
to a common founder couple (labels listed as year of birth, family number (ZA) and order on the pedigree 1-40).  Males are denoted as squares and females are denoted as 
circles in the pedigree.  The filled shapes are the probands that initially presented with the disease. 
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3.2 Whole genome SNP array 
In order to establish whether or not the probands were in fact closely related to one another, a 
whole genome SNP array was performed on the probands.  A total of 306 670 markers were 
included in the analysis in order to determine the identity by descent (IBD).  Two alleles are 
IBD if they are copies of the same ancestral gene.   
The data was analysed in three ways: 
i. In the six original probands only 
ii. Across all 40 probands 
iii. Comparing the 40 probands to the healthy control individuals 
Quality control (QC) was performed on the original six probands who were traced back to the 
common founder couple.  The genotyping rate (also known as the F_MISS rate) and the 
heterozygosity rate are calculated for each individual in order to identify outlier individuals 
that are based on both of the statistics and should therefore be excluded from the analysis.  
These results are shown in Supplementary Table 2, Appendix III.  The cut-off thresholds 
were determined to be as follows:  individuals with low genotyping were removed from the 
dataset (--mind 0.05); minor allele frequencies of greater than 0.01 were removed from the 
dataset (--maf 0.01) and the removal of all SNPs with missing call rates greater than 0.05 (--
geno 0.05).  Sample ZA111 (78.95) was removed from the analysis as it had a large number 
of SNPs that were missing and an excess of heterozygosity.  The inclusion of this individual 
could lead to skewed results particularly pertaining to the IBD shared regions. 
 
3.2.1 Original six probands 
Following the identification of appropriate cut-off thresholds for QC, IBD testing as well as 
the search for segmental sharing was conducted using PLINK (Purcell et al. 2007).  In order 
to identify related individuals, IBD was calculated.  This is based on the average proportion 
of alleles that are shared in common at specific genotyped SNPs.  A preliminary analysis was 
conducted on the sibling pair of family ZA92 (68.27 and 68.46) as a means of secondary QC.  
Siblings are expected to show an IBD score of approximately 0.5 because they are first-
degree relatives.  The IBD scores can be seen in Table 3.1.  PI(hat) scores are used as a 
measure to determine the probability of a pair of relatives being IBD and is therefore a 
measure of the overall IBD.  PI(hat) scores are calculated through the use of the following 
formula:  PI(hat) = Z2 + 0.5*(Z1) where Z1 is the probability that individuals will share one 
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allele at a specific marker position and Z2 is the probability that individuals will share two 
alleles at a specific marker position.  Z0 is the probability that individuals will share no 
alleles at a specific marker position.  While PI(hat) scores are an indication of the overall 
degree of relatedness, Z0, Z1 and Z2 are an indication of the type of relatedness between 
individuals. The affected siblings share a PI(hat) score of 0.4883, which can be rounded to 
0.5, therefore producing an expected IBD.  Note that IBD is calculated between two 
individuals at a time. 
 
Table 3.1 Identity by descent (IBD) scores shared between the siblings of family ZA92. 
FID1 IID1 FID2 IID2 Z0 Z1 Z2 PI(HAT) 
ZA92 68.27 ZA92 68.46 0.2449 0.5335 0.2216 0.4883 
 
FID – Family ID; IID – Individual ID; Z0 – probability that individuals at a specific marker will share no 
alleles; Z1 – probability that individuals at a specific marker will share 1 allele; Z2 – probability that individuals 
at a specific marker will share 2 alleles. 
 
Note that due to quality control measures, ZA111 was excluded from the analysis due to the 
sample’s high degree of missingness.  Although there are varying degrees of relatedness, it 
was determined that all of the individuals are related to one another. It is estimated that each 
generation is approximately 25 years (Takahata 1993; Cavalli-Sforza and Feldman 2003; 
Medeiros-Domingo et al. 2007; Greeff and Erasmus 2015) and for this reason, probands 
ZA89 (68.16) and ZA92 (68.27 and 68.46) are the most distantly related (approximately 150 
years; 6 generations) and ZA92 (68.27 and 68.46), ZA106 (78.67) and ZA134 (81.65) are the 
most closely related (approximately 100 years; 4 generations).  The results from the IBD 
shared between the original six probands are shown in Table 3.2.  From these results it is 
clear that each of the probands that were related to one another through genealogical tracking, 
are in fact genetically related to one another – although there are varying degrees of 
relatedness between various individuals.   
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Table 3.2 IBD shared between the original six probands and affected sibling traced back to a 
common founder couple.  




ZA106 78.67 ZA134 81.65 0.8936 0.1064 0.0000 0.0532 4 
ZA106 78.67 ZA78 67.82 0.9027 0.0973 0.0000 0.0487 5 
ZA106 78.67 ZA89 68.16 0.9044 0.0956 0.0000 0.0478 5 
ZA106 78.67 ZA92 68.27 0.9362 0.0638 0.0000 0.0319 5 
ZA134 81.65 ZA78 67.82 0.9031 0.0969 0.0000 0.0485 5 
ZA134 81.65 ZA89 68.16 0.9365 0.0635 0.0000 0.0317 5 
ZA134 81.65 ZA92 68.27 0.8873 0.1127 0.0000 0.0564 4 
ZA78 67.82 ZA89 68.16 0.9225 0.0775 0.0000 0.0388 5 
ZA78 67.82 ZA92 68.27 0.9192 0.0808 0.0000 0.0404 5 
ZA89 68.16 ZA92 68.27 0.9571 0.0429 0.0000 0.0214 6 
 
FID – Family ID; IID – Individual ID; Z0 – probability that individuals at a specific marker will share no 
alleles; Z1 – probability that individuals at a specific marker will share 1 allele; Z2 – probability that individuals 
at a specific marker will share 2 alleles. 
 
3.2.1.1 Identification of segmental sharing between the six original 
probands  
As already mentioned, the degree of recent shared ancestry for a pair(s) of individuals can be 
measured through the calculation of IBD (or PI(hat) scores).  Given that we identified that all 
of the aforementioned individuals are IBD, the regions that are shared by all of these 
individuals were then investigated.  This was done using PLINK’s segmental sharing 
algorithm which uses a Hidden Markov Model (HMM) to detect chromosomal segments that 
are shared by descent (Purcell et al. 2007).  Segmental sharing was first calculated in the 
sibling pair to identify shared IBD stretches between the sibling pair before applying this to 
the six probands.  There are 55-shared segments between the sibling pair, with the majority of 
them (8/55) on chromosome 3.  The segmental sharing results between the sibling pair are 
shown in Supplementary Table 3, Appendix III.  It is estimated that the sibling pair shares 
approximately 67% of the genome in IBD stretches.  This is calculated by taking the sum of 
the physical length of the segments that are shared / sum of the total lengths of chromosomes.  
It is expected that the siblings will share approximately 50% of IBD stretches, but this figure 
can vary between 0% and 100% depending on the specific loci.  This is due to the fact that 
there are hotspots for recombination at specific chromosomal regions.   
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The percentage of genome sharing between the original six probands was also subsequently 
calculated as a measure of “how related” individuals are to one another.   This is done by 
calculating the degree of segmental sharing and subsequently what percentage of the genome 
is shared to give a more accurate indication of relatedness as opposed to PI(hat) scores.  It is 
estimated that the original six probands share 1.54% of the genome with the overall lengths 
of the shared segments differing between 4192.60 KB and 14051.50 KB in length (Table 
3.3).  Individuals ZA78 and ZA89 (67.82 and 68.16) have the highest percentage of 
chromosomal sharing, as they share a total of 11.31% of chromosome 1.  ZA134 shares the 
most number of segments with other probands (4/5) and can therefore be regarded as the 
most related proband, with ZA92 (68.27) the least related as it shares only one segment on 
chromosome 3 with ZA134.  
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Table 3.3 Highest percentage of the chromosomes shared across the six original probands. 
 
FID1 IID1 FID2 IID2 CHR BP1 BP2 SNP1 SNP2 NSNP KB 
Percentage of 
CHR shared 
ZA134 8165 ZA92 6827 1 16001588 20423099 rs12746773 rs6699362 153 4421.51  3.56 
ZA78 6782 ZA89 6816 1 168149142 182200659 rs4657741 rs10494545 330 14051.5  11.31 
ZA106 7867 ZA134 8165 3 27253971 31488222 rs1445111 rs6766414 151 4234.25 2.12  
ZA78 6782 ZA89 6816 6 148981394 153173999 rs7451498 rs9384046 163 4192.6 2.33  
ZA106 7867 ZA89 6816 14 92280037 98263147 rs10134181 rs898927 244 5983.11 5.62  
ZA134 8165 ZA78 6782 16 49932806 54343840 rs4785195 rs1004299 129 4411.03 4.97  
ZA134 8165 ZA78 6782 16 59070616 64124789 rs990813 rs12596363 117 5054.17 5.69  
 
CHR – chromosome; IID – Individual ID; FID – Family ID; BP1 – start of the physical position of the segment (base pair); BP2 - end of the physical position of the segment 
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3.2.2 All 40 probands 
3.2.2.1 Calculation of IBD between the 40 probands  
Following the successful identification of IBD as well as shared segments between the 
siblings of ZA92 (68.27 and 68.46) as well as between the original six probands, the same 
quality control measures were implemented for the 40 probands that had been traced back to 
the common founder couple.  The same QC parameters were used as previously defined in 
Section 3.2, page 66.  Due to these parameters, individuals ZA340 (81.90) and ZA111 
(78.95) were removed from the analysis due to a high degree of missingness.  There are 702 
different comparisons (this is each proband compared to the other respectively) for IBD and 
the PI(hat) scores are shown in Supplementary Table 4, Appendix III.  It was determined that 
all of the 40 Afrikaner probands are related to one another with varying degrees of 
relatedness (Table 3.4, Figure 3.2).  Estimates of IBD coefficients, namely Z0 and Z1 scores 
are plotted as a means to infer relatedness.  Note that Z0 + Z1 = 1.  This is the probability that 
individuals will share one allele at a specific marker (Z1) or none (Z0).  Individuals that share 
no alleles and therefore have Z1 of less than 0.0100 are considered to be the least related to 
one another (and therefore the greatest number of generations between them) and have been 
circled in red (Figure 3.2).  These individuals are ZA150 (82.39), ZA190 (83.16), ZA411 
(10.110) and ZA34 (55.81).  The approximate degree of relatedness calculated by the average 
number of PI(hat) scores – therefore probands with higher PI(hat) scores are related to more 
probands. 
 













ZA140 14 23 0.01580000 6 
ZA142 27 10 0.00147500 6 
ZA103 19 18 0.00396486 8 
ZA116 27 10 0.00157568 8 
ZA128 15 23 0.00620811 8 
ZA16 16 11 0.00385556 8 
ZA175 29 8 0.00127027 8 
ZA194 21 16 0.00328919 8 
ZA213 15 22 0.00586216 8 
ZA216 16 21 0.00644324 8 
ZA233 12 25 0.00638649 8 
ZA24 13 24 0.00595676 8 
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ZA241 12 25 0.00678378 8 
ZA263 31 6 0.00130270 8 
ZA272 28 9 0.00152973 8 
ZA4 17 20 0.00443514 8 
ZA413 18 19 0.00523784 8 
ZA5 15 22 0.00561892 8 
ZA64 35 2 0.00046175 8 
ZA68 11 26 0.00762703 8 
ZA72 15 22 0.00710270 8 
ZA76 10 27 0.00644243 8 
ZA86 15 22 0.00602703 8 
ZA89 20 17 0.00453784 8 
ZA95 17 20 0.00594167 8 
ZA106 27 10 0.00251622 9 
ZA112 25 12 0.00213243 9 
ZA134 23 14 0.00295946 9 
ZA252 23 14 0.00278108 9 
ZA253 24 13 0.00285405 9 
ZA256 25 12 0.00239189 9 
ZA316 25 12 0.00225135 9 
ZA78 28 9 0.00200270 9 
ZA92 22 15 0.00297297 9 
ZA190 31 6 0.00064865 11 
ZA411 34 3 0.00061622 11 
ZA150 36 1 0.00017568 12 
ZA34 36 1 0.00017568 12 
 
3.2.2.2 Segmental sharing between the 40 probands 
Segmental sharing was calculated for all 40 of the related Afrikaner using PLINK, as 
described in Section 3.2.1, page 66.  There are 1413 shared segments across the 40 related 
probands.  For this reason, the shared segments across chromosomes rather than across 
individuals were calculated as there are too many shared segments to analyse properly.  
These results are shown in Table 3.5.  The average percentage of chromosomal segment 
sharing is 5.17%, with the greatest degree of segmental sharing in chromosome 19 and the 
smallest degree of sharing in chromosome 2.  The average length of shared segments in each 
chromosome is 5 748 298.77 base pairs (5 748.30KB).  Moreover, there is an average of 
238.32 SNPs that are shared per segment.  The 40 probands do not share large regions of 
chromosomes, thereby supporting the genealogy that the individuals are distantly related to 
one another. 




Figure 3.2 Relatedness inferences from IBD estimates.  Estimates of the IBD coefficients, namely Z0 and Z1 are used to infer relatedness.  Each point represents a pair of 
samples.  Note that the sum of the values will give total variance.  The pairs of samples that are circled in red are those pairs of samples that are the most unrelated to one 
another.  All 40 probands were found to be distantly related to one another through IBD estimates. 
Most related 
Least related 
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Table 3.5 The number of shared segments across the 40 probands (chromosomally). 
Chromosome Length of 
Chromosome (bp) 
Number of Shared 
Segments 
Average Length of 
Shared Segment (bp) 
Average Number of 
SNPs per Segment  
Percentage of 
Chromosome Shared 
1 247 249 719 93 8 541 490 282.82 3.35 
2 242 951 149 125 6 065 207 237.98 2.50 
3 199 501 827 86 6 822 114 264.71 3.41 
4 191 273 063 107 6 398 454 253.24 3.35 
5 180 857 866 87 5 557 209 204.47 3.07 
6 170 899 992 139 5 178 270 234.02 3.03 
7 158 821 424 80 6 030 635 240.60 3.80 
8 146 274 826 94 5 435 839 233.85 3.72 
9 140 273 252 59 5 512 568 227.24 3.93 
10 135 374 737 87 5 143 802 236.03 3.80 
11 134 452 384 68 7 175 158 235.29 5.33 
12 132 349 534 61 6 409 982 263.28 4.84 
13 114 142 980 47 4 637 914 215.06 4.06 
14 106 368 585 50  5 898 843 250.72 5.55 
15 100 338 915 33 5 725 393 241.36 5.71 
16 88 827 254 43 5 281 153 235.07 5 95 
17 78 774 742 40 7 575 798 288.73 9.61 
18 76 117 153 41 4 739 005 225.44 6.22 
19 63 811 651 20 7 123 259 286.95 11.16 
20 62 435 964 18 2 540 611 149.39 4.07 
21 46 944 323 19 4 591 567 247.42 9.78 
22 49 691 432 10 4 078 302 189.30 8.21 
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3.2.3 Comparison of the 40 probands to the controls 
3.2.3.1 The identification of IBD and segmental sharing in four 
unaffected, unrelated Afrikaner control individuals 
Given the unique ethnic background of the South African Afrikaner, a total of four 
unaffected, unrelated Afrikaner control patients were selected and also analysed using the 
whole genome SNP array.  This was to determine whether or not randomly selected, 
unrelated, healthy control individuals shared the same degree of IBD and segmental sharing 
as the genealogically related probands.  Estimates of IBD coefficients, namely Z0 and Z1 
scores are used plotted as a means to infer relatedness.  Due to the fact that the control 
individuals were randomly selected, it is expected that none of them would share IBD with 
the probands.  It was determined, however that control individual 11.937 shares a relationship 
with the original probands namely ZA134 (81.65), ZA78 (67.82), ZA89 (68.16) and ZA92 
(68.27) (Table 3.6).  Moreover, this individual shares a relationship with 21 other Afrikaner 
probands that are related to the founder couple but not to any of the other control individuals 
(Figure 3.3).  This is an indication that this control may be potentially related to the probands. 
 
Table 3.6 IBD shared between the original six probands and four randomly selected, 
unaffected Afrikaner controls. 
FID1 IID1 FID2 IID2 Z0 Z1 Z2 PI(HAT) 
ZA106 78.67 Control_1 12.057 1.0000 0.0000 0.0000 0.0000 
ZA106 78.67 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
ZA106 78.67 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
ZA106 78.67 Control_4 11.937 1.0000 0.0000 0.0000 0.0000 
ZA134 81.65 Control_1 12.057 1.0000 0.0000 0.0000 0.0000 
ZA134 81.65 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
ZA134 81.65 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
ZA134 81.65 Control_4 11.937 0.9927 0.0073 0.0000 0.0037 
ZA78 67.82 Control_1 12.057 1.0000 0.0000 0.0000 0.0066 
ZA78 67.82 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
ZA78 67.82 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
ZA78 67.82 Control_4 11.937 0.9688 0.0312 0.0000 0.0156 
ZA89 68.16 Control_1 12.057 1.0000 0.0000 0.0000 0.0000 
ZA89 68.16 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
ZA89 68.16 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
ZA89 68.16 Control_4 11.937 0.9920 0.0080 0.0000 0.0040 
ZA92 68.27 Control_1 12.057 1.0000 0.0000 0.0000 0.0000 
ZA92 68.27 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
ZA92 68.27 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
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ZA92 68.27 Control_4 11.937 0.9691 0.0309 0.0000 0.0155 
Control_1  12.057 Control_2 11.987 1.0000 0.0000 0.0000 0.0000 
Control_1 12.057 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
Control_1 12.057 Control_4 11.937 1.0000 0.0000 0.0000 0.0000 
Control_2 11.987 Control_3 11.976 1.0000 0.0000 0.0000 0.0000 
Control_2 11.987 Control_4 11.937 1.0000 0.0000 0.0000 0.0000 
Control_3 11.976 Control_4 11.937 1.0000 0.0000 0.0000 0.0000 
 
FID – Family ID; IID – Individual ID; Z0 – probability that individuals at a specific marker will share no 
alleles; Z1 – probability that individuals at a specific marker will share 1 allele; Z2 – probability that individuals 
at a specific marker will share 2 alleles. 
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Figure 3.3 Relatedness inferences from IBD estimates including the control individuals.  Estimates of the IBD coefficients, namely Z0 and Z1 are used to infer 
relatedness.  Each point represents a pair of samples. Only one control (shown here in red – Control 11.937) was found to share any relation to the 40 Afrikaner probands 
through IBD estimates. 
Most related 
Least related 
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3.3 Screening of the known PD genes 
 3.3.1 Sanger sequencing of the 12 exons of Parkin 
In order to identify the genetic cause of the disorder in these Afrikaner probands, we screened 
and excluded all of the common known pathogenic PD-causing mutations in these 
individuals.  As the Parkin gene is a common cause of PD with more than 150 mutations 
identified, all 12 Parkin exons were screened using Sanger sequencing to determine whether 
or not this was the underlying cause of the disease in the 40 founder families. Numerous 
polymorphisms were identified in some of the patients (Table 3.7), but 18 of the 40 patients 
(45%) carried no variants in Parkin.  However, it was determined that one patient, 95.94 
(ZA340) carries two homozygous variants namely R275W in exon 7 (this is a known 
pathogenic mutation) and M432V in exon 12.  Therefore, the remaining 39 probands were 
shown not to harbour pathogenic mutations in Parkin. 
 
Table 3.7 Sequence variants found in Parkin in 22 Afrikaner patients. 
Family 
Number 
Patient Exon Variant rs number Frequency 
ZA233 88.74 8 IVS8+48C>T None None 






G, 0.682; C, 0.318; 
n=4550 
C, 0.997; T, 0.003; 
n=4552 
ZA112 78.97 2 IVS2-35G>A None None 
ZA89 68.16 8 IVS8+48C>T None None 
ZA241 90.87 10 V380L rs1801582 G, 0.682; C, 0.318;  
n=4550 
ZA140 81.74 11 D394N rs1801334 G, 0.945; A, 0.055; 
n=4550 
ZA252 92.00 8 IVS8+48C>T None None 







G, 0.682; C, 0.318; 
n=4550 






C, 0.998; A, 0.002; 
n=1323 
None 
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10 V380L rs1801582 G, 0.682; C, 0.318; 
n=4550 
ZA5 38.23 11 D394N rs1801334 G, 0.945; A, 0.055; 
n=4550 
ZA190 83.16 10 V380L rs1801582 G, 0.682; C, 0.318; 
n=4550 
ZA24 54.73 10 V380L rs1801582 G, 0.682; C, 0.318; 
n=4550 
ZA106 78.67 8 IVS8+48C>T None None 
ZA5 38.36 8 IVS8+48C>T None None 








ZA175 83.01 10 V380L rs1801582 G, 0.682; C, 0.318; 
n=4550 
ZA316 95.64 8 IVS8+48C>T None None 







G, 0.682; C, 0.318; 
n=4550 







G, 0.682; C, 0.318; 
n=4550 














C, 0.998; A, 0.002; 
n=1323 
G, 0.682; C, 0.318; 
n=4550 
ZA128 81.58 10 V380L rs1801582 G, 0.682; C, 0.318; 
n=4550 
 
All frequencies are determined in the Exome Sequencing Project cohort population available in dbSNP; n - 
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3.3.2 MLPA results 
The 40 PD probands were subjected to MLPA in order to eliminate CNVs in the known PD 
genes as the possible cause for PD in these patients.  The two commercially available 
Parkinson’s disease MLPA kits (SALSA P051-B1 and P052-B1) were used and it was 
determined that none of the 40 probands included in the genealogical analysis carried exonic 
duplications, triplications or deletions and this could thus also be excluded as a possible cause 
for PD in these patients. 
 
3.4 Whole exome sequencing to identify a novel PD-causing gene 
Given the substantial evidence of a possible founder effect for PD in the Afrikaner 
individuals as well as conclusive genealogical evidence that the 40 probands are related to 
one another, three of the probands (from the original six probands) from families ZA92, 
ZA106 and ZA111 were selected for WES based on their family history as well as the young 
age at onset of the disease.  The individual pedigrees for each of the selected families are 
shown below in Figure 3.4, 3.5 and 3.6.  Moreover, the affected sibling of ZA92 (herein 
referred to as ZA92_sib) was also selected for WES.  The raw sequencing reads were 
realigned to the human reference genome hg19 as a means to identify SNPs, insertions and/or 
deletions.  The variants identified through WES are summarized in Table 3.8.   
 
 
Figure 3.4 Pedigree of family ZA92.   The pedigree shows the information available regarding this family.  
The arrow indicates the proband of the pedigree (68.27).  Males are denoted as squares and females are denoted 
as circles in the pedigree.  The filled shapes are the affected individuals. 
 
 





Figure 3.5 Pedigree of family ZA106.   The pedigree shows the information available regarding this family.  
The arrow indicates the proband of the pedigree (78.67).  Males are denoted as squares and females are denoted 




Figure 3.6 Pedigree of family ZA111.   The pedigree shows the information available regarding this family.  
The arrow indicates the proband of the pedigree (78.97).  Males are denoted as squares and females are denoted 
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Total number of 
variants 
74 938 76 117 77 700 79 070 
Total number of SNPs 71 144 72 220 73 784 75 536 
Total number of Indels 3 839 3 897 3 916 3 534 
SNP – single nucleotide polymorphism 
 
Although all of the known PD genes had previously been excluded as a cause for PD in these 
patients, we specifically analysed all of the known PD genes in the WES data, which revealed 
a number of known SNPs and one novel variant in the 5’UTR of EIF4G1 (Table 3.9).  No 
variants were found in DJ-1, SNCA, CHCHD2, DNAJC13 or UCHL1.  Notably, the findings 
confirm our previous findings and excluded all the known PD genes from causing the 
disorder in these individuals.  This means that it is likely that they harbour a mutation(s) in a 
novel PD-causing gene. 
 
Table 3.9 Variants detected in the known PD genes in the three PD probands ZA92, ZA106 
and ZA111 as well as the affected sibling ZA92 (sibling). 
PD Gene Variant In dbSNP Frequency (n=no. 
chromosomes) 
Present in 








Parkin V189L rs1801582 (ESP) C,0.174; 
G,0.826; n=4550 
Yes Yes Yes Yes 
3'UTR 
+118G>A 
rs6812138 (ESP) A, 0.092; 
G,0.908; n=4550 
No Yes No Yes 
3'UTR +413 
A>G 
rs4709583  (ESP) A,0.085; G, 
0.914; n=4550 
No Yes No No 
PINK1 Non-genic* rs3131713 (ESP) A, 0.883; G, 
0.117; n=4550  
Yes Yes Yes Yes 
N521T rs1042434 (ESP) C,0.677; 
G,0.333; n=4552 
Yes No Yes Yes 
3'UTR+37A>T rs686658 (CSAgilent) A, 
0.125; T,0.875; 
n=1324   
No No Yes Yes 
3'UTR+181 
C>G 
rs513414 (CEPH) C, 0.150; 
G, 0.850; n=184 
Yes No Yes No 
3'UTR+40A>G rs6893 (CEPH) C, 0.890; No No No Yes 
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T, 0.110; n=184 
LRRK2 R50H rs2256408 (ESP) A, 0.923; G, 
0.077;  n=4550 
Yes Yes Yes Yes 
N551K rs7308720 (ESP) C, 0.898; 
G0.102; n=4510 
No No Yes Yes 
R1398H rs7133914 (ESP) A,0.100; G, 
0.900;  n=4540 
No No Yes No 
S1647T rs3459182 No frequencies 
available 
No No Yes No 
M2397T rs3761863 (ESP) A,0.384; 
G,0.616;  n=4554 
Yes Yes Yes Yes 
3'UTR+140 
C>T 
rs6673790 No frequencies 
available 
Yes Yes Yes Yes 
SNCA - - - - - - - 
DJ-1 - - - - - - - 
ATP13A2 P1172P rs3170740 (CEPH) A, 0.760; 
G, 0.240; n=184 
Yes Yes Yes No 
Non-genic* rs7531163 (CSAgilent) A, 
0.283; G,0.717 
n=1324   
No Yes No Yes 
VPS35 3'UTR+281 
C>A 
rs808078 No frequencies 
available 
No Yes No Yes 
 
EIF4G1 
T161A rs1331914 (CEPH) C, 0.075; 
T, 0.925 
n=184 
No No No Yes 
M432V rs2178403 (ESP) C,0.841; 
T,0.159;  n=4552 
No No No Yes 
5’UTR Novel No frequencies 
available 
No No No Yes 
CHCHD2 - - - - - - - 
PD-associated genes 
DNAJC13 - - - - - - - 
GBA3 Y149X rs358231 (CSAgilent) A, 
0.816; T,0.184; 
n=569 
Yes Yes No No 
UCHL1 - - - - - - - 
FBXO7 M36I rs11107 (ESP) C, 0.632; 
T,0.368; n=4540 
No Yes Yes No 
PLA2G6 - - - - - - - 
MAPT - - - - - - - 
*Non-genic refers to areas on contigs that do not contain any genes; ESP, Exome Sequencing Project; 
CSAgilent, this population includes 662 participants of European descent from the ClinSeq project, all of whom 
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have undergone whole exome sequencing using Agilent's 38Mb or 50Mb capture kit; CEPH; Genomic DNA 
samples were obtained for a panel of 92 unrelated individuals chosen from Centre d'Etude du Polymorphisme 
Human (CEPH) pedigrees. The genomic DNA comprised of UTAH (93%), French (4%), and Venezuelan (3%) 
samples were purchased from Coriell Cell Repository and pooled in equimolar amounts for use. 
 
The exclusion of the known PD-causing genes indicates that the genetic cause for this disease 
is likely to be as a result of novel variations in a novel gene.  For this reason, along with the 
genealogical information, all low frequency and novel variants that occur in all four affected 
patients were identified.   
 
3.4.1 Analysis of WES data using the hypothesis based approach 
As described in Section 2.6.1, page 49, the hypothesis-based approach for WES data analysis 
assumes a number of factors to be known about the disease including a detailed account of all 
possible phenotypic characteristics and the mode of inheritance.  In the case of PD, 
phenotypic characteristics such as bradykinesia, resting tremor, postural instability and 
rigidity were all terms that were used to prioritise variants across affected individuals.  The 
candidate list of variants was subjected to the Biological Database Network 
(http://biodbnet.abcc.ncifcrf.gov/db/db2db.php) and GO ontologies for cellular, biological 
and molecular processes were obtained. Genes that have been extensively studied and have 
either been associated with the disease phenotype and subsequently with various clinical 
presentations are moved to the top of the priority list, while lesser known genes that have 
been studied less extensively, move down the priority list.  Moreover, genes that have 
variants with low frequencies and have been associated with an aspect of the disease 
phenotype are prioritised and placed higher up on the list as well.  
 
The identification of common variants between the custom method and Ingenuity Variant 
Analysis were prioritised for further analysis.  The results showed a total of 74 non-
synonymous variants with low frequency in the databases across all four PD affected 
individuals.  The results are summarized in Appendix IV.  Variants with the lowest frequency 
or for which no frequency information is available have been prioritised and ordered at the 
top of the table.  Further analysis of the variants removed all of the genes for which there 
were multiple SNPs per single gene.  Moreover, a number of genes that have been flagged in 
numerous WES projects that recurrently produce SNPs, but which have been identified as 
false positives (Fajardo et al. 2012; http://massgenomics.org/2013/06/ngs-false-
positives.html), were removed.    The elimination of these genes resulted in a total of 22 
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genes (24 variants) remaining for further analysis.  The results are summarized in Table 3.10.  
Variants with the lowest frequency or for which no frequency information is available have 
been prioritised and ordered at the top of the table. 
 
Of these shared variants, it was necessary to determine which were likely to be disease-
causing; the list of 24 variants was prioritised according to the following criteria: 
1) were non-synonymous or nonsense variants, AND  
2) the average allele frequency of the variant in the databases had to be less than or 
equal to 0.03, AND  
3) the read depth had to be greater than or equal to 50, AND  
4) if the variants were predicted as being potentially deleterious according to SIFT, 
PolyPhen2 or MutationTaster, AND 
5) were predicted to be in a conserved domain using PhyloP, which considers 
evolutionary conservation across multiple species, thereby emphasising the fact that 
evolutionary conservation is essential in determining whether or not a non-
synonymous variant is likely to be pathogenic (Li et al. 2013). 
Read depth refers to the number of times each base was sequenced in total.  This is 
predetermined by the platform used and for the Illumina Human All Exon Kit, it is predicted 
that each base will be covered a minimum of 50x - therefore anything below this coverage 
may be an artefact rather than a true variant (Charier et al. 2012).  These criteria provided an 
ordered list of variants and 12 of the 24 were chosen for Sanger sequencing verification in all 
four of the patients who had been subjected to WES (Table 3.10).  Verification with Sanger 
sequencing is a necessary and important step, as NGS technology is known to produce a 
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Table 3.10 Overlapping prioritised SNPs across four individuals affected with PD. 








TPSD1 H143R 0 rs72775466 T B 0.102904  N/A 
PRB2 R357Q 0 - NA NA 0.001769  N/A 
PLIN4 A883T 0 rs80238130 - - -  N/A 
NOTCH2N
L 
T158I 0 rs75586173 T D 0.997294  Artefact 
KIR3DL1 S239N 0 - T NA 3.9E-5  N/A 
IL28A F137L 0 - NA B 1.9E-5  N/A 
HBD S87A 0 - T NA 0.162278  N/A 
KATNAL2 S301C 0 rs76539063 D P 0.9725871  Real but in control 
individuals 
CLIP1 L271F 0 rs79909185 D P 0.974668  N/A 
CASP1 G85E 0 rs2509649 T B 0.097257  N/A 
ANAPC1 Q451H 0 rs79100806 T B 0.360565  Artefact 
IL32 D172G 0 rs2981599 D P 0.981577  Real but in control 
individuals 
PRSS3 A145T 0 rs855581 D P 0.999736  Artefact 
TIMM23 N9D 0 rs4935252 D P 0.999742  Artefact 
TIMM23 G23E 0.50/0.50 (n 
= 2) 
rs373071373 D P 0.85697  Real 
YY1AP1 Q424R 0.998/0.002 
(n = 1315) 
rs113197997 T B 0.294756  N/A 
MYO5B V1703A 0.981/0.019 
(n = 259) 
rs138128932 NA B 0.145661  N/A 
MAP2K3 Q73X 0.50/0.50 (n 
= 2) 
rs55796947 NA NA 1  Artefact 
KCNJ12 
KCNJ18 
R118Q 0.50/0.50 (n 
= 2) 
rs1657740 T B 0.021368  N/A 
GPRIN2 W91R 0.50/0.50 (n 
= 2) 
rs3127820 D B 4.0E-6  Artefact 
C22orf42 M120I 0.958/0.042 
(n = 3420) 
rs144597334 D B 2.91E-4  Artefact 
BCLAF1 T837N 0.50/0.50 (n 
= 2) 
rs62431284 D P 5.0E-6  Artefact 
CNTN5 S23A 0.50/0.50 (n 
= 2) 
rs10790978 - - -  N/A 
CNTN5 L70R 0.50/0.50 (n 
= 2) 
rs7125822 - - -  Artefact 
P - pathogenic; D - damaging; T - tolerated; B - benign; NA - stop/gain mutation; n - number of chromosomes; 
 - selected for further analysis; - not selected for further analysis; N/A – not sequenced. 
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3.4.1.1 Sanger sequencing validation  
In order to validate whether or not the prioritised SNPs were real or sequencing artefacts, 
primer pairs were designed for each SNP.  The primer sequences as well as the individual 
annealing temperature for each of the 12 SNPs are summarized in Appendix V. 
 
The results of the Sanger sequencing are shown in Supplementary Figure 1, Appendix VI; in 
total the three probands and the affected sibling were sequenced.  Numerous variants (A145T 
in PRSS3, Q73X in MAP2K3, T158I in NOTCH2NL, Q451H in ANAPC1, N9D in TIMM23, 
W91R in GPRIN2, M120I in C22orf42, T837N in BCLAF1 and L70R in CNTN5) were 
identified as sequencing artefacts as Sanger sequencing revealed the patients to be 
homozygous for the wild type allele.  However, D172G in IL32, G23E in TIMM23 and 
S301C in KATNAL2 were found to be real, heterozygous variants and were analysed further 
through various genotyping techniques in order to determine the frequency of the variants in 
patients and control individuals. 
 
3.4.1.2 Frequency in ethnically matched control samples 
3.4.1.2.1 Genotyping of G23E in TIMM23  
The G23E variant in TIMM23 was prioritised for further analysis as it was found to be a real 
variant across all four individuals and was found to significantly alter the protein properties; 
glycine is converted into glutamic acid (Figure 3.7).  Glutamic acid carries a negative charge 
that is hypothesised to affect protein folding; moreover, it is hypothesised that the mutation of 
glycine into glutamic acid is likely to abolish protein functioning.   
 
Figure 3.7 Diagrammatic representation of the amino acid change inducing the G23E variant in TIMM23.   
 
 
The genotyping was performed by a commercial company, IKMB (Institut für Klinische 
Molekularbiologie – Institute for Clinical Molecular Biology) in Kiel, Germany in order to 
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determine the frequency of the variant in the South African PD patients as well as ethnically 
matched controls.  A total of 1148 samples were genotyped – 458 of these were PD patients 
and 690 were ethnically matched controls (184 Afrikaner controls, 160 white controls, 180 
mixed ancestry controls and 166 black controls). Figure 3.8 shows that the genotyping using 
TaqMan® SNP genotyping assay was unsuccessful; the result for the genotyping was 
considered to be “undetermined” as no positive genotyping calls could be made.  The 
genotyping calls that were expected were either homozygous A/A (wild type); heterozygous 
A/G or homozygous G/G.  It was determined that this was as a result of an erroneous 
sequence in dbSNP from which the primers and probes had been designed. 
 
Given the problematic TaqMan® SNP genotyping assay, a total of ten Afrikaner control 
individuals were Sanger sequenced in order to determine whether or the G23E variant was, in 
fact, present in controls.  The rationale behind this is that unaffected control patients should 
not harbour a variant that is carried by PD affected patients.  The sequence alignment of the 
G23E variant in the controls shows that the SNP is in fact present in all of the controls 
(Figure 3.9) and the variant was thus excluded from the study for further analysis.   
 





Figure 3.8 TaqMan® SNP genotyping assay result obtained from IKMB.    Three heterozygous positive 
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Figure 3.9 Sequence alignments of ten controls as well as the probands and affected sibling.  The location 
of the identified SNP is indicated by the red arrow.  The wild type is the reference sample, the mutant is the 
sample in which a heterozygous change would be present. 
 
3.4.1.2.2 Genotyping of D172G in IL32 
The D172G variation in IL32 could be easily identified using both the normalized and 
difference graphs obtained from HRM analysis (Appendix VI, Supplementary Figure 2).  Of 
the 31 Afrikaner controls that were screened, it was determined that ten individuals shared a 
melt profile that was the same as the positive controls that had been included in the run.  For 
this reason, the ten individuals were selected and Sanger sequenced in order to determine 
whether or not the SNP was in fact present in these individuals.  The results obtained from 
Sanger sequencing confirmed the presence of the D172G variant in the controls (in some 
cases in the homozygous form) and the variant was thus excluded from any further analysis 
(Appendix VI, Supplementary Figure 3). 
 
3.4.1.2.3 Genotyping of S301C in KATNAL2 
The S301C variation in KATNAL2 could be easily identified using the normalized and 
difference graph obtained from HRM analysis (Appendix VI, Supplementary Figures 4 and 
5).  Of the 31 Afrikaner controls that were screened, it was determined that one sample 
shared a melt profile that was the same as the positive controls that had been included in the 
run.  Additionally, there were numerous control samples that had altered HRM profiles and 
for this reason were also selected for Sanger sequencing.  The results obtained from Sanger 
sequencing confirmed the presence of the S301C variant in five of the controls (Appendix VI, 
Supplementary Figure 6).  Therefore, the variant was excluded from further analysis. 
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3.4.2 Analysis of family ZA92 only using the hypothesis based approach 
The difficulties in identifying a single variant across two families that may be accountable for 
PD in the South African patient cohort resulted in a new approach to data analysis and focus 
was placed on family ZA92.  A comparison of WES data was conducted between the affected 
siblings and the unaffected family member (ZA_92_unaffected, related control) that was also 
subjected to WES.  Subsequent bioinformatics identified a plausible variant, P1150S 
(rs34344550) in EFCAB6 that met all of the necessary filtering criteria as previously 
established.  The EFCAB6 gene produces the EF-hand calcium-binding domain containing 
protein 6, a protein that negatively regulates the androgen receptors by recruiting histone 
deacetylase complex.  Moreover, the protein DJ-1 (known to be involved in PD) antagonises 
this reticence by the abolition of this complex (http://www.ncbi.nlm.nih.gov/gene/64800; 
Niki et al. 2003).  The proline to serine substitution was found to significantly alter the 
properties of the expressed protein (Figure 3.10).  The mutant residue is considerably smaller 
than the wild type residue and the wild type residue is considered to be more hydrophobic 
than the mutant residue and it is hypothesised that significant hydrophobic interactions that 
may occur, either on the surface or in the core of the protein, may be lost due to this alteration 
in amino acid sequence.  Additionally, prolines are recognized as molecules that have an 
extremely rigid structure, therefore sometimes forcing the backbone into a specific 





Figure 3.10 Diagrammatic representation of the amino acid change inducing the P1150 variant in 
EFCAB6.   
 
 
The strong evidence that the P1150S variant in EFCAB6 may alter protein folding and 
therefore possibly protein functioning led to further investigations as to whether or not this 
gene (and variant) may play a role in PD.  The protein product of EFCAB6 is more 
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commonly known as DJ-1 binding protein, and the protein actively interacts with DJ-1 with 
the interaction spanning amino acid numbers 372 -570 of the DJ-1 protein (Niki et al. 2003).  
The global frequency of the P1150S variant has been reported to be low in six ethnic groups 
that have been extensively studied (Table 3.11).  
 
Table 3.11 Global frequency data of P1150S in EFCAB6.  




South Asian 222 16 606 2 0.0134 
European (Non 
Finnish) 
474 67 658 3 0.0070 
Latino 54 11 602 0 0.0047 
African 12 10 556 0 0.0011 
East Asian 2 8 766 0 0.0002 
European (Finnish) 1 6 732 0 0.0001 
Totals 765 121 938 5 0.00440063 
*Table taken and adapted from ExAC Browser (http://exac.broadinstitute.org/).  
 
Moreover, subsequent communication with our collaborators at the Institut du Cerveau et de 
la Moelle épinière (ICM) in Paris, France revealed the frequency of the P1150S variant was 
recorded at 0.0039457 in more than 15 000 control individuals. 
Given the insurmountable evidence that the P1150S variant was found at a low frequency in 
multiple ethnic groups as well as the fact that the gene in which the variant was identified is a 
confirmed interactor of a known PD gene, namely DJ-1, further investigation into the 
possible pathogenic effects of the variant was deemed necessary.    
 
  3.4.2.1 Sanger sequencing validation 
Sanger sequencing was performed for validation purposes and P1150S variant was found to 
be real in the affected sibling pair, but more importantly was found to be absent in the related, 




Stellenbosch University  https://scholar.sun.ac.za
93 
 





Figure 3.11 Sequence alignments of ZA92 family as well as an unrelated, unaffected control for the 
P1150S variant in EFCAB6.  The location of the identified SNP is indicated by the red arrow.  The wild type is 
the reference sample, the mutant is the sample in which a heterozygous change would be present. 
 
 
  3.4.2.2 Genotyping of P1150S in EFCAB6 
Genotyping was performed using HRM for both variants and two positive controls namely 
ZA92 and ZA92 (affected sibling) were included in each run. A total of 690 ethnically 
matched control samples were sequenced.  The ethnic breakdown of the control samples were 
as follows:  184 Afrikaner controls, 160 white controls, 180 mixed ancestry controls and 166 
black controls.  The P1150S variant could be easily identified using the normalized and 
difference graphs obtained through HRM analysis (Figure 3.12 and 3.13).   
 
 
Figure 3.12 HRM normalised graph indicating the heterozygous P1150S variant in the sequence 
confirmed positive controls. 
 
Heterozygous P1150S variant 




Figure 3.13 HRM difference graph indicating the heterozygous P1150S variant in the sequence confirmed 
positive controls. 
 
Of the 690 control samples that were screened for the variant, none of the control samples 
were identified as carriers of the P1150S variant.  Subsequently, a total of 458 PD probands 
were screened for the variant, given its absence in the control population and any samples 
that exhibited altered HRM profiles were subjected to Sanger sequencing however none of 
the query samples were confirmed to carry the variant.  The frequency of the P1150S variant 
was concluded to be 0.22% (1/458) in the probands and 0% (0/690) control samples.   
 
Family members of the individual who was originally identified as a carrier of the P1150S 
variant were sequenced in order to identify additional P1150S–carrying individuals.  The 
variant was identified in both of the children of the proband (Figure 3.14).  Currently, the two 
children are younger than the identified AAO of their mother (55 years).  Subsequently, the 
children of the affected sibling, ZA92_sib were also sequenced and the variant was also 
identified in these individuals.  Both of the children are also younger than the AAO of their 
father (68 years).  Given the fact that the cousins are all younger than the AAO of disease in 
their respective parents, it is not possible to rule out the fact that P1150S may be pathogenic. 
However, no symptoms of PD in the children are currently apparent.   
Heterozygous P1150S variant 




Figure 3.14 Sequencing results from the proband with the P1150S variant and additional family 
members.  The variant is present in both children of the proband, one of the siblings and not in the unaffected 
sibling. 
 
Following the identification of P1150S in EFCAB6 in the South African population, it was 
necessary to determine whether or not the variant had been identified in other PD individuals 
and simultaneously determine whether or not the variant possibly co-segregates with the 
disease in this population.  It was determined, however that the P1150S variant does not co-
segregate with the disease in five Canadian families and it was found in a heterozygous state 
in five patients and six healthy controls (Prof. Matthew Farrer, personal communication) – 
for this reason, the variant was excluded as a possible disease-causing variant in the South 
African PD population. 
 
3.4.3 Analysis of WES data using the hypothesis-free approach  
The identification of a single gene and variant that could be attributed to PD in the South 
African patients was proving to be a challenge and for this reason, we decided to use a 
hypothesis-free approach to prioritise sequence variants.  To this end, we designed a novel in-
house bioinformatics pipeline for the filtering of variants, called TAPER™.  In order to 
determine whether or not TAPER™ was an efficient means for data analysis, proof of 
concept experiments were conducted.  This was performed on existing WES data for which a 
disease-causing gene and variant had been identified.  The datasets that were used were 
sourced from various collaborators (Dr. Suzanne Lesage, Institut du Creveau et de la Moelle 
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épinière, Hôpital Pitié Salpêtrière, Paris, France; Mr Daniel Evans, Centre for Applied 
Neurogenetics, University of British Columbia, Vancouver, Canada) as well as files sourced 
from previously published papers; the datasets used were those that previously identified 
variants in Parkinson’s disease as well as severe intellectual disability and microcephaly and 
ataxia and myoclonic epilepsy (Pena and Coimbra 2015; Srour et al. 2015).  The results for 
the proof of concept study are shown in Appendix VII Supplementary Table 1.  TAPER™ 
was successfully used to identify the same variants that had previously been implicated in 
specific diseases.  TAPER™ was subsequently applied to the original six family pedigree 
rather than to the larger 40 family pedigree.  The rationale behind TAPER™ and the steps 
that it uses is comprehensively explained in Section 2.6.2, page 54 and it is unique in that it 
assumes no phenotypic or clinical distinctions as a means of prioritisation when analysing 
WES data.  The results from this prioritization method are shown in Table 3.12. 
 
Following the identification of variants in each individual proband that was subjected to WES 
using TAPER™, a new candidate gene list was constructed.  The construction of the new 
candidate list involved the following steps: 
 Variants that overlap across the affected sibling pair in ZA92 but are absent from all 
controls – a total of 45 variants in 39 genes were found to overlap; 
 Variants that were found to be in shared segments (as identified in Section 3.2.1.1); 
 Variants that are found in at least three of the four WES individuals (ZA92, ZA92 
(affected sibling), ZA106 or ZA111); 
 Variants that fall into chromosomally shared regions; 
 Prioritization of variants that were found to be involved in other movement disorders 
or any pathways previously associated with PD; 
 Variants with high Combined Annotation Dependent Depletion (CADD) scores.  
CADD is a method for objectively integrating numerous diverse annotations into a 
single score (C-score) for each variant.  A scaled CADD score of 20 means that the 
variant is amongst the top 1% of deleterious variants; a scaled CADD score of 30 
means that the variant is in the top 0.1% of deleterious variants. For this reason, the 
higher the CADD score, the more likely the variant is to be pathogenic (Kircher et al. 
2014). 
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A list of 20 variants in 20 genes were selected and of these, a total of six of the prioritised 
variants were selected for further analysis based on the function and possible link to disease 
(Table 3.13).  
Table 3.12 Summary of the total number of variants obtained through each filtration step. 
 ZA92 
proband 
ZA92 sibling ZA106 ZA111 
Total variants in VCF file 74 938 76 117 77 700 79 070 
Total number of variants 
assigned to exonic regions 
by wANNOVAR 
19 596 19 955 20 881 20 966 
All synonymous and non-
frameshifts removed 
9 479 9 646 10 237 10 251 
Remove all variants with a 
frequency >1% in 1KGP 
1 086 1 127 1 403 1 357 
Remove all variants with a 
frequency >1% in ESP6500 
911 965 1 193 1 156 
Remove all variants with 
positive FATHMM scores 
384 416 469 474 
Remove all variants with 
negative GERP+++ scores 
246 265 282 293 
Remove all variants on X 
and Y chromosomes 
242 261 276 286 
Variants linked to relevant 
diseases 
56 54 46 68 
*VCF - Variant Called Format; 1KGP - 1000 Genomes Project; ESP6500 - Exome Sequencing Project 6500; 
GERP - Genomic Evolutionary Rate Prediction; FATHMM - functional analysis through hidden Markov 
Models 
 
Table 3.13 Shortlist of candidate genes prioritised for further analysis. 





CASP7 E43D . 8.23E-06 . . 29.47 Yes 
WNK1 S719G . 0.001785 . . 31.01 Yes 
MAST2 T867R . . . . 15.99 CADD score too 
low 
DCDC2B V78A 0.0014 5.28E-03 0.0058 rs144804850 26.80 No neurological 
disease 
association 
CACNA1E R2157Q 0.0002 4.65E-04 0.001 rs2480373 35.00 No neurological 
disease 
association 
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MIPEP V626M . 4.07E-05 . . 26.91 Yes 
SETD8 L332P . . . rs61955127 23.40 No neurological 
disease 
association 
SLC5A2 N654S 0.002 5.27E-03 0.007 rs61742739 17.94 No neurological 
disease 
association 
SYNJ1 V1405I . 1.65E-04 . rs79652470 29.40 Yes 
EPB41L5 R28C 0.0016 3.19E-03 0.0042 rs141466977 14.78 No neurological 
disease 
association 
PKP4 D1127V 0.0016 3.21E-03 0.0036 rs148782148 18.59 No neurological 
disease 
association 
CYP1B1 R368H 0.0042 5.94E-03 0.0016 rs79204362 24.91 No neurological 
disease 
association 
CYP2D6 R365H . 0.12 . rs1058172 34.00 No; frequency 
too high 
KLHL5 R36S 0.004 7.46E-03 0.0091 rs140053546 7.59 CADD score too 
low 
WDR36 R529Q 0.0002 7.81E-04 0.0013 rs116529882 30.00 No neurological 
disease 
association 
SYNJ2 M534T 0.0008 5.26E-03 0.0043 rs140670406 18.25 Yes 
REEP4 R209W . 3.25E-05 . . 12.26 CADD score too 
low 
USP17 C357S . 7.863e-05 . . 34.89 Yes 
COL27A1 R1688Q . 2.03E-03 0.0011 rs149629527 None No neurological 
disease 
association 
COL6A5 L2591X . . . . 8.78 CADD score too 
low 
CASP7 – Caspase 7, Apoptosis-Related Cysteine Peptidase; WNK1 - Lysine Deficient Protein Kinase 1; 
MIPEP - Mitochondrial Intermediate Peptidase; SYNJ1 - synaptojanin1; SYNJ2 – synaptojanin2; USP17 - 
Ubiquitin Specific Peptidase 17; SNV – single nucleotide variant;  CADD – combined annotation dependent 
depletion 
  3.4.3.1 Sanger sequencing validation 
A total of six variants were shortlisted for further analysis based on the fact that they had 
previously been associated with other movement disorders or had been directly implicated in 
pathways that had previously been associated with PD and other movement disorders and 
were validated using Sanger sequencing.  The primer sequences as well as the annealing 
temperature for each of the SNPs is summarised in Supplementary Table 2, Appendix VII.   
The results of the genotyping are shown in Table 3.14 and the Sanger Sequencing and 
genotyping results are shown in Appendix VIII.  Three of the candidate variants namely 
S719G in WNK1, E43D in CASP7 and V626M in MIPEP were excluded from the analysis as 
they were found in the control individuals.  The M534T variant in SYNJ2 was not sequenced 
or genotyped as it was determined that this variant does not co-segregate with disease (Prof. 
Matthew Farrer, personal communication).  Two of the remaining variants were found to be 
of interest, namely V1405I in SYNJ1 and C357S in USP17. 
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Table 3.14 Summary of the genotyping results obtained for the six variants shortlisted for further analysis. 




Frequency in Controls Frequency in Patients 




















WNK1 S719G Unknown 3 (2.03%) 1 (0.63%) 2 (1.2%) 3 (1.67%) DNS 
CASP7 E43D Unknown 2 (1.09%) 1 (0.63%) 1 (0.60%) 0 DNS 
MIPEP V626M Unknown 1 (0.54%) 1 (0.63%) 2 (1.2%) 1 (0.56%) DNS 
SYNJ1 V1405I Unknown 0 0 0 0 1 (0.68%) 0 0 0 0 
SYNJ2 M534T No DNS DNS 
USP17 C357S Unknown 1 (0.54%) 0 0 0 12 (8.11%) 2 (1.15%) 0 4 (3.85%) 0 
 
CASP7 – Caspase 7, Apoptosis-Related Cysteine Peptidase; WNK1 - Lysine Deficient Protein Kinase 1; MIPEP - Mitochondrial Intermediate Peptidase; SYNJ1 -  






Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
100 
 
3.4.3.2 Frequency in ethnically matched control samples 
3.4.3.2.1 Genotyping of V1405I in SYNJ1 
In silico analysis was performed on the V1405I variant using the methods previously 
described.  In SYNJ1 sequence O43426 (Swiss-Prot) (NP_003886.3), the variation is at 
residue 1366.  In the nucleotide to protein translation of NM_001150306, it is at position 
1319. For the purposes of this study, the O43426 Swiss-Prot sequence was used.  It 
should be noted that there are four isoforms for the SYNJ1 protein and the V1366I variant 
(corresponding to V1405I) is only present in isoform 1.  It was determined that there is a 
catalytic domain that lies from position 500-899 as well as two conserved domains within 
this protein, namely the SAC domain (from residues 119-449) and an RNA recognition 
motif (RRM) domain (from residues 902-971).  The SAC domain is a region of homology 
between the N terminus of synaptojanin and the otherwise unrelated yeast protein Sac1p 
and is approximately 400bp in length (www.ebi.ac.uk/interpro/entry/IPR002013).  The 
RRM motif is on average 90 amino acids that are known to bind to single stranded RNAs 
(www.ebi.ac.uk/interpro/entry/IPR000504).    Additionally, this protein carries a 3 x 3 
amino acid (Asparagine, Proline and Phenylalanine) repeats at positions 1396-1398, 
1406-1408 and 1417-1419.  It was therefore concluded that the residue of interest at 
position 1366 does not fall into any of the conserved or catalytic domains.  In addition to 
the variant at position 1366 in this isoform, there is an additional natural variant at 
position 1388 namely the V1388A variant.  In terms of the physio-chemical properties, 
this is a change from a medium sized hydrophobic residue to a small sized hydrophobic 
residue.   
 
Variant V1366I was analysed and it was determined that the amino acid substitution is a 
conservative one – both of the proteins are hydrophobic and similar in size (Figure 3.15).  
However, it was not possible to model the section of the protein containing the variant 
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Valine                                                                                                Isoleucine 
 
Figure 3.15 Diagrammatic representation of the amino acid change inducing the V1366I variation in 
SYNJ1.   
 
Following the examination of the amino acid substitution, a scan for eukaryotic linear 
motifs (ELM) (Dinkel et al. 2012) was conducted on the sequence.  It was determined that 
there are a number of potential phosphorylation sites in this vicinity: 
1. Residues 1368 and 1375:  Glycogen Synthase Kinase (GSK) 3 phosphorylation 
site  
2. Residue 1368:  Casein Kinase (CK) 1  phosphorylation site 
3. Residue 1359 and 1365:  PI3 Kinase-related Kinase (PIKK) phosphorylation site 
 
In addition to these phosphorylation sites, it was determined that there is a potential 
binding motif (residues 1361 and 1365) for the Ubiquitin Specific Protease (USP)7 
deubiquitinating enzyme.  It is, however very difficult to draw any definitive conclusions 
as to what the effect of the variant may be on the protein.  The so-called natural variant, 
V1388A is not anticipated to have an effect on the function of the protein and the 
replacement of the Valine with Isoleucine is conservative.  However, due to the proximity 
of the variant, there is a possibility that the V1366I substitution could interfere with 
phosphorylation or the binding by the USP7 deubiquitinating enzyme.  However, it was 
not possible to determine the position of the residue in the 3 dimensional structure.  There 
is no solved structure in the protein data bank and therefore we were unable to generate a 
reliable model due to the lack of a suitable template. 
 
The V1405I variant was found to be homozygous and only in the affected sibling pair.  
However, this variant was not found in any of the controls that were subsequently 
selected for genotyping and Sanger sequencing validation in the patients (Figure 3.16 and 
3.17).  This variant can be easily identified through the use of HRM and was identified in 
0.22% (1/458) probands and in none of the controls. 




Figure 3.16 HRM difference graph for the V1405I variant in SYNJ1. The homozygous variant is 
indicated by the red arrow and can be easily distinguished from wild type samples. 
 
V1405I in SYNJ1 (GTT > ATT) 
 
 
Figure 3.17 Sequence alignments of selected samples for the V1405I variant in SYNJ1.  The 
location of the SNP is indicated by the red arrow.  The wild type is the reference sample while the mutant 
sample is a construct indicating the position of the variant in a homozygous state. 
 
 
Homozygous V1405I variant 
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3.4.3.2.2 Genotyping of C357S in USP17 
In silico analysis was performed on the C357S variant using the methods previously 
described.  In USP17 sequence Q6R6M4 (Swiss-Prot) the variation is at residue 357, as 
previously expected.  It was determined that there is an Ubiquitin Specific-processing 
Protease (USP) domain that spans the position 80-375.  The USPs make up the largest 
family of deubiquitinating enzymes and ubiquitination is a reversible process that affects 
a number of cellular processes such as protein degradation, trafficking, cell signalling and 
DNA damage response. USP is composed of a conserved catalytic core that is 
interspersed at five independent points with insertions; these insertions may be as large as 
the catalytic domain itself.  The insertions are capable of folding into independent 
domains that are involved in the regulation of deubiquitinase activity 
(http://www.ebi.ac.uk/interpro/entry/IPR028889).  The region is conserved across 
multiple species and interestingly, the variant falls within this domain, at position 357.   
 
Variant C357S was analysed and it was determined that the amino acid substitution was 
not a conservative one – the hydrophobic Cysteine is substituted with a hydrophilic Serine 
amino acid; however the amino acids are similar in size (Figure 3.18).  It was not possible 
to model the section of the protein that contains this amino acid, as there is no suitable 
template.   
                                            
Cysteine                                                                                              Serine 
 
Figure 3.18 Diagrammatic representation of the amino acid change inducing the C357S variant in 
USP17. 
 
Following the examination of the amino acid substitution, a scan for eukaryotic linear 
motifs (ELM) (Dinkel et al. 2012) was conducted on the sequence.  It was determined that 
there are a number of potential phosphorylation sites in this vicinity: 
1. Residues 357 and 364:  Glycogen Synthase Kinase (GSK) 3 phosphorylation site  
2. Residue 358-340:  Casein Kinase (CK) 1  phosphorylation site 
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3. Residue 361-367:  PI3 Kinase-related Kinase (PIKK) phosphorylation site 
 
In addition to these phosphorylation sites, it was determined that there is a potential 
binding motif (residues 229-233 and 305-309) also for the USP7 deubiquitinating 
enzyme.  It is, however very difficult to draw any definitive conclusions as to what the 
effect of the variant may be on the protein.  It was not possible to determine the position 
of the residue in the 3 dimensional structure.  There is no solved structure in the protein 
data bank and therefore we were unable to generate a reliable model due to the lack of a 
suitable template.  
 
The homozygous C357S was found to be real and in 18 PD probands (12 Afrikaner, 2 
White and 4 Mixed Ancestry) – however, one Afrikaner proband was found to carry this 
variant in a homozygous state.  The Sanger sequencing results for this variant is shown in 
Figure 3.19 and the HRM difference graphs for the genotyping USP17 is shown in Figure 
3.20.  This variant can be easily identified through the use of HRM and was identified in 
3.93% (18/458) probands and 0.14% (1/690) controls. 
 
C357S in USP17 (TGT > TCT) 
 
 
Figure 3.19 Sequence alignments of selected samples for the C357S variant in USP17.  The 
location of the SNP is indicated by the red arrow.  The wild type is the reference sample while the mutant 
sample is a construct indicating the position of the variant in a homozygous state. 




Figure 3.20 HRM difference graph for the C357S variant in USP17. The homozygous variant is 
indicated by the red arrow and can be easily distinguished from wild type samples. 
Homozygous C357S variant 
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CHAPTER 4:  Discussion 
 
The present study undertook an investigation into whether a founder effect for PD might exist 
in the South African Afrikaner patients and this was analysed using genealogical tracking and 
WES.  Moreover, the study aimed to determine whether this putative disease-causing 
mutation could be attributed to the development of PD in other South African ethnic groups. 
It has been determined that the known PD genes do not play a significant role in the South 
African PD cohort and it was therefore sought to identify a novel variant.  WES was 
performed on three PD probands and an affected sibling and a number of candidate genes 
were identified using a hypothesis-based approach, however, these were identified as either 
sequencing artefacts or as high frequency variants in ethnically matched controls.  A novel 
variant prioritisation tool TAPER™ was designed and applied to the WES data and a number 
of plausible candidate genes were identified.  Of these, two genes (SYNJ1 and USP17) were 
prioritised for verification and further study.  SYNJ1 had previously been identified, as a role 
player in early-onset PD while the protein product of USP17 is involved in the 
deubiquitination of tagged proteins so as to regulate cellular processes.  In silico analysis was 
employed to determine the possible effects of each of the variants on the protein product and 
how this may contribute to the pathobiology of disease. 
 
4.1 Genealogical analysis 
In a previous study conducted by our group, a total of 262 South African PD patients were 
screened for the known genes that cause PD (B Glanzmann, MSc thesis, March 2013).  Of 
these, 76 (29.0%) were self-identified as Afrikaner and none of the known PD genes played 
any significant role in disease in these individuals.  Genealogical tracking was subsequently 
performed on 12 of the Afrikaner probands and complete pedigrees were constructed for each 
of the families.  It was then determined that six of these Afrikaner individuals could be traced 
back to a common founder couple who had immigrated to the country in the 1600s.   
 
Following the discovery that six of the apparently unrelated PD probands trace back to a 
common founder couple, genealogical analysis was conducted on additional selected 
Afrikaner patients.  Since the advent of the present study, a total of 48 Afrikaner probands 
were selected for genealogical analysis based on the age at onset of the disease as well as the 
positive family history of PD.  Of these, a total of 40 probands traced back to the same 
common founder couple.  Given that some progenitors of Afrikaners have large numbers of 
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present day descendants, it has been suggested that any two present day Afrikaners may share 
these progenitors as ancestors to some degree (Greeff 2007).  However, this does not seem to 
be the case and this is illustrated with genealogical data that is available for long QT 
syndrome (Geldenhuys et al. 2014).  Here, 22 families were shown to share a common 
founder couple through the construction of 12 complete and ten partial ancestral charts.  In 
the 12 complete ancestral charts that had been constructed, only four were found to have 
direct ancestral lines to the founder couple.  Given that the total number of both male and 
female progenitors for the Afrikaner population between the period of 1657 and 1806 is 
estimated at 4000, the likelihood that 40 randomly selected Afrikaner individuals would share 
a common founder couple is rather unlikely (Geldenhuys et al. 2014).  
 
4.2 Whole genome SNP array 
SNP genotyping is used to outline the nature and the extent of chromosomal variation, 
analyse population genetic structure and to find specific loci that may contribute to disease.  
SNPs are used as proxies for the unobserved sequence variants in the surrounding DNA, 
thereby allowing for the measurement of the flow of genetic material through populations 
(Manolio, Brooks, and Collins 2008).  
 
IBD is the foundation for many of the significant problems in genetics, some of which 
include haplotype phase, an understanding of familial diseases and the detection of 
population structure (Browning and Browning 2013).  For the majority of applications, it is 
useful to know not just whether or not two alleles are identical at a specific locus but whether 
IBD extends on either side of the locus, thereby giving an indication of segmental sharing 
(Browning and Browning 2013).   This is important as it allows for the identification of a 
chromosomal region with a specific length that is transmitted from a common ancestor 
without recombination (Browning and Browning 2013; Glodzik et al. 2013).  In general, the 
longer the shared segment between two individuals, the more recent the ancestor (Speed and 
Balding 2015).   
 
We performed the whole genome SNP array on the 40 Afrikaner probands; in addition to 
this, we included one affected sibling, one unaffected sibling, two QC samples and four 
additional, unrelated, unaffected control individuals all of whom were at an age that was 
older than the AAO of the probands when they were recruited for the study.  Due to costs and 
Stellenbosch University  https://scholar.sun.ac.za
109 
 
logistical reasons (24 samples could be genotyped per array), we were only able to include 
four controls.  The inclusion of the affected and unaffected siblings was to determine whether 
or not our IBD calculations were correct as siblings are expected to have an IBD of 0.5.  
Although only the data for the affected sibling is shown in the results, when the same analysis 
was conducted using the unaffected sibling, an IBD of 0.5 was obtained for all three siblings, 
suggesting that the IBD calculations were correct.  The whole genome SNP array was to 
determine whether or not the 40 probands were, in fact, related to one another through the 
calculation of IBD and the identification of segmental sharing.  In addition to this, we aimed 
to determine whether randomly selected Afrikaner control individuals were related to any of 
the 40 probands.  We successfully determined that all 40 of the Afrikaner probands were 
related to one another with varying degrees of relatedness (ranging between 8-12 generations 
back), which provided the necessary genetic support for the genealogical data.  Furthermore, 
a total of three of the four control individuals were shown to share no relatedness between 
any of the probands or any of the controls.  However, one of the control individuals, namely 
11.937 (Control_4) shared a significant degree of IBD with the 21 of the probands.  This 
could be due to a number of factors one of which may be that although this individual stated 
that they had no family history of PD, this may not actually be the case.  Moreover, our 
control population is a relatively small one – for the purposes of this study, only 184 
Afrikaner controls were available for the study and for this reason, more controls need to be 
included in future work so as to see whether the phenomenon seen in Control_4 is a common 
occurrence in the Afrikaner population. 
 
4.3 Whole exome sequencing  
Given the strong supporting evidence that the 40 Afrikaner probands may have PD for the 
same genetic reason due to their degree of relatedness, a NGS approach, namely WES was 
employed on select individuals for novel gene discovery.  Three of the Afrikaner probands 
and one affected sibling were selected for WES in order to identify common variants that 
may be attributed to disease.  Approximately 78 000 variants were identified per individual 
and following sample QC, VCF file generation and variant calling, there were approximately 
20 000 variants for analysis.   
High throughput sequencing technologies such as WES have shown a rapid development and 
have made a significant impact on how genetic research is being conducted especially in 
cases where the genetic cause for a disease is unknown (Pabinger et al. 2013).  WES has 
Stellenbosch University  https://scholar.sun.ac.za
110 
 
become technically feasible and cost-effective. It can typically yield hundreds of thousands of 
variants per sequenced individual; however, advances in WES technologies coupled to a 
lower cost of sequencing have resulted in a data deluge that poses numerous challenges and 
threatens to overwhelm the analytical capacity of many laboratories and possibly generate an 
analysis bottleneck (Pabinger et al. 2013). 
 
There are currently more than 600 bioinformatics tools available for data analysis and 
interpretation (van Dijk et al. 2014).  These tools include those that assess the quality of short 
reads and those that can be used for sequence alignment.  Also, there are relatively standard 
means for obtaining a processed file that can be further scrutinized for variant identification.  
Initial bioinformatics analysis conducted on the four WES individuals made use of a 
combination of an in-house or custom method, whereby variants across all four affected 
individuals were compared and analysed using open source software and basic scripting 
methods coupled to variants called by the commercially available software program, IVA 
(www.ingenuity.com).  Filtering of these variants left a total of 24 variants in 22 genes of 
which 12 were selected for further analysis.  Of these, a total of 75% (9/12) were sequencing 
artefacts while two (D172G in IL32 and S301C in KATNAL2) were found in control 
individuals and therefore excluded as possibly disease-causing.  The remaining G23E variant 
in TIMM23 was found to be real and therefore selected for further analysis.  TIMM23 was 
considered to be a good candidate as the protein encoded by this gene forms part of a 
complex that is located in the inner mitochondrial membrane.  This complex is significant as 
it is responsible for the mediation of transport of transit peptide-containing proteins across the 
mitochondrial membrane (Zhang et al. 2012). 
 
Genotyping was conducted on 1148 individuals (458 PD probands and 690 ethnically 
matched control individuals) using the TaqMan® SNP genotyping assay.  No genotype calls 
could be made and Sanger sequencing was then performed on 10 randomly selected control 
individuals.  The G23E variant was present in all of these individuals and it was determined 
that there was an error in the sequence that was obtained from dbSNP – a G nucleotide was 
missing from the sequence that had been used for the design of the TaqMan® probes.  The 
errors in dbSNP are not uncommon – in a study which investigated the dbSNP Build 129 for 
contamination with what was termed as “Single Nucleotide Differences” or SNDs as a 
parallel to SNPs, it was determined that the frequency of the SNDs was 8.32%.  Although the 
dbSNP build used for this project was 138, it remains reasonable to assume that not all of the 
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errors have necessarily been corrected and that new errors may still be introduced into the 
database (Kitts et al. 2014).   
 
 4.3.1 Analysis of P1150S in EFCAB6 identified in family ZA92  
The lack of success in the identification of a single variant that could be attributed to PD in 
the three probands led to the focus on only the affected siblings of family ZA92.  Data 
analysis resulted in the identification of P1150S in EFCAB6 as a plausible disease-causing 
variant.  The proline to serine amino acid change at position 1150 was found to significantly 
change the properties of the expressed protein and may therefore affect protein folding and 
possibly function.  EFCAB6 binds to a known PD causing gene, namely DJ-1 as well as to an 
androgen receptor to form a ternary complex in the cells (Niki et al. 2003).  This binding 
protein subsequently recruits histone-deacetylase complexes so as to repress transcription 
activity of an androgen receptor (Niki et al. 2003).   
 
Sanger sequencing confirmed that the P1150S variant was found in a heterozygous state in 
both affected siblings, but was absent from the unaffected sibling.  However, this variant was 
not identified in the unaffected sibling who is currently 69 years of age.  Subsequent 
genotyping using HRM did not identify the variant in any of the 184 ethnically matched 
controls that were examined and following this, the 458 South African PD probands were 
then genotyped.  No additional probands were found to carry this variant and the frequency 
of the P1150S variant was concluded to be 0.22% (1/458) in the PD patients.   
 
The available family members of the proband and the affected sibling of ZA92 were screened 
and it was determined that the P1150S variant was found in both children of the proband 
(aged 45 and 47 years of age respectively) and in both children of the affected sibling (aged 
48 and 49 years of age respectively).  However, this variant was not identified in the 
unaffected sibling who is currently 69 years of age.  Genetic material for both of the parents 
of the affected siblings was not available as these individuals were deceased and it was 
therefore not possible to investigate whether or not this variant co-segregates with the disease 
in the family.  However, it was determined that this variant does not co-segregate with 
disease in five Canadian families (Prof. Matthew Farrer; personal communication) and for 
this reason; the P1150S variant was excluded as a possible disease-causing mutation in the 
South African cohort. 
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4.3.2 Analysis of WES using a hypothesis-free approach 
WES has provided a means for researchers to gain access to a highly enriched subset of the 
human genome in which to search for variants and possibly provide insights into a specific 
disease.  Following our own shortcomings in the identification of a novel variant that could 
be associated with PD, we developed a novel toolkit for the filtration of WES data, namely 
TAPER™.  TAPER™ is significant as it is considered to be a hypothesis-free approach to 
data analysis.  By this it is meant that no extensive phenotypic information about the disease 
of interest is necessary and factors such as inheritance patterns or knowledge of disease 
pathways are not required for variant prioritization.  This is a unique approach to data 
analysis and is of particular relevance in resource-constrained research environments such as 
those in South Africa because in many cases, detailed information on inheritance patterns or 
family history of the disorder is not available thereby making some of the conventional 
analytical approaches difficult to apply. 
 
The use of TAPER™ identified a total of 20 variants in 20 genes that met all of the 
prioritisation criteria.  Following prior bioinformatics analysis, this is the shortest list that had 
been obtained for this project.  Variants that were found in both affected siblings and at least 
one other proband that had undergone WES were prioritised for further analysis.  Of these, 
six genes and six variants were selected based on the fact that they had previously been 
associated with other movement disorders or had been directly implicated in pathways that 
had previously been associated with PD and related movement disorders. 
 
Of the six prioritised genes and variants, three were excluded from further analysis due to 
their frequency in ethnically matched control individuals – the frequency cut-off for variants 
was 0.50% of the total number of control individuals genotyped.  This was determined by 
halving the frequency cut-off previously established for the probands (namely 1.0%).  Given 
the uniqueness of the South African population, it is expected that a pathogenic variant will 
be at a much lower frequency in control individuals than in the affected patients.  The S719G 
variant in WNK1 was found in 1.30% (9/690) of control individuals; the E43D variant in 
CASP7 was found in 0.58% (4/690) of control individuals while the V626M variant in 
MIPEP was found in 0.72% (5/690) of control individuals.  Further genotyping in the 
patients was therefore not conducted on any of these variants.  The M534T variant in SYNJ2 
was neither sequenced nor genotyped as the variant does not co-segregate with the disease in 
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the Canadian population.  The remaining two variants, V1405I in SYNJ and C357S in USP17 
were found to be plausible PD-causing variants.   
 
  4.3.2.1 V1405I in SYNJ1 
V1405I was only found to be a real variant in the affected sibling pair and was identified in a 
homozygous state.  A total of 690 control individuals were genotyped and this variant was 
not identified in any controls.  Moreover, this variant was absent from the additional 457 PD 
probands screened. 
 
Synaptojanin (SYNJ1) is a 145kDa protein that is located on chromosome 21q22 and 
interacts with growth factor receptor-bound protein 2 (Grb2) as well as a phosphoprotein that 
is involved in synaptic vesicle recycling and endocytosis (Krebs et al. 2013).  There are four 
known isoforms of SYNJ1; two isoforms of 170kDa (isoform A: NP_003886.3, 1612 amino 
acids) and 145kDa (isoform B: NP_982271.2, 1350 amino acids) have been extensively 
studied.  Both isoforms are generated from two open reading frames (ORFs) that are 
separated by an in-frame TAA stop codon (McPherson et al. 1996).  Interestingly, both 
isoforms A and B are ubiquitously expressed but the 145kDa isoform is expressed at 
significantly higher levels in the brain where it is localized on coated endocytic intermediates 
in the nerve terminals (Ramjaun and McPherson 1996; McPherson et al. 1996).  Both 
isoforms harbour numerous functional domains: a C-terminal proline-rich domain (PRD), a 
5′-phosphatase domain in the centre and a suppressor of actin1 Sac1-like domain on the N-
terminal.  The longer 170kDa isoform carries an extra PRD translated from the second ORF 
(Figure 4.1).  There are two additional SYNJ1 isoforms listed in RefSeq (isoform C: 
NP_001153774.1, 1295 amino acids and isoform D: NP_001153778.1, 1526 amino acids) 
that are of unknown functional relevance.  Isoforms C and D have significantly shorter N-
terminus and a distinct C-terminus.  Although these isoforms are much shorter than isoform 
A, the functional domains of isoform C and D are the same as in isoforms A and B (Krebs et 
al. 2013; Drouet and Lesage 2014). 
 
Mutations in SYNJ1 have previously been associated with PD.  A homozygous mutation, 
Arg258Gln (R258Q) has previously been identified by two independent research teams in 
two consanguineous families, one from Sicily in Italy and one from Iran (Krebs et al. 2013; 
Quadri et al. 2013).  In both cases, homozygosity mapping coupled to WES were used to 
identify this variant in these individuals.  The R258Q mutation is found in exon 5, and is 
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found in the Sac1 domain of the protein (Figure 4.1).  This mutation is predicted to be 
damaging across multiple programs and the arginine at position 258 has been shown to be 
conserved in thirteen SYNJ1 orthologs and five Sac1-like domains containing proteins 
(Krebs et al. 2013; Quadri et al. 2013).  Moreover, this mutation damages the Sac1 
phosphatase activity targeting phosphatidylinositol monophosphate, suggesting that impaired 
synaptic vesicle recycling could be involved in PD pathology (Krebs et al. 2013; Quadri et al. 
2013). 
 
Mutations in this gene are extremely rare; to date there are only six early-onset (AAO 
younger than 30 years of age) PD patients (from three families with two affected siblings 
respectively) who carry the homozygous R258Q mutation.  Screening of the parents of the 
affected sibling pairs shows that are all parents are heterozygous for this variant while 
unaffected siblings are homozygous carriers for the wild type allele or heterozygous mutation 
carriers (Krebs et al. 2013; Quadri et al. 2013; Olgiati et al. 2014).   
 
Figure 4.1 Functional and interaction domains of isoforms A and B of SYNJ1.  The 145kDa (top) and 
170kDa (bottom) isoforms contain an N-terminal Sac1 domain, a central 5′-phosphatase domain and two 
functional inositol phosphatase domains.   Numerous protein-protein interaction domains are found in the C-
terminal region:  one or more PRD domains, AP2 binding motifs (WxxF, FxDxF, and DxF, indicated in pink), 
and Eps15 binding motifs (NPF: asparagine-proline-phenylalanine, indicated in blue).  The homozygous 
mutation Arg258Gln, found in Parkinson’s disease patients, is indicated in red and the V1405I variant identified 
in the present study is shown in purple. Numbers indicate the amino acid positions along the proteins. Sac1 - 
suppressor of actin1; PRD - proline-rich domain; AP2 - adaptor protein complex 2; Eps15 - epidermal growth 
factor receptor pathway substrate 15 (Taken from Drouet and Lesage 2014). 
Val1405Il
e 
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In the present study, the V1405I variant identified in the affected sibling pair was found to be 
absent from their unaffected sibling.  Moreover, this variant was not identified in any of the 
other PD patients or controls screened.  Although this variant is not a novel variant 
(rs79652470), it has not been identified in any population group in a homozygous form.  In 
addition to this, the global frequency of the variant in a heterozygous state is extremely low, 
at 0.01104%.  This frequency is as low as some of the well-established PD-causing mutations 
such as G2019S in LRRK2, R1441C in LRRK2, R275W in Parkin and G430D in Parkin 
(Table 4.1).  To date, this variant has not been found in a homozygous form in any of the PD 
patients available to us from the laboratories of our collaborators (Prof. Matthew Farrer, 
personal communication; Dr. Suzanne Lesage, personal communication). 
 
The R258Q mutation is, to date, the only mutation in SYNJ1 that has been associated with 
PD.  It is plausible that the V1405I (Valine to Isoleucine) homozygous variant could be 
attributed to the disease.  Following in silico analysis, it was determined that the amino acid 
substitution is a conservative one; both amino acids are similar in size and are hydrophobic.  
However, the effect of the amino acid substitution could not be determined because of the 
fact that there is no suitable crystal structure available for analysis.  The V1405I variant is 
predicted to be deleterious by SIFT, damaging by PolyPhen2, deleterious by FATHMM and 
the CADD score is 29.40 (this figure means that the variant is amongst the top 1% of 
deleterious variants).  Moreover, GERP+++ and PhyloP predict the variant to be in a highly 
conserved region, with both programs predicting high conservation scores, thus indicating 
that the variant may be damaging potentially affecting protein structure and function.   
 
The functions of SYNJ1 in actin dynamics and synaptic vesicle recycling in both pre- and 
postsynaptic compartments are of relevance to aid in the understanding of the 
physiopathology of PD (Drouet and Lesage 2014).  Research into synaptic vesicle trafficking 
pathways has provided strong evidence that these pathways may be implicated in PD 
mechanisms.  Most of the proteins that have been implicated in autosomal dominant PD, as 
well as those responsible for autosomal recessive forms of Parkinsonism, have been 
implicated, directly or indirectly, in synaptic vesicle turnover (Figure 4.2).  SYNJ1 is a 
phosphoinositide phosphatase protein that is required for proper synaptic activity.  The 
identification of the homozygous V1405I in an affected sibling pair and its absence in both 
the ethnically matched controls as well as the low frequency in the global population 
according to the ExAC database is an indication that this variant may be pathogenic and 
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Figure 4.2 Synaptic recycling and PD genes.  Diagrammatic representation of a presynaptic terminal showing 
the PD genes (shown in red boxes) and their respective role in synaptic vesicle recycling.  (a) During 
endocytosis, invagination of the clathrin-coated membrane requires endophilin.  Endophilin harbours numerous 
SH3 domains that interact with the SYNJ1 PRD domain and/or Parkin.  (b) LRRK2 is responsible for the 
phosphorylation of endophilin, which leads to the dissociation of the latter from clathin-coated vesicles.  (c) 
SYNJ1 is recruited to the coated vesicles through endophilin and will dephosphorylate PI4,5P into PI, thereby 
shedding clathrin and its adaptor from the bilayer.  (d) Uncoating of the vesicles also requires auxilin 
intervention and subsequent chaperoning of the clathrin molecules.  The postendocytic vesicles are then able to 
return to the reserve pool where they undergo clustering, or return directly to the release site and begin an 
exocytosis step.  (e) Synaptic vesicles are docked and then fused to the membrane by means of a multi-protein 
complex that includes synaptobrevin and αSYN.  (f) PTEN is a lipid phosphatase that is inhibited by DJ-1, and 
can increase levels of the mitochondrial PINK1 protein. This pathway is involved in NMDA receptor signalling. 
(g) Proper mitochondrial functioning leads to ATP synthesis, necessary to mobilize the reserve pool of vesicles 
during synapse stimulation.  Abbreviations: PI4,5P - phosphatidylinositol 4,5-bisphosphates; PI - 
phosphatidylinositol; ATP - adenosine triphosphate; SYNJ1 - synaptojanin 1; LRRK2 - leucine-rich repeat 
serine/threonine-protein kinase 2; PTEN - phosphatase and tensin homologue; PINK1 - PTEN induced putative 
kinase 1; DJ-1 - Parkinson’s disease protein 7; αSYN - alpha-synuclein;  NMDR - N-methyl-D-aspartate 
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Table 4.1 Global population frequencies of V1405I in SYNJ1 and C357S USP17 as 
compared to other PD causing genes. 










African 2 9 832 0 0.0002034 
European (Non-
Finnish) 
11 64 422 0 0.0001707 
East Asian 0 8 466 0 0 
European 
(Finnish) 
0 6 478 0 0 
Latino 0 11 386 0 0 
Other 0 888 0 0 
South Asian 0 16 280 0 0 
TOTAL 13 117 752 0 0.0001104 
USP17 
(C357S) 
African 0 5 744 0 0 
European (Non-
Finnish) 
1 2 980 0 0.0003356 
East Asian 0 1 022 0 0 
European 
(Finnish) 
0 82 0 0 
Latino 0 844 0 0 
Other 0 56 0 0 
South Asian 0 1990 0 0 
TOTAL 1 12 718 0 7.863e-05 
LRRK2 
(G2019S) 
African 3 10 396 0 0.0002886 
European (Non-
Finnish) 
42 66 730 0 0.0006294 
East Asian 0 8 654 0 0 
European 
(Finnish) 
0 6 641 0 0 
Latino 2 11 536 0 0.0001734 
Other 0 908 0 0 
South Asian 0 16 512 0 0 
TOTAL 47 121 350 0 0.0003873 
LRRK2 
(R1441C) 
African 0 10 389 0 0 
European (Non-
Finnish) 
1 66 692 0 1.499e-05 
East Asian 0 8 652 0 0 





0 6 608 0 0 
Latino 0 11 526 0 0 
Other 0 906 0 0 
South Asian 0 16 512 0 0 
TOTAL 1 121 294 0 8.244e-06 
Parkin 
(G430D) 
African 1 8 598 0 0.0001772 
European (Non-
Finnish) 
10 56 440 0 0.0001163 
East Asian 0 7 228 0 0 
European 
(Finnish) 
0 5 052 0 0 
Latino 0 9 674 0 0 
Other 0 760 0 0 
South Asian 0 14 510 0 0 
TOTAL 11 102 262 0 0.0001076 
Parkin 
(R275W) 
African 3 10 206 0 0.0002939 
European (Non-
Finnish) 
204 65 874 0 0.003097 
East Asian 0 8 564 0 0 
European 
(Finnish) 
13 6 558 0 0.001982 
Latino 15 11 324 0 0.001325 
Other 2 884 0 0.00262 
South Asian 9 16 046 0 0.005609 
TOTAL 246 119 456 0 0.002059 
Taken from ExAC Genome Browser (http://exac.broadinstitute.org).  Date accessed: 28 August 2015. 
 
4.3.2.2 C357S in USP17 
The C357S variant in USP17 was identified in homozygous form in all four individuals who 
had undergone WES.  Subsequent genotyping revealed that the variant was in a total of 
18/458 probands of which twelve were Afrikaner, four were Mixed Ancestry and two were 
White (Table 3.14, page 99).  All probands found to carry this variation were homozygous.  
Interestingly, of the twelve Afrikaner probands that were found to carry this variant, 7/12 
(58.3%) form part of the large, 40 family pedigree.  The same variant, was however, 
identified in a single Afrikaner control individual.  This control is 80 years of age and was 
sourced from the Western Province Blood Transfusion Services (WPBTS) in Cape Town.  
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This individual has been de-identified and it is not possible to assess whether or not this 
individual may have developed PD subsequent to his participation in the study.   
 
Although the C357S variant is not a novel variant, and is present in the ExAC database, it has 
not been recorded in either dbSNP or Ensembl.  Moreover, it has not been identified in any 
population group in a homozygous form (Table 4.1).  In addition to this, the global frequency 
of the variant in a heterozygous state is extremely low, at 0.007863%.  This frequency is as 
low as some of the well-established PD-causing mutations such as G2019S in LRRK2, 
R1441C in LRRK2, R275W in Parkin and G430D in Parkin (Table 4.1).  To date, this variant 
has not been found in a homozygous form in any of the PD patients available to us from the 
laboratories of our collaborators (Prof. Matthew Farrer, personal communication; Dr. 
Suzanne Lesage, personal communication). 
 
The effect of the amino acid change (Cysteine to Serine) could not be determined due to the 
fact that there is no crystal structure available for analysis.  However, the C357S variant is 
predicted to be deleterious by SIFT, damaging by PolyPhen2, deleterious by FATHMM and 
the CADD score is 34.89 (this figure means that the variant is amongst the top 0.1% of 
deleterious variants).  Moreover, GERP+++ and PhyloP predict the variant to be in a highly 
conserved region, with both programs predicting high conservation scores, thus indicating 
that the variant may be detrimental should it be present in an individual. 
 
Ubiquitin Specific-processing Protease 17 (USP17) is a 59.6kDa protein that is located on 
chromosome 8p23.1.  USP17 interacts with SET nuclear proto-oncogene, which inhibits the 
acetylation of nucleosomes by histone acetylases (Cunha et al. 2014) and CBX1 (chromobox 
homolog 1), which is a highly conserved nonhistone protein (Bian et al. 2014).  USP17 is a 
deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins so as to 
regulate multiple cellular processes.  
 
USP17 is an immediate early gene that belongs to a subfamily of cytokine inducible 
deubiquitinating enzymes (DUBs).  DUBs are important as they are involved in the removal 
of ubiquitin from post-translationally modified proteins which is important for numerous 
cellular functions such as transcription, cell cycle progression, DNA repair and apoptosis (de 
la Vega et al. 2011).  USP17 is induced by interleukin (IL)-4 and IL-6, which regulate the 
growth and differentiation of leukocytes.  However, more recently, it was demonstrated that 
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USP17 controls the functioning of the small GTPase Ras through posttranslational processing 
and membrane localization (Burrows et al. 2004; Burrows et al. 2009).  Mutations in this 
gene do not appear to be common but very little work has been done on the gene itself.  
There is a known variant, C89S that abolishes both enzymatic activity and the effects on cell 
proliferation (Burrows et al. 2004).  The major domain of this protein is the USP domain, 
which spans the amino acids 80 – 375.  The novel variant that was identified in the South 
African Afrikaner is found in this domain.   
 
The post-translational modification of proteins through the covalent attachment of ubiquitin 
targets these proteins for degradation by the proteasome.  Ubiquitination and deubiquitination 
are therefore thought to work in combination with each other and the selectivity of 
proteolysis will be determined by the combination of ubiquitination enzymes and DUBs that 
are present at a specific time point (de la Vega et al. 2011).  Moreover, DUBs play numerous 
roles in the UPS.  Mutations in genes that code for these DUBs could therefore significantly 
alter the functioning and processing of proteins within a cell and pathway.  DUBs are 
involved in the activation of so-called ubiquitin pro-proteins and this is done co-
translationally (Reyes-Turcu, Ventii, and Wilkinson 2009).  Ubiquitin is not expressed 
independently, but is rather, expressed as linear polyubiquitination that consists of multiple 
mono-ubiquitin that must undergo processing to yield a mature ubiquitin monomer or as a 
pro-protein that is fused to other ribosomal proteins (Reyes-Turcu, Ventii, and Wilkinson 
2009; Dikic and Bremm 2014).  DUBs also recycle ubiquitin and importantly, DUBs reverse 
the ubiquitination or ubiquitin-like modification of specific target proteins (Nijman et al. 
2005; Kumar et al. 2015).  This role of DUBs is of particular significance as it antagonises 
the ubiquitination of proteins thereby playing a role that is similar to that of the phosphatases 
in a phosphatase/kinase pathway (Reyes-Turcu, Ventii, and Wilkinson 2009; Dikic and 
Bremm 2014).  Lastly, DUBs are responsible for the regeneration of monoubiquitin from 
unanchored polyubiquitin.  Given the significant role that DUBs such as USP17 play in the 
UPS, disruptions in this pathway due to mutations in genes coding for DUBs may contribute 
to the pathobiology of PD. 
 
4.4  Limitations of the study 
The most successful studies that have identified a novel disease-causing gene using WES 
have mainly relied on discrete filtration of data and in most cases, this has been coupled to 
Stellenbosch University  https://scholar.sun.ac.za
121 
 
linkage data (Trinh and Farrer 2013).  This is the first WES project to be conducted on South 
African PD patients and for this reason, there were numerous limitations.  Limitations of 
employing WES as a method for novel mutation detection include the fact that a significant 
portion of the human genome is not examined (98.8%).  Moreover, structural variations such 
as CNVs are difficult to detect using this method.  Additional factors such as analytical and 
technical limitations that could contribute to difficulties in novel variant identification were 
also identified. 
 
Technical limitations could account for the lack of a specific variant being identified in the 
South African Afrikaner.  One such limitation could be that the causal variant was covered 
but was not accurately called.  This was illustrated by Dewey et al. where challenges to the 
interpretation of NGS data such as assembly and variant calling against the human reference 
genome were highlighted (Dewey et al. 2011).  Variants that were identified as heterozygous 
by the variant calling software were identifying the major allele as the minor allele;  
essentially an allele swop.  This could lead to a large number of false positive calls, the 
identification of numerous sequencing artefacts or the putative variant being missed.  Another 
technical limitation of WES is that part or all of the gene of interest may not be in the target 
definition of a specific exon - WES technologies are continually being improved and probes 
in specific sequence capture methods are designed based on the current sequence information 
that is available from databases such as consensus coding sequence (CCDS) database and 
Refseq database.  It is for this reason then, that unknown exons or yet to be annotated exons 
cannot be captured.  In addition to this, the role of variations in the non-coding regions of the 
genome in Mendelian disease has yet to be determined.  One such example is the intronic 
hexanucleotide repeat in C9orf72, associated with ALS and frontotemporal dementia 
(McMillan et al. 2014).  This variant was missed using WES alone as the variant did not form 
part of the target exome definition and was only identified through Sanger sequencing.   
 
One of the most prominent analytical limitations in developing countries that are resource 
constrained pose a significant challenge when employing this technology to specific diseases 
in these individuals.  A limited number of bioinformaticists and the lack of adequate 
computational infrastructure further limit the successful application and implementation of 
NGS technologies such as WES to various diseases.  The scarcity of trained bioinformaticists 
means that laboratory scientists with limited bioinformatics knowledge are left with the 
daunting task of prioritising candidate disease-causing variants.  Another analytical limitation 
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of the present study is the fact that there are no trios available for WES analysis.  The parents 
of the probands were not available for WES as a means to exclude or include specific 
variants as plausible disease-causing candidates.  Lack of trios and additional first and second 
degree family members meant that comprehensive co-segregation studies could not be 
conducted.  Rare recessive variants as well as cases where two mutations come from the 
same parent compound the analytical limitations of WES.  The lack of a universal analysis 
pipeline is an additional facet that must be taken into account.  Depending on the filtration 
criteria that are used, a pathogenic variant may be present in an individual but may not be 
identified as this is dependent on the filtration parameters that are employed.  Finally, a 
significant analytical limitation is the fact that there are no population specific databases – 
pathogenic mutations may be successfully identified in the affected individuals through an 
appropriate filtration method, but these mutations may be present at low frequencies in the 
background population.  There are currently more than 17 million SNPs that have been 
identified in the human genome but there is an error rate of approximately 15-17% (Day 
2010; Kitts et al. 2014).  Using an appropriate MAF for the variants and the use of additional 
databases such as 1KGP and ESP6500 will help to reduce this type of error.   Over and above 
the population specific variants, there is no way to account for pseudogenes or low 
penetrance alleles (variants may be excluded as potential candidates based on the fact that 
they are found in healthy control individuals who never develop the disease).  Moreover, 
phenocopies are another significant problem and may be present at a relatively high 
frequency of 18% in PD patients (Prof Matt Farrer, personal communication), thereby further 
compounding the problems with data filtration pipelines.  Finally, the whole genome SNP 
array did not identify runs of homozygosity (ROH) and this could be attributed to the small 
number of SNPs that were genotyped.  Expanding the number of SNPs (SNP density) may 
have identified ROH and provided us with a better means to identify regions of interest in the 
four samples subjected to WES.  Improvements to NGS technologies such as WES as well as 
an improved understanding of variation of the human exome in diverse populations may 
allow some of these limitations to be overcome in the near future. 
 
4.5 Future work 
A relatively small number of plausible disease-causing variants were identified during the 
course of the current study.  Two of these, namely V1405I in SYNJ1 and C357S in USP17 
were identified as potential disease-causing candidates and should be analysed further.  Given 
Stellenbosch University  https://scholar.sun.ac.za
123 
 
the low frequency of the V1405I variant in SYNJ1, it is possible that this is a family specific 
rare polymorphism.  However, in future studies the frequency of this variant should be 
assessed in the approximately 41 000 PD patients and 41 000 controls potentially available 
from the GEOPD consortium of which we are a member (http://www.geopd.org/about/).  The 
same should be conducted for the C357S variant as it is found in 58.3% of the Afrikaner 
probands that belong to the large 40 family pedigree.  In the case of USP17, the effect of the 
C357S variant on deubiquitination and protein aggregation could be investigatedthrough the 
use of high performance liquid chromatography (HPLC) and fluorescence assays using 
ubiquitin-amidomethylcoumarin assays (Russel and Wilkinson 2005).  HPLC can be used to 
monitor the enzymatic activity of DUBs while fluorescence assays such as Ub-
amidomethylcoumarin (AMC) assays have been used to identify substrate specificity.  The 
quantification of the rate of release of the fluorescent tag from a substrate allows for the 
calculation of the amount of DUB enzymatic activity.  In the case of the V1405I variant, the 
protein product SYNJ1 is a phosphoinositide phosphatase protein that is required for proper 
synaptic activity.  The in vitro functional effect of the variant could be analysed using 
phosphoinositide phosphatase assay to assess the effect of the variant on the synaptic activity.  
This is a colorimetric method for the determination of inorganic phosphate that utilizes 
malachite green, and is used for the quantification of protein phosphatase activity 
(Mavrantoni et al. 2015).  The assay is based on the change of absorbance at 620mn due to 
the formation of malachite green complexes and is able to detect phosphate release from 
protein phosphate substrates. 
Future work on the South African PD cohort should focus on the identification of families for 
which multiple affected individuals are available for study.  Also, further analysis using WES 
should involve the inclusion of parents of affected individuals where possible.  Most of the 
successes of WES have been achieved on rare Mendelian disorders rather than complex 
diseases such as PD.  The variants that have been identified using WES are typically high 
penetrance alleles that co-segregate with the disease.  It is hypothesised that WES coupled to 
linkage mapping strategies has the potential to provide important insights into complex 
diseases such as PD (Gustavsson et al. 2015).  The challenges experienced with population 
specific variants are highlighted throughout the course of the current study.  The challenge 
going forwards is the need to expand control or background population databases to include 
data from various South African ethnic groups so as to aid novel gene discovery. 
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As the cost of NGS technologies continue to decrease, it is likely that whole genome 
sequencing will take precedence over WES. For this approach, it should be noted that taking 
advantage of the more complete and comprehensive dataset for putative disease-causing 
variants in patients is reliant on the development of more universal analytical strategies, 
especially those that make use of non-coding variation.  It is therefore necessary for more 
detailed phenotypic curation as well as the need for improved statistical, technical and 
bioinformatics strategies to aid in the reduction of false positive and negative variant calls, 
for the selection and prioritization of indels and candidate variants as well as for the 
prediction and annotation of potential functional impact of the variant(s) of interest.  The 
identification of candidate genes for complex diseases such as PD is a realistic goal, however 
narrowing down candidate gene lists is likely to require unprecedented collaborative efforts 
in the field of neurogenetics.  This should involve the development of large consortia groups 
for data sharing and with streamlined and high-throughput approaches to conduct candidate 
prioritization and screening in replication cohorts of well-characterized patients. 
 
4.6 Concluding remarks 
Neurodegenerative diseases such as PD present a significant health burden and affect the 
quality of life of both patients as well as their caregivers.  However, this is not isolated to 
individuals alone, but also has a significant impact on the wider society and on the economy 
(WHO 2014).  As the life expectancy of global populations increases it is hypothesised that 
this burden will increase even further (Collins et al. 2011, WHO 2014).  Moreover, the 
chronic nature of the diseases, especially those who present with juvenile or early onset PD, 
adds to the challenges faced by the global healthcare system.  Over the last 20 years, several 
risk factors and a large number of genes have been identified and this knowledge has helped 
ease the burden on both global disease and affected patients (Singleton 2015).  It remains 
important to pinpoint additional genes that may in some way be associated with this disease 
so as to gain key biological insights that underlie this debilitating disorder (Novarino et al. 
2014). As more PD genes are identified, an understanding into the relationships between 
genes, their protein products and the pathways in which they are found, is generating 
significant insight into the pathobiological network of processes and interactions that may 
lead to disease onset (MacLeod et al. 2013; Beilina et al. 2014).  Knowledge gained through 
the identification of variants in genes that may be associated with PD may show coordinated 
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disease networks as well as common risk alleles and rare mutations that may be found in the 
same biological pathway (Singleton 2015).   
The advent of NGS technologies such as WES has enabled researchers to analyse biological 
systems and to make biological discoveries at a level that was never before possible.  As the 
sequencing technologies have improved, data analysis technologies have evolved but it was 
determined that none of those that were implemented were successful in the identification of 
a plausible novel PD causing variant in the South African cohort.  For this reason, a novel 
filtration method, namely TAPER™ was designed to facilitate novel gene discovery in 
complex disorders using a hypothesis-free approach in resource-limited environments.  
Through the use of TAPER™, we successfully identified and validated two potentially 
disease-causing variants in the South African PD cohort namely V1405I in SYNJ1I and 
C357S in USP17.  However, the results from this study show that although the genealogical 
and whole genome SNP array data supported the possibility of a founder effect for PD in the 
South African Afrikaner, the WES results did not.  It was determined that the Afrikaner 
probands linked to a common founder couple are related but are unlikely to have PD for the 
same genetic reason and therefore from our work, it is concluded that a founder effect for the 
disease in these patients does notappear to be present. 
 
There are numerous genes that have been linked to PD but the pathogenic processes that are 
driven by these genes remain poorly understood.  However, it is plausible that the 
identification of new PD genes have the potential to provide key insights into the underlying 
pathogenic processes that predispose an individual to develop PD.  The identification of 
novel disease-causing variants is likely to increase and improve the insights into the 
pathobiology of this disease in South African patients.  In conclusion, the present study 
represents an important first step in the application of WES and bioinformatics to the 
identification of new PD-causing genes in South African patients.  Future studies will build 
on the lessons learnt and will be more focussed and better designed to ensure a higher chance 
of success. 
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Appendix I Diagnostic criteria for Parkinson’s disease 
Step 1:  Diagnosis of Parkinsonian Syndrome 
 Bradykinesia and at least two of the following: 
o Muscular rigidity 
o Resting tremor of 4-6 Hertz 
o Postural instability that is not by primary visual, vestibular, cerebellar or proprioceptive 
dysfunction 
Step 2: Exclusion criteria for PD 
 History of repeated strokes with stepwise progression of Parkinsonian features 
 History of repeated head injury and definite encephalitis  
 Oculogyric crises 
 Neuroleptic treatment at onset of symptoms 
 More than one affected relative 
 Sustained remission 
 Strictly unilateral features after 3 years 
 Supranuclear gaze palsy 
 Cerebellar signs 
 Early severe autonomic involvement 
 Early severe dementia with disturbances of memory, language, and praxis 
 Babinski sign 
 Presence of cerebral tumour or communication hydrocephalus on imaging study 
 Negative response to large doses of levodopa in absence of malabsorption 
 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure 
Step 3:  Supportive prospective positive criteria for PD 
 Three or more are required for the diagnosis of definite PD in conjunction with Step 1: 
o Unilateral onset 
o Resting tremor must be present 
o Progressive disorder 
o Persistent asymmetry affecting the side of onset most 
o Excellent response to levodopa (70-100%) with response for 5 years 













Supplementary Table 1  List of the demographic and clinical information on the 40 South African Afrikaner 
probands and their family members which are available for genetic studies. 
Family No Family ID Gender Relationship Affected AAO Pedigree Pattern 





































5 ZA 272 Male Proband Y 62 AD 
6 ZA 72 Male Proband Y 68 AD 
7 ZA 263 Male Proband Y 58 AD 
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14 ZA 34 Male Proband Y 72 AR 
















































































































































































23 ZA 5 Male Proband Y 40 AR 
24 ZA 190 Female Proband Y 47 AD 
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Male Brother-in-law N 
27 ZA 411 Male Proband Y 65 AR 





















































31 ZA 4 Male Proband Y 44 AR 

















































35 ZA 316 Male Proband Y 58 AR 



































































38 ZA 150 Female Proband Y 50 AR 
39 ZA 256 Male Proband Y 45 AD 


















PD = Parkinson’s disease; ID = identification; AAO = age at onset of Parkinson’s disease in years; F = female;  
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Appendix III – Supplementary information pertaining to IBD 
 






MISS_PHENO N_MISS N_GENO F_MISS HET_RATE 
ZA106 78.67 N 279 306 670 0.0009098 0.404873188 
ZA111 78.95 N 6770 306 670 0.02175 0.415456146 
ZA134 81.65 N 632 306 670 0.002061 0.402841418 
ZA78 67.82 N 330 306 670 0.001076 0.407993171 
ZA89 68.16 N 948 306 670 0.003111 0.404157634 
ZA92 68.27 N 826 306 670 0.00271 0.407397957 
MISS_PHENO – missing phenotype (Yes/No); N_MISS – number of missing SNPs; N_GENO – number of 




Supplementary Table 3 Shared segments between the affected sibling pair of family ZA92. 
CHR BP1 BP2 SNP1 SNP2 NSNP KB 
1 16773880 116717619 rs821000 rs6658845 1698 99943.7 
1 160152057 236404391 rs1935306 rs2695057 1554 76252.3 
1 244965588 249081330 rs2365687 rs4926506 101 4115.74 
2 34739570 54708408 rs10176097 rs10171331 577 19968.8 
2 57658970 77947988 rs2310825 rs11676317 431 20289 
2 108033742 242955426 rs266243 rs13389823 2380 134922 
3 70895 12286720 rs9682794 rs9850825 402 12215.8 
3 16911330 54542933 rs9852648 rs7372541 719 37631.6 
3 74345173 81997510 rs9867036 rs6548786 137 7652.34 
3 88708334 99722396 rs7638288 rs6440967 122 11014.1 
3 154494952 164537423 rs6440957 rs4560300 166 10042.5 
3 170533587 175171066 rs6790486 rs1549108 113 4637.48 
3 176087269 182547256 rs301230 rs2049283 116 6459.99 
3 191020382 195573324 rs293862 rs903196 111 4552.94 
4 85422 63509409 rs7667153 rs12500171 1264 63424 
4 86652248 95155505 rs2062098 rs17309887 141 8503.26 
4 110409978 142570472 rs6856291 rs1519551 606 32160.5 
4 165129362 170237660 rs4502640 rs10017932 107 5108.3 
5 48534 180690937 rs10039735 rs1279912 3462 180642 
6 904145 4058782 rs2756313 rs12198921 107 3154.64 
6 21347410 63457733 rs1555083 rs2474878 859 42110.3 
6 88671941 108147644 rs632385 rs4946872 388 19475.7 
6 139807600 170886531 rs6916887 rs8770 819 31078.9 
7 44935 4708134 rs7456436 rs17828856 116 4663.2 
7 37712109 55238268 rs4723693 rs10228436 420 17526.2 
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7 69935641 105456869 rs4717530 rs740309 631 35521.2 
7 130154485 156711661 kgp9503409 rs2969124 525 26557.2 
8 5857354 72116724 rs890027 rs10957540 1274 66259.4 
8 77507613 146245372 rs7846606 rs35756786 1319 68737.8 
9 185632 137530346 rs2992854 rs7021140 2242 137345 
10 135656 135430043 rs10904561 rs4628635 2683 135294 
11 17530484 30452181 rs7104083 rs514644 323 12921.7 
11 75428958 109883416 rs554202 rs1648136 731 34454.5 
11 116383064 134926754 rs11599994 rs6590788 509 18543.7 
12 191619 21635232 rs11063263 rs3213212 498 21443.6 
12 28231087 55287990 rs10843085 rs9943768 468 27056.9 
12 102376027 118749798 rs4764862 rs461499 359 16373.8 
12 124854903 133754245 rs3782257 rs12320759 304 8899.34 
13 58000353 78044267 rs9569686 rs4885469 440 20043.9 
13 106210736 115025398 rs7991826 rs11617448 272 8814.66 
14 19465246 95108821 kgp9056199 rs11160197 1577 75643.6 
15 20184600 29418573 rs12906138 rs2672680 135 9233.97 
15 49832378 92684742 rs12232355 rs4777789 807 42852.4 
16 6724106 52625613 rs9929593 rs12920540 631 45901.5 
16 64439176 79906401 rs8054941 rs12102675 337 15467.2 
16 82303566 85370416 rs2967321 rs2326526 153 3066.85 
17 72487 9764531 rs12450662 rs2001486 274 9692.04 
17 12574501 81051007 rs1519251 rs7502442 1094 68476.5 
18 13034 3952770 rs12455984 rs6506142 143 3939.74 
18 57181744 78014582 rs4558500 rs12456851 517 20832.8 
19 288374 29219850 rs12981067 rs4474806 532 28931.5 
20 127720 7671888 rs753217 rs6055258 239 7544.17 
20 12693139 62892739 rs1333400 rs6062357 1089 50199.6 
21 16229925 36219566 rs2822964 rs2154450 491 19989.6 
22 16504399 49559242 kgp1568720 rs5769440 753 33054.8 
 
CHR – chromosome; BP1 – start of the physical position of the segment (base pair); BP2 - end of the physical 
position of the segment (base pair 2); SNP1 – start of the SNP segment; SNP2 – end of the SNP segment; NSNP 
– number of SNPs in the segment; KB – physical length of the segment 
 
 
Supplementary Table 4 Individual per sample comparison between the 40 probands. 
FID1 IID1 FID2 IID2 Z0 Z1 Z2 PI(HAT) 
ZA103 7268 ZA106 7867 0.9981 0 0.0019 0.0019 
ZA103 7268 ZA112 7897 1 0 0 0 
ZA103 7268 ZA116 7929 1 0 0 0 
ZA103 7268 ZA128 8158 0.9945 0 0.0055 0.0055 
ZA103 7268 ZA134 8165 0.9832 0.0168 0 0.0084 
ZA103 7268 ZA140 8174 1 0 0 0 
ZA103 7268 ZA142 8239 1 0 0 0 
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ZA103 7268 ZA150 5645 1 0 0 0 
ZA103 7268 ZA16 10181 0.9986 0 0.0014 0.0014 
ZA103 7268 ZA175 8316 1 0 0 0 
ZA103 7268 ZA190 8338 1 0 0 0 
ZA103 7268 ZA194 8415 1 0 0 0 
ZA103 7268 ZA213 8430 0.989 0.0095 0.0016 0.0063 
ZA103 7268 ZA216 8874 0.98 0.02 0 0.01 
ZA103 7268 ZA233 5473 0.9714 0.0275 0.0011 0.0149 
ZA103 7268 ZA24 9087 0.9639 0.0361 0 0.018 
ZA103 7268 ZA241 9200 0.9893 0.0091 0.0016 0.0062 
ZA103 7268 ZA252 9231 0.9818 0.0165 0.0017 0.0099 
ZA103 7268 ZA253 9260 1 0 0 0 
ZA103 7268 ZA256 9434 1 0 0 0 
ZA103 7268 ZA263 9458 1 0 0 0 
ZA103 7268 ZA272 9564 1 0 0 0 
ZA103 7268 ZA316 5581 1 0 0 0 
ZA103 7268 ZA34 7594 0.0134 0 0 0.0066 
ZA103 7268 ZA4 3836 0.9767 0.0233 0 0.0116 
ZA103 7268 ZA411 10110 1 0 0 0 
ZA103 7268 ZA413 10141 0.9877 0.0123 0 0.0062 
ZA103 7268 ZA5 3823 1 0 0 0 
ZA103 7268 ZA64 6734 1 0 0 0 
ZA103 7268 ZA68 6764 0.9754 0.0246 0 0.0123 
ZA103 7268 ZA72 6768 0.9953 0.0021 0.0026 0.0036 
ZA103 7268 ZA76 6782 0.9857 0.0143 0 0.0072 
ZA103 7268 ZA78 6772 1 0 0 0 
ZA103 7268 ZA86 6807 1 0 0 0 
ZA103 7268 ZA89 6816 0.9883 0.0107 0.001 0.0063 
ZA103 7268 ZA92 6827 0.9823 0.0177 0 0.0088 
ZA103 7268 ZA95 6924 0.9837 0.0163 0 0.0082 
ZA106 7867 ZA112 7897 1 0 0 0 
ZA106 7867 ZA116 7929 0.9943 0.0057 0 0.0029 
ZA106 7867 ZA128 8158 1 0 0 0 
ZA106 7867 ZA134 8165 0.9807 0.0193 0 0.0096 
ZA106 7867 ZA140 8174 1 0 0 0 
ZA106 7867 ZA142 8239 1 0 0 0 
ZA106 7867 ZA150 5645 1 0 0 0 
ZA106 7867 ZA16 10181 0.9972 0 0.0028 0.0028 
ZA106 7867 ZA175 8316 1 0 0 0 
ZA106 7867 ZA190 8338 1 0 0 0 
ZA106 7867 ZA194 8415 1 0 0 0 
ZA106 7867 ZA213 8430 1 0 0 0 
ZA106 7867 ZA216 8874 1 0 0 0 
ZA106 7867 ZA233 5473 0.9816 0.0184 0 0.0092 
ZA106 7867 ZA24 9087 1 0 0 0 
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ZA106 7867 ZA241 9200 1 0 0 0 
ZA106 7867 ZA252 9231 1 0 0 0 
ZA106 7867 ZA253 9260 1 0 0 0 
ZA106 7867 ZA256 9434 1 0 0 0 
ZA106 7867 ZA263 9458 1 0 0 0 
ZA106 7867 ZA272 9564 1 0 0 0 
ZA106 7867 ZA316 5581 1 0 0 0 
ZA106 7867 ZA34 7594 1 0 0 0 
ZA106 7867 ZA4 3836 0.9753 0.0247 0 0.0124 
ZA106 7867 ZA411 10110 1 0 0 0 
ZA106 7867 ZA413 10141 1 0 0 0 
ZA106 7867 ZA5 3823 0.9573 0.0427 0 0.0213 
ZA106 7867 ZA64 6734 1 0 0 0 
ZA106 7867 ZA68 6764 1 0 0 0 
ZA106 7867 ZA72 6768 1 0 0 0 
ZA106 7867 ZA76 6782 0.9888 0.0112 0 0.0056 
ZA106 7867 ZA78 6772 1 0 0 0 
ZA106 7867 ZA86 6807 0.9838 0.0162 0 0.0081 
ZA106 7867 ZA89 6816 1 0 0 0 
ZA106 7867 ZA92 6827 1 0 0 0 
ZA106 7867 ZA95 6924 0.9614 0.0386 0 0.0193 
ZA112 7897 ZA116 7929 1 0 0 0 
ZA112 7897 ZA128 8158 1 0 0 0 
ZA112 7897 ZA134 8165 1 0 0 0 
ZA112 7897 ZA140 8174 1 0 0 0 
ZA112 7897 ZA142 8239 1 0 0 0 
ZA112 7897 ZA150 5645 0.134 0 0 0.0066 
ZA112 7897 ZA16 10181 1 0 0 0 
ZA112 7897 ZA175 8316 0.9947 0.0022 0.0031 0.0042 
ZA112 7897 ZA190 8338 1 0 0 0 
ZA112 7897 ZA194 8415 0.9933 0 0.0067 0.0067 
ZA112 7897 ZA213 8430 0.9856 0.0119 0.0025 0.0085 
ZA112 7897 ZA216 8874 1 0 0 0 
ZA112 7897 ZA233 5473 0.996 0.004 0 0.002 
ZA112 7897 ZA24 9087 1 0 0 0 
ZA112 7897 ZA241 9200 0.9613 0.0387 0 0.0194 
ZA112 7897 ZA252 9231 1 0 0 0 
ZA112 7897 ZA253 9260 1 0 0 0 
ZA112 7897 ZA256 9434 0.9848 0.0152 0 0.0076 
ZA112 7897 ZA263 9458 1 0 0 0 
ZA112 7897 ZA272 9564 1 0 0 0 
ZA112 7897 ZA316 5581 1 0 0 0 
ZA112 7897 ZA34 7594 1 0 0 0 
ZA112 7897 ZA4 3836 0.9931 0.001 0.0059 0.0064 
ZA112 7897 ZA411 10110 1 0 0 0 
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ZA112 7897 ZA413 10141 1 0 0 0 
ZA112 7897 ZA5 3823 0.9952 0 0.0048 0.0048 
ZA112 7897 ZA64 6734 1 0 0 0 
ZA112 7897 ZA68 6764 0.9957 0.0043 0 0.0021 
ZA112 7897 ZA72 6768 0.9838 0.0162 0 0.0081 
ZA112 7897 ZA76 6782 1 0 0 0 
ZA112 7897 ZA78 6772 0.9953 0.0034 0.0013 0.003 
ZA112 7897 ZA86 6807 0.9877 0.0123 0 0.0061 
ZA112 7897 ZA89 6816 1 0 0 0 
ZA112 7897 ZA92 6827 1 0 0 0 
ZA112 7897 ZA95 6924 1 0 0 0 
ZA116 7929 ZA128 8158 1 0 0 0 
ZA116 7929 ZA134 8165 1 0 0 0 
ZA116 7929 ZA140 8174 0.9892 0.0108 0 0.0054 
ZA116 7929 ZA142 8239 1 0 0 0 
ZA116 7929 ZA150 5645 1 0 0 0 
ZA116 7929 ZA16 10181 0.9944 0.0056 0 0.0028 
ZA116 7929 ZA175 8316 1 0 0 0 
ZA116 7929 ZA190 8338 1 0 0 0 
ZA116 7929 ZA194 8415 1 0 0 0 
ZA116 7929 ZA213 8430 0.9746 0.0254 0 0.0127 
ZA116 7929 ZA216 8874 1 0 0 0 
ZA116 7929 ZA233 5473 1 0 0 0 
ZA116 7929 ZA24 9087 1 0 0 0 
ZA116 7929 ZA241 9200 0.9883 0.0117 0 0.0058 
ZA116 7929 ZA252 9231 1 0 0 0 
ZA116 7929 ZA253 9260 1 0 0 0 
ZA116 7929 ZA256 9434 1 0 0 0 
ZA116 7929 ZA263 9458 1 0 0 0 
ZA116 7929 ZA272 9564 1 0 0 0 
ZA116 7929 ZA316 5581 0.991 0.009 0 0.0045 
ZA116 7929 ZA34 7594 1 0 0 0 
ZA116 7929 ZA4 3836 1 0 0 0 
ZA116 7929 ZA411 10110 1 0 0 0 
ZA116 7929 ZA413 10141 1 0 0 0 
ZA116 7929 ZA5 3823 0.9886 0.0114 0 0.0057 
ZA116 7929 ZA64 6734 1 0 0 0 
ZA116 7929 ZA68 6764 0.9881 0.0105 0.0014 0.0067 
ZA116 7929 ZA72 6768 1 0 0 0 
ZA116 7929 ZA76 6782 0.9948 0.0052 0 0.0026 
ZA116 7929 ZA78 6772 1 0 0 0 
ZA116 7929 ZA86 6807 0.9817 0.0183 0 0.0092 
ZA116 7929 ZA89 6816 1 0 0 0 
ZA116 7929 ZA92 6827 1 0 0 0 
ZA116 7929 ZA95 6924 1 0 0 0 
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ZA128 8158 ZA134 8165 1 0 0 0 
ZA128 8158 ZA140 8174 0.9927 0.0037 0.0036 0.0055 
ZA128 8158 ZA142 8239 1 0 0 0 
ZA128 8158 ZA150 5645 1 0 0 0 
ZA128 8158 ZA16 10181 0.9891 0 0.0109 0.0109 
ZA128 8158 ZA175 8316 1 0 0 0 
ZA128 8158 ZA190 8338 0.9871 0.0094 0.0035 0.0082 
ZA128 8158 ZA194 8415 0.9869 0 0.0131 0.0131 
ZA128 8158 ZA213 8430 0.9677 0.0323 0 0.0162 
ZA128 8158 ZA216 8874 0.9882 0.0118 0 0.0059 
ZA128 8158 ZA233 5473 0.9922 0 0.0078 0.0078 
ZA128 8158 ZA24 9087 0.9844 0.0145 0.0011 0.0084 
ZA128 8158 ZA241 9200 0.9651 0.034 0.0008 0.0178 
ZA128 8158 ZA252 9231 0.9884 0 0.0116 0.0116 
ZA128 8158 ZA253 9260 1 0 0 0 
ZA128 8158 ZA256 9434 1 0 0 0 
ZA128 8158 ZA263 9458 1 0 0 0 
ZA128 8158 ZA272 9564 1 0 0 0 
ZA128 8158 ZA316 5581 0.9701 0.0255 0.0044 0.0172 
ZA128 8158 ZA34 7594 1 0 0 0 
ZA128 8158 ZA4 3836 0.9868 0 0.0132 0.0132 
ZA128 8158 ZA411 10110 0.9893 0 0.0107 0.0107 
ZA128 8158 ZA413 10141 0.9748 0.0252 0 0.0126 
ZA128 8158 ZA5 3823 0.9987 0 0.0013 0.0013 
ZA128 8158 ZA64 6734 1 0 0 0 
ZA128 8158 ZA68 6764 0.9889 0.0111 0 0.0055 
ZA128 8158 ZA72 6768 0.984 0.0137 0.0023 0.0092 
ZA128 8158 ZA76 6782 0.9792 0.0193 0.0015 0.0111 
ZA128 8158 ZA78 6772 1 0 0 0 
ZA128 8158 ZA86 6807 0.976 0.024 0 0.012 
ZA128 8158 ZA89 6816 0.9659 0.0341 0 0.017 
ZA128 8158 ZA92 6827 1 0 0 0 
ZA128 8158 ZA95 6924 0.982 0.018 0 0.009 
ZA134 8165 ZA140 8174 0.9911 0.008 0.0009 0.0049 
ZA134 8165 ZA142 8239 1 0 0 0 
ZA134 8165 ZA150 5645 1 0 0 0 
ZA134 8165 ZA16 10181 0.9907 0 0.0093 0.0093 
ZA134 8165 ZA175 8316 1 0 0 0 
ZA134 8165 ZA190 8338 1 0 0 0 
ZA134 8165 ZA194 8415 1 0 0 0 
ZA134 8165 ZA213 8430 1 0 0 0 
ZA134 8165 ZA216 8874 1 0 0 0 
ZA134 8165 ZA233 5473 0.9938 0.0062 0 0.0031 
ZA134 8165 ZA24 9087 1 0 0 0 
ZA134 8165 ZA241 9200 1 0 0 0 
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ZA134 8165 ZA252 9231 1 0 0 0 
ZA134 8165 ZA253 9260 1 0 0 0 
ZA134 8165 ZA256 9434 1 0 0 0 
ZA134 8165 ZA263 9458 1 0 0 0 
ZA134 8165 ZA272 9564 0.9869 0.009 0.0041 0.0086 
ZA134 8165 ZA316 5581 0.9804 0.0088 0.0109 0.0153 
ZA134 8165 ZA34 7594 1 0 0 0 
ZA134 8165 ZA4 3836 1 0 0 0 
ZA134 8165 ZA411 10110 1 0 0 0 
ZA134 8165 ZA413 10141 0.9778 0.0222 0 0.0111 
ZA134 8165 ZA5 3823 0.9897 0.0078 0.0026 0.0065 
ZA134 8165 ZA64 6734 1 0 0 0 
ZA134 8165 ZA68 6764 0.9791 0.0209 0 0.0104 
ZA134 8165 ZA72 6768 0.9914 0.0086 0 0.0043 
ZA134 8165 ZA76 6782 0.9944 0 0.0056 0.0056 
ZA134 8165 ZA78 6772 1 0 0 0 
ZA134 8165 ZA86 6807 0.9847 0.0153 0 0.0077 
ZA134 8165 ZA89 6816 1 0 0 0 
ZA134 8165 ZA92 6827 0.9905 0.0095 0 0.0047 
ZA134 8165 ZA95 6924 1 0 0 0 
ZA140 8174 ZA142 8239 1 0 0 0 
ZA140 8174 ZA150 5645 1 0 0 0 
ZA140 8174 ZA16 10181 0.9714 0.0286 0 0.0143 
ZA140 8174 ZA175 8316 1 0 0 0 
ZA140 8174 ZA190 8338 1 0 0 0 
ZA140 8174 ZA194 8415 0.9809 0.0191 0 0.0096 
ZA140 8174 ZA213 8430 0.9847 0.0148 0.0005 0.0079 
ZA140 8174 ZA216 8874 0.9527 0.0473 0 0.0237 
ZA140 8174 ZA233 5473 0.9972 0.0005 0.0023 0.0025 
ZA140 8174 ZA24 9087 0.9815 0.0185 0 0.0093 
ZA140 8174 ZA241 9200 0.9586 0.0414 0 0.0207 
ZA140 8174 ZA252 9231 0.9906 0.0052 0.0042 0.0068 
ZA140 8174 ZA253 9260 0.983 0.017 0 0.0085 
ZA140 8174 ZA256 9434 1 0 0 0 
ZA140 8174 ZA263 9458 0.9948 0.0013 0.0039 0.0045 
ZA140 8174 ZA272 9564 0.9835 0.0165 0 0.0082 
ZA140 8174 ZA316 5581 1 0 0 0 
ZA140 8174 ZA34 7594 1 0 0 0 
ZA140 8174 ZA4 3836 1 0 0 0 
ZA140 8174 ZA411 10110 1 0 0 0 
ZA140 8174 ZA413 10141 0.9705 0.0295 0 0.0147 
ZA140 8174 ZA5 3823 0.9847 0.0153 0 0.0076 
ZA140 8174 ZA64 6734 1 0 0 0 
ZA140 8174 ZA68 6764 0.9685 0.0315 0 0.0158 
ZA140 8174 ZA72 6768 0.9655 0.0322 0.0024 0.0184 
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ZA140 8174 ZA76 6782 0.9832 0.0168 0 0.0084 
ZA140 8174 ZA78 6772 1 0 0 0 
ZA140 8174 ZA86 6807 0.9901 0.0099 0 0.0049 
ZA140 8174 ZA89 6816 1 0 0 0 
ZA140 8174 ZA92 6827 0.9856 0.0144 0 0.0072 
ZA140 8174 ZA95 6924 0.9917 0.0083 0 0.0041 
ZA142 8239 ZA150 5645 1 0 0 0 
ZA142 8239 ZA16 10181 0.9921 0.0079 0 0.004 
ZA142 8239 ZA175 8316 1 0 0 0 
ZA142 8239 ZA190 8338 1 0 0 0 
ZA142 8239 ZA194 8415 1 0 0 0 
ZA142 8239 ZA213 8430 1 0 0 0 
ZA142 8239 ZA216 8874 0.9874 0.0126 0 0.0063 
ZA142 8239 ZA233 5473 1 0 0 0 
ZA142 8239 ZA24 9087 0.9903 0.0028 0.0069 0.0083 
ZA142 8239 ZA241 9200 1 0 0 0 
ZA142 8239 ZA252 9231 1 0 0 0 
ZA142 8239 ZA253 9260 0.9876 0.0072 0.0053 0.0088 
ZA142 8239 ZA256 9434 0.9834 0.0166 0 0.0083 
ZA142 8239 ZA263 9458 1 0 0 0 
ZA142 8239 ZA272 9564 0.993 0.007 0 0.0035 
ZA142 8239 ZA316 5581 1 0 0 0 
ZA142 8239 ZA34 7594 1 0 0 0 
ZA142 8239 ZA4 3836 1 0 0 0 
ZA142 8239 ZA411 10110 1 0 0 0 
ZA142 8239 ZA413 10141 1 0 0 0 
ZA142 8239 ZA5 3823 1 0 0 0 
ZA142 8239 ZA64 6734 1 0 0 0 
ZA142 8239 ZA68 6764 0.9933 0.0067 0 0.0033 
ZA142 8239 ZA72 6768 1 0 0 0 
ZA142 8239 ZA76 6782 0.9953 0 0.0047 0.0047 
ZA142 8239 ZA78 6772 1 0 0 0 
ZA142 8239 ZA86 6807 0.9885 0.0111 0.0004 0.0059 
ZA142 8239 ZA89 6816 1 0 0 0 
ZA142 8239 ZA92 6827 1 0 0 0 
ZA142 8239 ZA92 6924 1 0 0 0 
ZA150 5645 ZA16 10181 1 0 0 0 
ZA150 5645 ZA175 8316 1 0 0 0 
ZA150 5645 ZA190 8338 1 0 0 0 
ZA150 5645 ZA194 8415 1 0 0 0 
ZA150 5645 ZA213 8430 1 0 0 0 
ZA150 5645 ZA216 8874 1 0 0 0 
ZA150 5645 ZA233 5473 1 0 0 0 
ZA150 5645 ZA24 9087 1 0 0 0 
ZA150 5645 ZA241 9200 1 0 0 0 
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ZA150 5645 ZA252 9231 1 0 0 0 
ZA150 5645 ZA253 9260 1 0 0 0 
ZA150 5645 ZA256 9434 1 0 0 0 
ZA150 5645 ZA263 9458 1 0 0 0 
ZA150 5645 ZA272 9564 1 0 0 0 
ZA150 5645 ZA316 5581 1 0 0 0 
ZA150 5645 ZA34 7594 1 0 0 0 
ZA150 5645 ZA4 3836 1 0 0 0 
ZA150 5645 ZA411 10110 1 0 0 0 
ZA150 5645 ZA413 10141 1 0 0 0 
ZA150 5645 ZA5 3823 1 0 0 0 
ZA150 5645 ZA64 6734 1 0 0 0 
ZA150 5645 ZA68 6764 0.987 0.013 0 0.0065 
ZA150 5645 ZA72 6768 1 0 0 0 
ZA150 5645 ZA76 6782 1 0 0 0 
ZA150 5645 ZA78 6772 1 0 0 0 
ZA150 5645 ZA86 6807 1 0 0 0 
ZA150 5645 ZA89 6816 1 0 0 0 
ZA150 5645 ZA92 6827 1 0 0 0 
ZA150 5645 ZA95 6924 1 0 0 0 
ZA16 10181 ZA175 8316 1 0 0 0 
ZA16 10181 ZA190 8338 1 0 0 0 
ZA16 10181 ZA194 8415 0.9932 0 0.0068 0.0068 
ZA16 10181 ZA213 8430 0.9927 0.0073 0 0.0036 
ZA16 10181 ZA216 8874 0.957 0.043 0 0.0215 
ZA16 10181 ZA233 5473 0.9992 0 0.0008 0.0008 
ZA16 10181 ZA24 9087 1 0 0 0 
ZA16 10181 ZA241 9200 0.9918 0.0082 0 0.0041 
ZA16 10181 ZA252 9231 0.9971 0 0.0029 0.0029 
ZA16 10181 ZA253 9260 1 0 0 0 
ZA16 10181 ZA256 9434 1 0 0 0 
ZA16 10181 ZA263 9458 0.9968 0.0001 0.003 0.0031 
ZA16 10181 ZA272 9564 1 0 0 0 
ZA16 10181 ZA316 5581 1 0 0 0 
ZA16 10181 ZA34 7594 1 0 0 0 
ZA16 10181 ZA4 3836 0.9957 0 0.0043 0.0043 
ZA16 10181 ZA411 10110 1 0 0 0 
ZA16 10181 ZA413 10141 1 0 0 0 
ZA16 10181 ZA5 3823 1 0 0 0 
ZA16 10181 ZA64 6734 1 0 0 0 
ZA16 10181 ZA68 6764 0.9869 0.0131 0 0.0066 
ZA16 10181 ZA72 6768 0.9685 0.0315 0 0.0157 
ZA16 10181 ZA76 6782 0.9863 0.0114 0.0023 0.008 
ZA16 10181 ZA78 6772 1 0 0 0 
ZA16 10181 ZA86 6807 0.9677 0.0323 0 0.0162 
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ZA16 10181 ZA89 6816 0.9826 0.0174 0 0.0087 
ZA16 10181 ZA92 6827 1 0 0 0 
ZA16 10181 ZA95 6924 0.9893 0.0107 0 0.0053 
ZA175 8316 ZA190 8338 1 0 0 0 
ZA175 8316 ZA194 8415 1 0 0 0 
ZA175 8316 ZA213 8430 1 0 0 0 
ZA175 8316 ZA216 8874 1 0 0 0 
ZA175 8316 ZA233 5473 0.9948 0 0.0052 0.0052 
ZA175 8316 ZA24 9087 0.9889 0.0111 0 0.0056 
ZA175 8316 ZA241 9200 0.9905 0.0054 0.0041 0.0068 
ZA175 8316 ZA252 9231 1 0 0 0 
ZA175 8316 ZA253 9260 0.9901 0.0099 0 0.0049 
ZA175 8316 ZA256 9434 1 0 0 0 
ZA175 8316 ZA263 9458 1 0 0 0 
ZA175 8316 ZA272 9564 1 0 0 0 
ZA175 8316 ZA316 5581 1 0 0 0 
ZA175 8316 ZA34 7594 1 0 0 0 
ZA175 8316 ZA4 3836 1 0 0 0 
ZA175 8316 ZA411 10110 1 0 0 0 
ZA175 8316 ZA413 10141 1 0 0 0 
ZA175 8316 ZA5 3823 1 0 0 0 
ZA175 8316 ZA64 6734 1 0 0 0 
ZA175 8316 ZA68 6764 0.981 0.019 0 0.0095 
ZA175 8316 ZA72 6768 1 0 0 0 
ZA175 8316 ZA76 6782 0.9971 0 0.0029 0.0029 
ZA175 8316 ZA78 6772 1 0 0 0 
ZA175 8316 ZA86 6807 1 0 0 0 
ZA175 8316 ZA89 6816 0.9921 0 0.0079 0.0079 
ZA175 8316 ZA92 6827 1 0 0 0 
ZA175 8316 ZA95 6924 1 0 0 0 
ZA190 8338 ZA194 8415 1 0 0 0 
ZA190 8338 ZA213 8430 1 0 0 0 
ZA190 8338 ZA216 8874 1 0 0 0 
ZA190 8338 ZA233 5473 0.9952 0 0.0048 0.0048 
ZA190 8338 ZA24 9087 1 0 0 0 
ZA190 8338 ZA241 9200 0.9951 0.0021 0.0028 0.0039 
ZA190 8338 ZA252 9231 1 0 0 0 
ZA190 8338 ZA253 9260 1 0 0 0 
ZA190 8338 ZA256 9434 1 0 0 0 
ZA190 8338 ZA263 9458 1 0 0 0 
ZA190 8338 ZA272 9564 1 0 0 0 
ZA190 8338 ZA316 5581 1 0 0 0 
ZA190 8338 ZA34 7594 1 0 0 0 
ZA190 8338 ZA4 3836 1 0 0 0 
ZA190 8338 ZA411 10110 1 0 0 0 
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ZA190 8338 ZA413 10141 1 0 0 0 
ZA190 8338 ZA5 3823 1 0 0 0 
ZA190 8338 ZA64 6734 1 0 0 0 
ZA190 8338 ZA68 6764 0.9944 0.0056 0 0.0028 
ZA190 8338 ZA72 6768 0.9929 0.0056 0.0015 0.0043 
ZA190 8338 ZA76 6782 1 0 0 0 
ZA190 8338 ZA78 6772 1 0 0 0 
ZA190 8338 ZA86 6807 1 0 0 0 
ZA190 8338 ZA89 6816 1 0 0 0 
ZA190 8338 ZA92 6827 1 0 0 0 
ZA190 8338 ZA95 6924 1 0 0 0 
ZA194 8415 ZA213 8430 0.9783 0.0217 0 0.0109 
ZA194 8415 ZA216 8874 1 0 0 0 
ZA194 8415 ZA233 5473 1 0 0 0 
ZA194 8415 ZA24 9087 0.9994 0.0005 0.0001 0.0004 
ZA194 8415 ZA241 9200 0.9876 0.0124 0 0.0062 
ZA194 8415 ZA252 9231 1 0 0 0 
ZA194 8415 ZA253 9260 0.9894 0.0093 0.0014 0.006 
ZA194 8415 ZA256 9434 0.9942 0.0056 0.0002 0.003 
ZA194 8415 ZA263 9458 1 0 0 0 
ZA194 8415 ZA272 9564 1 0 0 0 
ZA194 8415 ZA316 5581 1 0 0 0 
ZA194 8415 ZA34 7594 1 0 0 0 
ZA194 8415 ZA4 3836 0.9944 0.0056 0 0.0028 
ZA194 8415 ZA411 10110 1 0 0 0 
ZA194 8415 ZA413 10141 1 0 0 0 
ZA194 8415 ZA5 3823 1 0 0 0 
ZA194 8415 ZA64 6734 1 0 0 0 
ZA194 8415 ZA68 6764 0.9783 0.0217 0 0.0108 
ZA194 8415 ZA72 6768 1 0 0 0 
ZA194 8415 ZA76 6782 0.9847 0.0153 0 0.0076 
ZA194 8415 ZA78 6772 1 0 0 0 
ZA194 8415 ZA86 6807 0.9811 0.0189 0 0.0094 
ZA194 8415 ZA89 6816 0.9619 0.0381 0 0.019 
ZA194 8415 ZA92 6827 0.9971 0.0029 0 0.0014 
ZA194 8415 ZA95 6924 0.984 0.016 0 0.008 
ZA213 8430 ZA216 8874 0.981 0.019 0 0.0095 
ZA213 8430 ZA233 5473 0.9868 0.0132 0 0.0066 
ZA213 8430 ZA24 9087 0.9959 0.0024 0.0017 0.0029 
ZA213 8430 ZA241 9200 0.9896 0.0081 0.0024 0.0064 
ZA213 8430 ZA252 9231 1 0 0 0 
ZA213 8430 ZA253 9260 1 0 0 0 
ZA213 8430 ZA256 9434 1 0 0 0 
ZA213 8430 ZA263 9458 0.9825 0.0152 0.0023 0.0099 
ZA213 8430 ZA272 9564 0.9862 0.0138 0 0.0069 
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ZA213 8430 ZA316 5581 1 0 0 0 
ZA213 8430 ZA34 7594 1 0 0 0 
ZA213 8430 ZA4 3836 0.9928 0 0.0072 0.0072 
ZA213 8430 ZA411 10110 1 0 0 0 
ZA213 8430 ZA413 10141 0.9921 0 0.0079 0.0079 
ZA213 8430 ZA5 3823 0.9768 0.0232 0 0.0116 
ZA213 8430 ZA64 6734 1 0 0 0 
ZA213 8430 ZA68 6764 0.9524 0.0476 0 0.0238 
ZA213 8430 ZA72 6768 0.98 0.02 0 0.01 
ZA213 8430 ZA76 6782 0.9884 0.0108 0.0008 0.0062 
ZA213 8430 ZA78 6772 1 0 0 0 
ZA213 8430 ZA86 6807 0.9668 0.0332 0 0.0166 
ZA213 8430 ZA89 6816 0.9866 0.0134 0 0.0067 
ZA213 8430 ZA92 6827 0.9629 0.0371 0 0.0186 
ZA213 8430 ZA95 6924 1 0 0 0 
ZA216 8874 ZA233 5473 0.9602 0.0398 0 0.0199 
ZA216 8874 ZA24 9087 0.9741 0.0259 0 0.013 
ZA216 8874 ZA241 9200 0.9948 0.0052 0 0.0026 
ZA216 8874 ZA252 9231 0.9878 0.0122 0 0.0061 
ZA216 8874 ZA253 9260 1 0 0 0 
ZA216 8874 ZA256 9434 0.9864 0.0136 0 0.0068 
ZA216 8874 ZA263 9458 1 0 0 0 
ZA216 8874 ZA272 9564 1 0 0 0 
ZA216 8874 ZA316 5581 1 0 0 0 
ZA216 8874 ZA34 7594 1 0 0 0 
ZA216 8874 ZA4 3836 0.9935 0.0065 0 0.0033 
ZA216 8874 ZA411 10110 1 0 0 0 
ZA216 8874 ZA413 10141 0.9861 0.0139 0 0.007 
ZA216 8874 ZA5 3823 0.9712 0.0288 0 0.0144 
ZA216 8874 ZA64 6734 1 0 0 0 
ZA216 8874 ZA68 6764 0.9585 0.0415 0 0.0207 
ZA216 8874 ZA72 6768 0.956 0.044 0 0.022 
ZA216 8874 ZA76 6782 0.983 0.017 0 0.0085 
ZA216 8874 ZA78 6772 0.9871 0.0129 0 0.0065 
ZA216 8874 ZA86 6807 1 0 0 0 
ZA216 8874 ZA89 6816 0.966 0.034 0 0.017 
ZA216 8874 ZA92 6827 0.9781 0.0219 0 0.0109 
ZA216 8874 ZA95 6924 0.9587 0.0413 0 0.0207 
ZA233 5473 ZA24 9087 0.9409 0.0591 0 0.0296 
ZA233 5473 ZA241 9200 0.9722 0.0278 0 0.0139 
ZA233 5473 ZA252 9231 1 0 0 0 
ZA233 5473 ZA253 9260 1 0 0 0 
ZA233 5473 ZA256 9434 1 0 0 0 
ZA233 5473 ZA263 9458 1 0 0 0 
ZA233 5473 ZA272 9564 1 0 0 0 
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ZA233 5473 ZA316 5581 1 0 0 0 
ZA233 5473 ZA34 7594 1 0 0 0 
ZA233 5473 ZA4 3836 0.9975 0.0021 0.0005 0.0015 
ZA233 5473 ZA411 10110 1 0 0 0 
ZA233 5473 ZA413 10141 0.97 0.03 0 0.015 
ZA233 5473 ZA5 3823 1 0 0 0 
ZA233 5473 ZA64 6734 1 0 0 0 
ZA233 5473 ZA68 6764 0.9729 0.0271 0 0.0136 
ZA233 5473 ZA72 6768 0.9789 0.0182 0.0029 0.012 
ZA233 5473 ZA76 6782 0.9733 0.0267 0 0.0134 
ZA233 5473 ZA78 6772 1 0 0 0 
ZA233 5473 ZA86 6807 1 0 0 0 
ZA233 5473 ZA89 6816 1 0 0 0 
ZA233 5473 ZA92 6827 0.9628 0.0372 0 0.0186 
ZA233 5473 ZA95 6924 0.9705 0.0295 0 0.0147 
ZA24 9087 ZA241 9200 0.9634 0.0366 0 0.0183 
ZA24 9087 ZA252 9231 0.994 0 0.006 0.006 
ZA24 9087 ZA253 9260 0.9987 0.0013 0 0.0006 
ZA24 9087 ZA256 9434 0.997 0 0.003 0.003 
ZA24 9087 ZA263 9458 0.9962 0.0038 0 0.0019 
ZA24 9087 ZA272 9564 0.9824 0.0176 0 0.0088 
ZA24 9087 ZA316 5581 1 0 0 0 
ZA24 9087 ZA34 7594 1 0 0 0 
ZA24 9087 ZA4 3836 0.9883 0.0099 0.0018 0.0068 
ZA24 9087 ZA411 10110 1 0 0 0 
ZA24 9087 ZA413 10141 0.9908 0.0064 0.0028 0.006 
ZA24 9087 ZA5 3823 0.9722 0.0278 0 0.0139 
ZA24 9087 ZA64 6734 1 0 0 0 
ZA24 9087 ZA68 6764 1 0 0 0 
ZA24 9087 ZA72 6768 1 0 0 0 
ZA24 9087 ZA76 6782 0.9643 0.0357 0 0.0178 
ZA24 9087 ZA78 6772 0.9872 0.0128 0 0.0064 
ZA24 9087 ZA86 6807 0.9772 0.0228 0 0.0114 
ZA24 9087 ZA89 6816 0.985 0.015 0 0.0075 
ZA24 9087 ZA92 6827 0.9969 0.0019 0.0012 0.0021 
ZA24 9087 ZA95 6924 0.9712 0.0288 0 0.0144 
ZA241 9200 ZA252 9231 0.9937 0.0063 0 0.0031 
ZA241 9200 ZA253 9260 0.9838 0.0162 0 0.0081 
ZA241 9200 ZA256 9434 0.9785 0.0215 0 0.0107 
ZA241 9200 ZA263 9458 1 0 0 0 
ZA241 9200 ZA272 9564 1 0 0 0 
ZA241 9200 ZA316 5581 1 0 0 0 
ZA241 9200 ZA34 7594 1 0 0 0 
ZA241 9200 ZA4 3836 0.9842 0.0158 0 0.0079 
ZA241 9200 ZA411 10110 0.9938 0.0062 0 0.0031 
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ZA241 9200 ZA413 10141 0.9797 0.0198 0.0004 0.0104 
ZA241 9200 ZA5 3823 0.958 0.042 0 0.021 
ZA241 9200 ZA64 6734 1 0 0 0 
ZA241 9200 ZA68 6764 1 0 0 0 
ZA241 9200 ZA72 6768 0.9573 0.0427 0 0.0214 
ZA241 9200 ZA76 6782 0.9907 0.0077 0.0016 0.0055 
ZA241 9200 ZA78 6772 1 0 0 0 
ZA241 9200 ZA86 6807 0.9908 0.0092 0 0.0046 
ZA241 9200 ZA89 6816 0.9782 0.0218 0 0.0109 
ZA241 9200 ZA92 6827 0.9756 0.0244 0 0.0122 
ZA241 9200 ZA95 6924 1 0 0 0 
ZA252 9231 ZA253 9260 1 0 0 0 
ZA252 9231 ZA256 9434 1 0 0 0 
ZA252 9231 ZA263 9458 1 0 0 0 
ZA252 9231 ZA272 9564 1 0 0 0 
ZA252 9231 ZA316 5581 0.9958 0.001 0.0031 0.0037 
ZA252 9231 ZA34 7594 1 0 0 0 
ZA252 9231 ZA4 3836 0.9839 0.0076 0.0085 0.0123 
ZA252 9231 ZA411 10110 1 0 0 0 
ZA252 9231 ZA413 10141 1 0 0 0 
ZA252 9231 ZA5 3823 0.9965 0.0035 0 0.0017 
ZA252 9231 ZA64 6734 1 0 0 0 
ZA252 9231 ZA68 6764 0.9767 0.0233 0 0.0117 
ZA252 9231 ZA72 6768 0.9931 0.0015 0.0054 0.0061 
ZA252 9231 ZA76 6782 0.991 0 0.009 0.009 
ZA252 9231 ZA78 6772 1 0 0 0 
ZA252 9231 ZA86 6807 0.9759 0.0241 0 0.012 
ZA252 9231 ZA89 6816 1 0 0 0 
ZA252 9231 ZA92 6827 1 0 0 0 
ZA252 9231 ZA95 6924 1 0 0 0 
ZA253 9260 ZA256 9434 0.9893 0.0107 0 0.0053 
ZA253 9260 ZA263 9458 1 0 0 0 
ZA253 9260 ZA272 9564 0.991 0.009 0 0.0045 
ZA253 9260 ZA316 5581 0.9936 0.0053 0.0011 0.0037 
ZA253 9260 ZA34 7594 1 0 0 0 
ZA253 9260 ZA4 3836 1 0 0 0 
ZA253 9260 ZA411 10110 1 0 0 0 
ZA253 9260 ZA413 10141 1 0 0 0 
ZA253 9260 ZA5 3823 0.9561 0.0439 0 0.022 
ZA253 9260 ZA64 6734 1 0 0 0 
ZA253 9260 ZA68 6764 0.9703 0.0297 0 0.0149 
ZA253 9260 ZA72 6768 1 0 0 0 
ZA253 9260 ZA76 6782 0.9964 0.0023 0.0013 0.0024 
ZA253 9260 ZA78 6772 1 0 0 0 
ZA253 9260 ZA86 6807 1 0 0 0 
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ZA253 9260 ZA89 6816 1 0 0 0 
ZA253 9260 ZA92 6827 1 0 0 0 
ZA253 9260 ZA95 6924 0.9681 0.0319 0 0.0159 
ZA256 9434 ZA263 9458 1 0 0 0 
ZA256 9434 ZA272 9564 1 0 0 0 
ZA256 9434 ZA316 5581 1 0 0 0 
ZA256 9434 ZA34 7594 1 0 0 0 
ZA256 9434 ZA4 3836 1 0 0 0 
ZA256 9434 ZA411 10110 1 0 0 0 
ZA256 9434 ZA413 10141 0.9984 0.0016 0 0.0008 
ZA256 9434 ZA5 3823 1 0 0 0 
ZA256 9434 ZA64 6734 1 0 0 0 
ZA256 9434 ZA68 6764 1 0 0 0 
ZA256 9434 ZA72 6768 1 0 0 0 
ZA256 9434 ZA76 6782 0.9901 0.0099 0 0.005 
ZA256 9434 ZA78 6772 1 0 0 0 
ZA256 9434 ZA86 6807 0.9498 0.0502 0 0.0251 
ZA256 9434 ZA89 6816 0.978 0.022 0 0.011 
ZA256 9434 ZA92 6827 0.9963 0.0037 0 0.0019 
ZA256 9434 ZA95 6924 1 0 0 0 
ZA263 9458 ZA272 9564 1 0 0 0 
ZA263 9458 ZA316 5581 1 0 0 0 
ZA263 9458 ZA34 7594 1 0 0 0 
ZA263 9458 ZA4 3836 1 0 0 0 
ZA263 9458 ZA411 10110 1 0 0 0 
ZA263 9458 ZA413 10141 1 0 0 0 
ZA263 9458 ZA5 3823 0.9814 0.0186 0 0.0093 
ZA263 9458 ZA64 6734 1 0 0 0 
ZA263 9458 ZA68 6764 1 0 0 0 
ZA263 9458 ZA72 6768 0.9611 0.0389 0 0.0195 
ZA263 9458 ZA76 6782 1 0 0 0 
ZA263 9458 ZA78 6772 1 0 0 0 
ZA263 9458 ZA86 6807 1 0 0 0 
ZA263 9458 ZA89 6816 1 0 0 0 
ZA263 9458 ZA92 6827 1 0 0 0 
ZA263 9458 ZA95 6924 1 0 0 0 
ZA272 9564 ZA316 5581 1 0 0 0 
ZA272 9564 ZA34 7594 1 0 0 0 
ZA272 9564 ZA4 3836 1 0 0 0 
ZA272 9564 ZA411 10110 1 0 0 0 
ZA272 9564 ZA413 10141 1 0 0 0 
ZA272 9564 ZA5 3823 0.9933 0.0067 0 0.0033 
ZA272 9564 ZA64 6734 1 0 0 0 
ZA272 9564 ZA68 6764 0.9756 0.0244 0 0.0122 
ZA272 9564 ZA72 6768 1 0 0 0 
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ZA272 9564 ZA76 6782 1 0 0 0 
ZA272 9564 ZA78 6772 1 0 0 0 
ZA272 9564 ZA86 6807 1 0 0 0 
ZA272 9564 ZA89 6816 1 0 0 0 
ZA272 9564 ZA92 6827 0.9994 0 0.0006 0.0006 
ZA272 9564 ZA95 6924 1 0 0 0 
ZA316 5581 ZA34 7594 1 0 0 0 
ZA316 5581 ZA4 3836 0.9884 0.0116 0 0.0058 
ZA316 5581 ZA411 10110 1 0 0 0 
ZA316 5581 ZA413 10141 1 0 0 0 
ZA316 5581 ZA5 3823 1 0 0 0 
ZA316 5581 ZA64 6734 1 0 0 0 
ZA316 5581 ZA68 6764 0.9975 0.0025 0 0.0013 
ZA316 5581 ZA72 6768 0.986 0.0117 0.0022 0.0081 
ZA316 5581 ZA76 6782 0.9742 0.0258 0 0.0129 
ZA316 5581 ZA78 6772 1 0 0 0 
ZA316 5581 ZA86 6807 1 0 0 0 
ZA316 5581 ZA89 6816 0.9902 0.004 0.0058 0.0078 
ZA316 5581 ZA92 6827 0.9967 0.0033 0 0.0016 
ZA316 5581 ZA95 6924 0.9978 0.0015 0.0007 0.0014 
ZA34 7594 ZA4 3836 1 0 0 0 
ZA34 7594 ZA411 10110 1 0 0 0 
ZA34 7594 ZA413 10141 1 0 0 0 
ZA34 7594 ZA5 3823 1 0 0 0 
ZA34 7594 ZA64 6734 1 0 0 0 
ZA34 7594 ZA68 6764 1 0 0 0 
ZA34 7594 ZA72 6768 1 0 0 0 
ZA34 7594 ZA76 6782 1 0 0 0 
ZA34 7594 ZA78 6772 1 0 0 0 
ZA34 7594 ZA86 6807 1 0 0 0 
ZA34 7594 ZA89 6816 1 0 0 0 
ZA34 7594 ZA92 6827 1 0 0 0 
ZA34 7594 ZA95 6924 1 0 0 0 
ZA4 3836 ZA411 10110 1 0 0 0 
ZA4 3836 ZA413 10141 0.9797 0.0203 0 0.0102 
ZA4 3836 ZA5 3823 1 0 0 0 
ZA4 3836 ZA64 6734 1 0 0 0 
ZA4 3836 ZA68 6764 0.9662 0.0338 0 0.0169 
ZA4 3836 ZA72 6768 0.9712 0.0206 0.0082 0.0185 
ZA4 3836 ZA76 6782 0.9854 0.0146 0 0.0073 
ZA4 3836 ZA78 6772 1 0 0 0 
ZA4 3836 ZA86 6807 0.9907 0.0085 0.0009 0.0051 
ZA4 3836 ZA89 6816 0.9888 0.0034 0.0078 0.0095 
ZA4 3836 ZA92 6827 0.9981 0.0016 0.0003 0.0011 
ZA4 3836 ZA95 6924 1 0 0 0 
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ZA411 10110 ZA413 10141 1 0 0 0 
ZA411 10110 ZA5 3823 1 0 0 0 
ZA411 10110 ZA64 6734 1 0 0 0 
ZA411 10110 ZA68 6764 1 0 0 0 
ZA411 10110 ZA72 6768 1 0 0 0 
ZA411 10110 ZA76 6782 1 0 0 0 
ZA411 10110 ZA78 6772 1 0 0 0 
ZA411 10110 ZA86 6807 1 0 0 0 
ZA411 10110 ZA89 6816 1 0 0 0 
ZA411 10110 ZA92 6827 1 0 0 0 
ZA411 10110 ZA95 6924 0.982 0.018 0 0.009 
ZA413 10141 ZA5 3823 0.9887 0.0113 0 0.0057 
ZA413 10141 ZA64 6734 1 0 0 0 
ZA413 10141 ZA68 6764 0.9869 0.0131 0 0.0066 
ZA413 10141 ZA72 6768 0.9844 0.0049 0.0107 0.0132 
ZA413 10141 ZA76 6782 0.9599 0.0371 0.0031 0.0216 
ZA413 10141 ZA78 6772 0.9772 0.0211 0.0017 0.0122 
ZA413 10141 ZA86 6807 0.9823 0.0156 0.0021 0.0099 
ZA413 10141 ZA89 6816 0.9689 0.0311 0 0.0155 
ZA413 10141 ZA92 6827 1 0 0 0 
ZA413 10141 ZA95 6924 0.9855 0.0145 0 0.0072 
ZA5 3823 ZA64 6734 1 0 0 0 
ZA5 3823 ZA68 6764 0.9639 0.0361 0 0.0181 
ZA5 3823 ZA72 6768 0.9886 0.0114 0 0.0057 
ZA5 3823 ZA76 6782 0.9771 0.0229 0 0.0115 
ZA5 3823 ZA78 6772 0.9917 0.0083 0 0.0041 
ZA5 3823 ZA86 6807 1 0 0 0 
ZA5 3823 ZA89 6816 0.9818 0.0182 0 0.0091 
ZA5 3823 ZA92 6827 0.9933 0.0067 0 0.0034 
ZA5 3823 ZA95 6924 0.9881 0.0119 0 0.0059 
ZA64 6734 ZA68 6764 1 0 0 0 
ZA64 6734 ZA72 6768 1 0 0 0 
ZA64 6734 ZA76 6782 0.0175 0 0 0.0351 
ZA64 6734 ZA78 6772 1 0 0 0 
ZA64 6734 ZA86 6807 1 0 0 0 
ZA64 6734 ZA89 6816 1 0 0 0 
ZA64 6734 ZA92 6827 1 0 0 0 
ZA64 6734 ZA95 6924 0.0175 0 0 0.0351 
ZA68 6764 ZA72 6768 1 0 0 0 
ZA68 6764 ZA76 6782 0.9837 0.0163 0 0.0081 
ZA68 6764 ZA78 6772 1 0 0 0 
ZA68 6764 ZA86 6807 0.9809 0.0191 0 0.0095 
ZA68 6764 ZA89 6816 1 0 0 0 
ZA68 6764 ZA92 6827 0.9662 0.0338 0 0.0169 
ZA68 6764 ZA95 6924 0.9688 0.0312 0 0.0156 
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ZA72 6768 ZA76 6782 0.971 0.0253 0.0037 0.0163 
ZA72 6768 ZA78 6772 0.9738 0.0262 0 0.0131 
ZA72 6768 ZA86 6807 0.9792 0.0208 0 0.0104 
ZA72 6768 ZA89 6816 0.9939 0.0031 0.003 0.0046 
ZA72 6768 ZA92 6827 1 0 0 0 
ZA72 6768 ZA95 6924 0.9634 0.0366 0 0.0183 
ZA76 6782 ZA78 6772 1 0 0 0 
ZA76 6782 ZA86 6807 0.9681 0.0319 0 0.016 
ZA76 6782 ZA89 6816 0.9972 0 0.0028 0.0028 
ZA76 6782 ZA92 6827 1 0 0 0 
ZA76 6782 ZA95 6924 0.9801 0.0199 0 0.01 
ZA78 6772 ZA86 6807 0.9932 0.0068 0 0.0034 
ZA78 6772 ZA89 6816 1 0 0 0 
ZA78 6772 ZA92 6827 1 0 0 0 
ZA78 6772 ZA95 6924 0.9806 0.0194 0 0.0097 
ZA86 6807 ZA89 6816 0.9868 0.0132 0 0.0066 
ZA86 6807 ZA92 6827 1 0 0 0 
ZA86 6807 ZA95 6924 0.9742 0.0258 0 0.0129 
ZA89 6816 ZA92 6827 1 0 0 0 
ZA89 6816 ZA95 6924 1 0 0 0 
ZA92 6827 ZA950 6924 0.9915 0.0085 0 0.0043 
 
FID – Family ID; IID – Individual ID; Z0 – probability that individuals at a specific marker will share no 
alleles; Z1 – probability that individuals at a specific marker will share 1 allele; Z2 – probability that  




Stellenbosch University  https://scholar.sun.ac.za
164 
 
Appendix IV – Novel and rare non-synonymous variants identified in four WES PD probands using the 
hypothesis based approach 
Gene SNP Frequency rs number SIFT PolyPhen2 MutationTaster 
ANAPC1 Q451H 0 rs79100806 T B 0.360565 
AQP7 Y115H 0 rs74668961 D B 0.999905 
AQP7 E202D 0 rs114937176 T B 0.064028 
CASP1 G85E 0 rs2509649 T B 0.097257 
CCDC144NL X222Q 0 rs4605228 NA NA 0 
CLIP1 L271F 0 rs79909185 D P 0.974668 
GXYLT1 Y233X 0 rs77044712 NA NA 1 
GXYLT1 Y234C 0 rs79044728 D D 0.998509 
HBD S87A 0 - T NA 0.162278 
HNRNPCL1,LOC649330 D255Y 0 rs141207681 D B 0.727625 
HNRNPCL1,LOC649330 S286R 0 rs148930640 D B 0.410105 
HNRNPCL1,LOC649330 A248V 0 rs149302457 D B 0.094496 
HNRNPCL1,LOC649330 T287A 0 rs149796618 T B 0.090357 
HNRNPCL1,LOC649330 D265N 0 rs2359486 T B 0.001468 
HNRNPCL1,LOC649330 P253L 0 rs150590256 T B 3.44E-4 
HNRNPCL1,LOC649330 E245D 0 rs146075045 T B 1.59E-4 
HNRNPCL1,LOC649330 V258D 0 rs2076063 T B 5.1E-5 
IL28A F137L 0 - NA B 1.9E-5 
IL32 D172G 0 rs2981599 D P 0.981577 
KATNAL2 S301C 0 rs76539063 D P 0.9725871 
KIR3DL1 S239N 0 - T NA 3.9E-5 
MLL3 S772L 0 rs4024453 D P 0.453495 
MLL3 T316S 0 rs10454320 T P 0.436638 
NOTCH2NL T158I 0 rs75586173 T D 0.997294 
PABPC1 R374C 0 - D D 0.996115 
PABPC1 E372G 0 - D D 0.988773 
PABPC3 A181T 0 rs112107735 T B 0.984775 
PABPC3 I195V 0 rs76861216 T B 0.972619 
PABPC3 P191T 0 rs76264750 T B 0.004658 
PABPC3 Q172R 0 rs75475407 T B 6.0E-5 
PLIN4 A883T 0 rs80238130 - -  -  
PPIAL4G F112L 0 rs6604511 D P 0.702685 
PRAMEF4 G94E 0 - T NA 0.004287 
PRAMEF4 L19V 0 - D NA 9.8E-4 
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PRB2 R357Q 0 - NA NA 0.001769 
PRSS1 D218Y 0 - T B 0.356489 
PRSS1 V213I 0 - T B 0.284652 
PRSS3 T60S 0 - T B 0.00535 
PRSS3 K152Q 0 - T B 0.003122 
PRSS3 S175N 0 - T B 1.34E-4 
PRSS3 K72E 0 rs151192741 T B 2.3E-5 
PRSS3 A145T 0 rs855581 D P 0.999736 
TIMM23 N9D 0 rs4935252 D P 0.999742 
TPSD1 H143R 0 rs72775466 T B 0.102904 
AQP7 A100T 0.50/0.50 (n = 2) rs77962308 T B 0.008256 
BCLAF1 T837N 0.50/0.50 (n = 2) rs62431284 D P 5.0E-6 
C22orf42 M120I 0.958/0.042 (n = 
3420) 
rs144597334 D B 2.91E-4 
CCDC144NL S217Y 1.00/0.00 (n = 120) rs2318592 D NA 0.00422 
CDC27 W644R 0.50/0.50 (n = 2) rs74348171 D NA 0.999988 
CDC27 Y641C 0.50/0.50 (n = 2) rs62075618 D NA 0.999985 
CDC27 H615Q 0.50/0.50 (n = 2) rs75661039 D NA 0.999889 
CDC27 H615R 0.50/0.50 (n = 2) rs76926116 D NA 0.999889 
CDC27 R631X 0.993/0.007 (n = 
129) 
rs77685276 NA NA 1 
CNTN5 S23A 0.50/0.50 (n = 2) rs10790978 - -  -  
CNTN5 L70R 0.50/0.50 (n = 2) rs7125822 -  - - 
GPRIN2 W91R 0.50/0.50 (n = 2) rs3127820 D B 4.0E-6 
GXYLT1 R227L 0.50/0.50 (n = 2) rs76555438 D D 0.998482 
GXYLT1 R230S 0.50/0.50 (n = 2) rs74583427 D D 0.995639 
GXYLT1 E218G 0.50/0.50 (n = 2) - D P 0.994118 
GXYLT1 Y233N 0.50/0.50 (n = 2) - D D 0.993666 
GXYLT1 E218K 0.50/0.50 (n = 2) rs77582546 D D 0.992851 
GXYLT1 N226S 0.50/0.50 (n = 2) rs78536827 T P 0.971514 
KCNJ12,KCNJ18 R118Q 0.50/0.50 (n = 2) rs1657740 T B 0.021368 
MAP2K3 Q73X 0.50/0.50 (n = 2) rs55796947 NA NA 1 
MLL3 L291F 1.00/0.00 (n=120) rs56850341 T D 0.885477 
MYO5B V1703A 0.981/0.019 (n = 
259) 
rs138128932 NA B 0.145661 
PABPC3 R469Q 0.50/0.50 (n = 2) rs140135080 T B 0.996872 
PABPC3 K444M 0.50/0.50 (n = 2) rs75484271 T B 0.002961 
PABPC3 G451A 0.919/0.081 (n = 
333) 
rs113617207 T B 7.6E-5 
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PABPC3 I448T 0.989/0.011 (n = 
375) 
rs112901832 T B 0.92257 
PABPC3 S446G 0.998/0.002 (n = 
325) 
rs78778235 T B 7.6E-4 
PPIAL4G A101V 0.50/0.50 (n = 2) rs2490183 D B 0.99409 
PRAMEF1 R213H 0.50/0.50 (n = 2) rs1063769 T B 1.6E-4 
PRAMEF1 R265G 0.50/0.50 (n = 4) rs74937070 T P 0.003856 
PRAMEF1 A257T 0.996/0.004 (n = 
939) 
rs1063779 T B 0.001722 
PSG9 T410I 1.00/0.00 (n = 2) rs1063001 D B 0.004537 
PSG9 H397R 1.00/0.00 (n = 2) rs2072285 T B 1.25E-4 
TIMM23 G23E 0.50/0.50 (n = 2) rs373071373 D P 0.85697 
YY1AP1 Q424R 0.998/0.002 (n = 
1315) 
rs113197997 T B 0.294756 
P - pathogenic; D - damaging; T - tolerated; B - benign; NA - stop/gain mutation; n - number of chromosomes 
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Appendix V-  Primer sequences designed for Sanger sequencing validation 
Gene SNP Primer sequence (5’ – 3’) % GC Tm (°C) PCR conditions (Ta in °C) Size of fragment  (bp) 
ANAPC1 Q451H For: TGG TGA TGG TTG TAT AAC ACT GTA 






BCLAF1 T837N For: TTC ACC CAC CAA ACC TAT ATC AA 






C22orf42 M120I For: CTG AAT CAT GAT GGC AGT CAA A 






GPRIN2 W91R For: CCG CCT GAG AGC ATG AA 






NOTCH2NL T158I For: ATG TGC CTC AGG GTT TAC AG 






MAP2K3 Q73X For: AGT GAT CAG TAC CGA GGC TA 






PRSS3 A145T For: CTG GGA GAG CAC AAC ATC AA 






IL32 D172G For: GTT CTG GCC TGG GTG AAG 






TIMM23 G23E For: CCC GCT GTT ATT GAG GAG TAA 






KATNAL2 S301C For: GCG TCC GGA TTG TTC CT 






CNTN5 L70R For: CCA CTT CAT ATG CTG CTT TGT T 






TIMM23 D9N For: GAC GCG CAA CTT AGT GTA GA 
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Appendix VI – Validation of candidate variants through Sanger sequencing and High Resolution 
Melt analysis 
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(F)  ANAPC1 (Q451H) 
 
 
(G)  BCLAF 1 (T837N) 
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Supplementary Figure 1 Sequence alignments of the prioritized variants common across three 
PD probands and one affected sibling.  The location of the specific SNP is indicated by the red 
arrow.  The wild type is the reference sample, the mutant sample is a construct indicating the position 
of the variant in a heterozygous state. 
  




Supplementary figure 2 HRM normalized graph indicating the heterozygous D172G variant in IL32 





Supplementary Figure 3 Sequence alignments of 10 control patients as well as the probands and 
affected sibling for IL32 (D172G).  The location of the SNP is indicated by the red arrow.  The wild 
type is the reference sample, the mutant is the sample in which a heterozygous change would be 
present. 
 
Heterozygous D172G variant 




Supplementary Figure 4 HRM normalized graph indicating the heterozygous S301C variant in 





Supplementary Figure 5 HRM difference graph indicating the heterozygous S301C variant in 
KATNAL2 in the positive controls as well as Afrikaner controls.  
Heterozygous S301C variant 
Heterozygous S301C variant 






Supplementary Figure 6 Sequence alignments of nine control patients as well as the probands 
and affected sibling in KATNAL2 (S301C).  The location of the SNP is indicated by the red arrow.  
The wild type is the reference sample, the mutant is the sample in which a heterozygous change would 
be present. 
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Appendix VII:  WES results obtained using the hypothesis-free approach 
 
Supplementary Table 1 Stepwise breakdown of results obtained by TAPER™ for already existing WES results. 
 
Parkinson’s disease dataset 1 – L34R in FBOX7 
 
Intellectual disability and 




dataset 1 – R297Q 
in KCNA2 
Parkinson’s disease dataset 2 – R275W and 
M432V in PARK2 
 Individual_1 Individual_2 Individual_3 Individual_1 Individual_2 Individual_1 Individual_1 Individual_2 Individual_3 
Total number of variants in VCF 
file 
55 726 55 336 55 289 54 426 54 574 60 128 104 307 108 243 97 833 
STEP 1: Total number of 
variants assigned to exonic 
regions by wANNOVAR 
19 727 19 969 20 353 24 573 24 425 23 747 19 850 19 972 19 863 
STEP 2: All synonymous and 
non-frameshifts removed 
9 465 9 544 9 766 12 227 12 248 11 693 9 752 9 777 9 838 
STEP 3: Remove all variants 
with a frequency >1% in 1KGP 
1 281 934 966 2 177 2 153 1 377 1 771 1 681 1 932 
STEP 4: Remove all variants 
with a frequency >1% in 
ESP6500 
917 797 819 1 928 1 906 941 1 335 1 445 1 575 
STEP 5: Remove all variants 
with negative GERP+++ scores 
718 615 651 1 243 1 261 688 1 014 1 126 1 232 
STEP 6: Remove all variants 
with FATHMM scores greater 
than 1.0 
262 224 240 252 231 257 413 301 328 
STEP 7: Variants removed from 
X and Y chromosome 
252 221 236 241 221 202 398 262 292 
STEP 8: Variants linked to 
relevant diseases 
34 37 31 56 57 23 2 2 2 
Variant of interest in shortlist? Yes Yes Yes Yes Yes Yes Yes Yes Yes 
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Supplementary Table 2 Primer sequences for the six candidate variants identified through the use of TAPER™ 
 
Gene SNP Primer sequence (5’ – 3’) % GC Tm (°C) PCR conditions (Ta in °C) Size of fragment  (bp) 
WNK1 S719G For:  GGGAGAGGATGGAACATTTCTT 






CASP7 E43D For:  GGACACGGGTCGCTTTG 






SYNJ1 V1405I For:  AACCCATTTAGAGCCAAGTCTG 






USP17 C357S For:  CTTGTCTATGTCCTCTATGCTGTG 






(Temperature range 62 – 50) 
201 
MIPEP V626M For:  CTGTGTCTCCACTGTGTTCT 
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Appendix VIII - Validation of candidate variants through Sanger sequencing and High Resolution Melt 
analysis 
(A) WNK1 (S719G) 
 
 
(B) CASP7 (E43D) 
 
(C) MIPEP (V626M) 
 
 
Supplementary Figure 11 Sequence alignments of the prioritized variants common across three PD 
probands and one affected sibling.  The location of the SNP is indicated by the red arrow.  The wild type is 
the reference sample, the mutant sample is a construct indicating the position of the variant in a homozygous 
state.  




Appendix IX – DNA isolation from blood using the phenol/chloroform method 
Extraction of nuclei from whole blood 
Blood from two 5ml EDTA tubes per patient was transferred into a 50ml Falcon tube.  The tube was then filled 
to 20 ml with ice-cold lysis buffer and inverted gently a few times.  Subsequently, the sample was incubated on 
ice for 5-10 min. The sample was then centrifuged at 2500-3000 rpm at room temperature in a Beckman model 
TJ-6 centrifuge (Scotland, UK). The supernatant was discarded and the pellet was resuspended in 20ml, ice-cold 
lysis buffer that was then followed by another round of incubation and centrifugation.  The supernatant was 
discarded and the pellet resuspended in DNA extraction buffer, after which the nuclei were either immediately 
used for DNA extraction, or stored at -70°C until DNA was required for genetic testing. 
 
Extraction of DNA from nuclei 
A total volume of 100µl of proteinase K (10μg/ml) was added to newly prepared or defrosted nuclei and the 
mixture was incubated overnight at 37°C. After this step, 2ml distilled water, 500µl 3M sodium-acetate and 
25µl phenol/chloroform were added to the sample. The tubes were subsequently inverted and mixed gently for 
10 min on a Voss rotator (Voss of Maldon, England) at 4°C. The mixture was then transferred to a glass Corex 
tube so that the aqueous phase could be clearly distinguished from the organic phase, followed by centrifugation 
in a Sorvall RC-5B refrigerated super-speed centrifuge (rotor SS 34, Dupont Instruments) at 8000rpm at 4°C for 
10 min.  The upper aqueous phase contained the DNA and was transferred to a clean Corex tube using a sterile 
plastic Pasteur pipette, while taking care not to disturb the interface or the organic phase.  Approximately 25ml 
chloroform/octanol was added to the aqueous phase after which the tube was closed with a polypropylene 
stopper and gently inverted for 10 min.  This mixture was centrifuged at 4°C, followed by the removal of the 
upper aqueous phase as described earlier.  The DNA was then ethanol precipitated by adding two volumes of 
ice-cold 96% ethanol and inverting gently until DNA strands appeared as a white precipitate.  The DNA strands 
were removed using a yellow-tipped Gilson pipette and placed in a clean,1.5ml Eppendorf microfuge tube. One 
millilitre 70% ethanol was then added to the DNA and the mixture centrifuged in a Beckman microfuge for 3 
min at 13000 rpm. The ethanol was carefully decanted and the 70% ethanol wash step was repeated one more 
time in order to remove any excess salts. After careful removal of most of the ethanol, the DNA pellet was air-
dried for 30-60 min at room temperature by inverting the Eppendorf microfuge tube on Carlton paper. Two 
hundred microlitres Tris-EDTA buffer was added and the DNA was resuspended, initially by stationary 
incubation at 37°C overnight and subsequently by gentle mixing in a Voss rotator at 4°C for a further 3 days. 
This was followed by stationary incubation at 4°C until the DNA had been fully resuspended. 
After 1-2 weeks, when the DNA had completely resuspended in the buffer, the optical density(OD) of the DNA 
was determined in a Milton Roy series 120i spectrophotometer (USA) at 260nm (OD260). The DNA 
l, was determined by diluting 10µl of DNA in 500µl of TE and multiplying the measured 
OD260 by a factor of 2.5, while the purity of the DNA was monitored by the OD260//OD280 ratio, which 
should be approximately 1.8 for pure DNA.  




Appendix X – Reagents and Solutions 
Cresol Loading Dye 
2% (v/v) 10mg/ml cresol stock solution 
0.9933M sucrose 
 
10x TBE Electrophoresis Buffer (pH 8.3) 
0.0890M Trizma Base 
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